DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF A PULSED-RELEASE TABLET DOSAGE FORM FOR LOW DOSE WATER SOLUBLE DRUGS by Palaniswamy, Suresh
University of Rhode Island 
DigitalCommons@URI 
Open Access Dissertations 
2000 
DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF A 
PULSED-RELEASE TABLET DOSAGE FORM FOR LOW DOSE 
WATER SOLUBLE DRUGS 
Suresh Palaniswamy 
University of Rhode Island 
Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss 
Recommended Citation 
Palaniswamy, Suresh, "DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF A PULSED-RELEASE 
TABLET DOSAGE FORM FOR LOW DOSE WATER SOLUBLE DRUGS" (2000). Open Access Dissertations. 
Paper 189. 
https://digitalcommons.uri.edu/oa_diss/189 
This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for 
inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more 
information, please contact digitalcommons@etal.uri.edu. 
( 
DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF A 
PULSED-RELEASE TAB LET DOSAGE FORM FOR LOW DOSE 
WATER SOLUBLE DRUGS 
BY 
SURESH PALANISWAMY 
A DISSERTATION SUBMITTED IN PARTIAL FULFILMENT OF THE 
REQUIREMENTFORTHEDEGREEOF 
DOCTOR OF PHILOSOPHY 
IN 
APPLIED PHARMACEUTICAL SCIENCES 
UNIVERSITY OF RHODE ISLAND 
2000 
DOCTOR OF PHILOSHOPHY DISSERTATION 
OF 
SURESHPALANISWAMY 
APPROVED: 
Dissertation Committee 
Major Professor 
UNNERSITY OF RHODE ISLAND 
2000 
ABSTRACT 
Various types of controlled release dosage forms such as wax matrix hydrophilic 
polymer matrix, osmotic pump and acrylic resin polymer encapsulated slow release for 
water soluble drugs have been developed and reported. However, there was no significant 
information available in the literature about the development and scale-up of pulse-release 
tablet dosage form for low dose water soluble drugs. This investigation was undertaken to 
develop, characterize and evaluate a new pulsed-release dosage form for a low dose water 
soluble drug with consistent drug release that combines polymer matrix and aqueous 
coating technology. 
The effect of scale-up on granulation, compression and coating of pulse-release 
tablet formulation containing low dose active drug made with hydroxypropyl 
methylcellulose (HPMC) as base excipients were investigated for two different 
formulation. The controlled release matrix tablets produced were seal coated using 
aqueous polymer latex dispersion to retard the drug release from the tablet cores for a 
period of 3-4 hours. Immediate release coat was developed to apply the initial dose of the 
drug onto the seal coated tablets. 
A factorial design was used to study the critical processing parameters that were 
known to influence coating process. The results of analysis of variance were used to 
predict the effect of various processing parameters on the response. Pair-wise comparisons 
of the dissolution results for two different scales and formulations using F2 metrics 
established by FDA SUPAC guidelines were used to evaluate similarity between drug 
release characteristics. 
Results indicate that adjustment of the blending time and headspace to blender 
capacity based on the size of the blenders used at various stages of scale-up is necessary to 
maintain constant blending geometry and equivalent mixing to produce uniform 
distribution of the active drug. Results also show that coating suspension spray rate and 
coating pan rotation speed significantly affect the coating uniformity. The content 
uniformity between tablets is significantly improved by using a low spray rate, low dJ"\lg 
concentration in the coating solution and slower pan speed. Stability test results indicate 
that the developed formulation was stable when stored at ambient and accelerated storage 
conditions. 
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PREFACE 
This thesis dissertation work has been prepared in accordance with the manuscript format 
option for dissertation preparation, as outlined in section 11-3 of The Graduate Manual of 
the University of Rhode Island. Contained within is a body of work divided into three 
sections. 
Included in Section I is Introduction, which introduces the reader to the review and 
subject of this dissertation, a statement of the problem, and the specific objective of the 
research. 
Section II is comprised of four manuscripts, containing the findings of the research, 
which comprises of this dissertation. The four manuscripts are presented in the format 
required by the journal to which they will be submitted. 
Section III contains appendices containing, ancillary data (information essential to, but 
not usually included in published manuscripts) and other details pertaining to the 
understanding of the concepts presented in section II. This dissertation closes with a 
complete bibliographic listing of all the references cited in the dissertation, arranged in 
alphabetical order by the author's last name. 
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SECTION I 
INTRODUCTION 
Typically, when a drug is either ingested or injected, the systemic drug level often 
exceeds the optimum therapeutic level for a brief period of time and then gradually 
declines from the therapeutic range to ineffective levels. Such "sawtooth" drug kinetic 
profiles are undesirable for many drugs, especially for drugs that have a low therapeutic 
index. Appropriately sustained drug blood levels can enhance therapeutic action and 
minimize undesirable side effects ( l ). 
It is well known fact that patient compliance is better when drug dosage is 
administered only once or twice daily. It has been reported that as the number of doses 
per day increases, there is a greater risk that patients either forget or neglect to take every 
dose (2). Thus, it would be desirable to reduce the daily number of doses, especially in 
long-term chronic treatment. 
With appropriate well designed controlled release dosage forms it is possible to 
reduce the frequency of dosing, maintain the therapeutic drug plasma concentration level 
for a longer periods of time, reduce undesirable toxic or adverse effects, and obtain a 
constant pharmacological action (3 ,4) . 
The oral route of administration has been recognized as convenient and more 
acceptable than any other route of drug administration (3). Because of the advantages 
offered by tablets such as, ease of administration, patient compliance, low cost 
manufacturability, packaging and shipping. A number of different designs and techniques 
were used to provide controlled release such as dissolution controlled, diffusion 
controlled, diffusion and erosion controlled, osmotically controlled and ion exchange. 
Thus tablets predominate in the oral controlled release market. Among the marketed 
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tablet formulations, non disintegrating matrix tablets are the most widely used. One of the 
earlier studies describing core tablets that release drugs through diffusion was by Sogren 
(4). In this study the tablet core was produced by direct compression of the granulated 
drug with insoluble plastic material so that a porous skeleton of the matrix material forms 
around the drug. 
In addition, a source of concern with controlled release dosage forms is the 
difficulty in designing the formulation to obtain the desired drug release profile and 
manufacturability. Scale-up of solid dosage forms, particularly controlled release dosage 
forms, may lead to changes in the pharmaceutical characteristics and drug release profiles 
from the laboratory scale to the production scale, such inconsistencies are construed to be 
mainly the result of variations in raw materials and differences in equipment (5,6). To 
date, many studies have been performed to resolve the problem of variation in raw 
materials (7,8,9); however, difficulties in scale-up may also result from poor in-process 
controls or incorrect extrapolation of the results generated during small-scale studies. A 
major source of problems related to equipment differences is the failure to apply 
engineering models and scale-up factors when a process is transferred from pilot scale to 
production scale. In practice, this initial transfer to production scale is often empirical or 
trial and error rather than a systematic application of engineering principles. 
Polymeric delivery systems may be used in a wide variety of pharmaceutical 
dosage forms. More recently, synthetic and semi-synthetic polymers have achieved wide 
use in tablet formulations, and polymeric coatings in the pharmaceutical industry. The 
oldest and most widely developed sustained release dosage forms involved coating with 
lipid substances such as: waxes (l 0) and fats i.e. Spansules®, which was one of the first 
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commercially available orally administered sustained release dosage form. The rate of 
drug release from such dosage form will depend upon the physical properties of the 
coating materials and of the drug itself. 
Controlled Release Through Coated Particles 
Since the introduction of the Spansule sustained release dosage form, there have 
been numerous studies on this type of coated particle dosage form. Coating of drug 
particles, granules or tablets with polymer can be achieved by pan coating or an air 
suspension coating process. A common procedure used to prepare drug-coated beads or 
granules is to coat nonpareil seeds with the drug and follow this with either a slowly 
dissolving wax or a polymer coat of varying thickness. There are a variety of slowly 
dissolving or disintegrating coatings available, such as those based on various 
combinations of carbohydrate sugars and cellulose, polyethylene glycol, polymeric 
materials or waxes. Examples of drug using coated granules include antihistamines 
(11 , 12); antihypertensives (13), and cardiac muscle dilators (14). 
There have been a wide range of drugs formulated as sustained release coated 
granules and compressed into tablets, such as phenothiazines (15-18), anticholinesterase 
agents (19), and aspirin (20, 21 ). With tablet dosage forms, the concern for the thickness 
and area of the granular coating remains, with additional problem areas such as the 
influence of excipients and compression on the disintegration and dissolution of the 
tablets. Interestingly, the role of excipients on the dissolution pattern of compressed 
coated granules has not been fully clarified. 
4 
Controlled Release Through Microencapsulation 
Microencapsulation has been defined as the process of enclosing small entities in 
a coating material to produce particles with modified characteristics (22). This process 
has been employed pharmaceutically to increase product stability (23,24), modify drug 
release, prevent drug incompatibility in formulations (24), and to improve certain 
physical characteristics of formulation such as compressibility and flow properties. 
Coacervation has been credited to be the earliest process used to encapsulate 
pharmaceuticals (25). In 1949 Bungenberg de Jong (26) discussed both simple and 
complex coacervation but did not apply the process to coating particles. A specific 
comparison of simple and complex coacervation processes between gelatin and gum 
arabic was made. Indomethacin (27), steroids (28,29) and cod liver oil (30) have been 
encapsulated using simple and or complex coacervation. Because of their solubility, 
polymers used in the aqueous coacervation process are not effective for controlled release 
applications. A number of microencapsulation formulations for oral controlled release 
have been studied and reported. Salib (31) encapsulated phenobarbitone in ethylcellulose 
using the coacervation technique. Deasy et al. (32) encapsulated highly water-soluble 
drug, sodium salicylate using different viscosity grades of ethylcellulose. Holiday et al. 
(33) described the microencapsulation of aspirin to produce a sustained release dosage 
form. Baken and Powell (34) reported paracetamol, aspirin, potassium chloride and 
theophylline microcapsules; prepared using an ethylcellulose-polyethylene system for 
controlled release which showed excellent stability. 
5 
Drug Release from Polymer Controlled Release System 
The release of drug from mjcrocapsules is a mass transport phenomenon 
involving diffusion of drug molecules from a high concentration region to a low 
concentration region. Mathematical models used to describe the kinetics of drug release 
from microcapsules are usual ly divided into two categories, which are: 
1. Drug release From Reservoir Device Microcapsules: In this system, a water-insoluble 
polymer film encases a core of drug (29,30,32,35). Assuming that the thermodynamic 
activity of the drug is maintained constant within the rnicrocapsule, then the steady-state 
release rate from the reservoir to the external sink have been demonstrated by Baker and 
Lonsdale (36) and follows thjs type of release profile: 
where: r0 =outside radius 
r; = inside radius 
dq/dt = rate of release 
D =diffusivity in the membrane 
k.i =partition coefficient 
cd =concentration of drug in the donor solution 
2. Drug Release From Matrix Microcapsules: In thjs system, the drug is dispersed 
throughout an insoluble polymer matrix. The drug release rate is dependent upon the drug 
diffusion rate. Based on a theoretical analysis of the law of simple diffusion. Higuchl (37) 
was able to mathematically derive an equation to describe the release of the drugs from a 
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homogenous matrix (monolithic solution) and from a granular matrix (monolithic 
dispersion). 
For drug release from spherical pellets the equation can be simplified to: 
1 + 2F-3P" =Kt 
Where F is the fraction of drug remaining in the pellet at time I, K is a constant, which 
varies with the type of matrix system. 
For a homogenous matrix system: K = 6DC,!Aa/, where Dis diffusion coefficient of the 
drug in the matrix polymer, C, is the solubility of the drug in the matrix polymer, A is the 
initial concentration of the drug in the matrix and a0 is the radius of the microsphere. 
For a granular matrix system: K = 6DcC,lrAa/, where D is the diffusion 
coefficient of the drug in the dissolution medium, li is the porosity which is the volume 
occupied by the drug granules, r is the tortuosity of the matrix and C,, A and a0 are the 
same as above. These models assume that the pellets are not coated, the polymer is not 
erodable, does not swell and the loading is relatively low. 
Controlled Release Through Matrix Tablets 
Matrix tablets are used to provide controlled release. One type of matrix 
controlled release tablet is prepared by compressing a mixture of a hydrophilic polymer 
and drug (38). In contact with moisture, the tablet swells to form a gel barrier, effecting 
delayed release of drug. Huber et al. (39) proposed that drug release was controlled both 
by drug diffusion through and by attrition of the gel sheath formed around the tablet. 
Lapidus and Lordi ( 40) reported data characterizing the release of chlorpheniramine 
maleate from a hydroxypropyl methylcellulose ether matrix . Release patterns measured 
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from one face of flat-surfaced tablets could be linearized when plotted as a function of the 
square root of time. This suggested that equations originally derived by the Higuchi 
brothers (37,41) for drug release from insoluble tablet matrices and from homogeneous 
ointments were applicable to this system. A number of studies investigating the effects of 
excipients on the release of variety of drugs from matrix tablets fo llowed, Huber and 
Christenson ( 42) investigated the release of tartrazine from two hydroxypropyl 
methylcellulose (HPMC) matrix tablets and found that higher viscosity grade HPMC 
released the tartrazine at a significantly slower rate. Sawayanagi et al. (43) examined the 
applicability of chitosan as a vehicle for making sustained release matrix tablets of water 
soluble drugs. Nakkano et al. (44) studied the release of theophylline from a 
hydroxypropyl cellulose matrix tablet. Ford et al. ( 45) investigated the effects of some 
formulation variables on the release rate of promethazine hydrochloride from 
hydroxypropyl methylcellulose (HPMC) tablet matrices. Baveja et al. ( 46) employed non-
ionic hydroxypropyl methylcellulose (HPMC) and anionic sodium carboxy 
methylcellulose (Na CMC) to prepare a near zero-order release from hydrophilic matrix 
tablets. Jambhekar et al. (47) studied the release of drug through the planar surface of a 
non-disintegrating insoluble matrix tablet. 
Another type of non-disintegrating controlled release tablet can be produced by 
compressing a mixture of insoluble inert plastic material and drug (4). Drug release is 
achieved by dissolution of the drug particles and is dependent upon the area of the 
interface between the plastic and the dissolving medium, the thickness of the diffusion 
layer which is the saturated solution formed at the interface between the solid and the 
liquid, and the difference in concentration between the diffusion layer and the solution. 
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When all of the drug has dissolved or leached out, the insoluble plastic skeleton still 
retains the original shape of the tablet. The release pattern may be controlled by varying 
the proportions of soluble and insoluble substances. Goodhart et al. (48) reported that 
phenylpropanolamine hydrochloride was released from a typical wax matrix by a 
diffusion mechanism. Farhadieh et al. ( 49) found that drug release from tablets 
compressed directly from mixtures of drug and methylacrylate-methylmethacrylate 
copolymer follow the square root of time dependence suggested by Higuchi. The 
magnitude of the release rate constant was found to be dependent on the matrix porosity 
and tortuosity as well as the solubility, diffusivity, and concentration of the drug. Khanna 
et al. (50) evaluated the drug release rate from two forms of Eudragit matrix tablets and 
reported the Eudragit RSPM in a concentration of 25% w/w was suitable for making 
sustained release tablets of propranolol hydrochloride. Fassihi (51) measured the 
compatibility of drug and polymer mixtures with directly compressible excipients. He 
found that the various formulation constituents affected tensile strength of tablets even at 
low compaction forces. 
Both types of controlled release tablets mentioned above are designed to be 
nondisintegrating. Barkin et al. in a study that demonstrated significant therapeutic 
ramifications (52), pointed out that the widely used potassium chloride tablet 
formulations, usually in the form of wax matrix slow release tablets, can cause 
gastrointestinal ulceration, hemorrhage, obstruction and perforations (53,54). They 
suggested a microencapsulated potassium chloride preparation that does not use a wax 
matrix and which disperses polymer-coated potassium chloride crystals over a wide 
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surface area in the intestinal lumen for over 8 to 10 hours would represent a new 
generation of tablet. 
Controlled Release Through Pulse-Release Tablets 
A pulse-release tablet is one that provides the usual single dose of the drug 
immediately after administration and delivers the next dose after a period of time. Pulse-
release tablets are not true sustained release products. However, the dosage form is 
designed to extend the activity of the second dose of the drug often after the effect of the 
first dose has diminished. Ideally, the lag time period should be only time-dependent. 
Also, a 4-6 hour lag time seems to be the upper limit for systemic administration due to 
gastrointestinal transit time. Drug release after the predetermined time should be rapid 
and complete. In this type of dosage form the core serves as the base onto which the 
initial dose is applied by usual coating techniques. Chlor-Trimetron Repetab® and 
Proventil Repetab® marketed by Schering-Plough illustrates this approach. The most 
important ingredient used in the barrier coating of Repetabs® a com protein, zein. Zein is 
claimed to have time-dependent, erosion properties. Zein is a proven timed-release 
barrier, because it has been applied to Repetab® technology and commercialized to yield 
several successful products. 
Water-soluble polymer to form a pulsed-release barrier 
Gazzaniga et al. (55,56) developed oral delayed release systems based upon a 
retarding swellable hydrophilic coating and coined the name "Chronotrophic®" for their 
delivery system. A hydroalcoholic solution of hydroxypropyl methylcellulose was used 
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along with polyethylene glycol 400 or diethylphthalate, talc and polyvinyl pyrolidone in 
the barrier coating system. The authors demonstrated that the lag time was linearly 
correlated with coating weight gain and drug release was independent of the pH of the 
medium. 
In an international patent, Shah (57) demonstrated the use of special grades of 
hydroxypropyl methylcellulose, e.g., Metolose® 60SH, 65SH, 90SH, and Methocel® 
F4M, as a hydrophilic matrix material to achieve bimodal drug release for several drugs, 
such as aspirin, ibuprofen, and adinazolarn. Bimodal release is characterized by a rapid 
initial release, followed by a period of constant release, and finalized by a second rapid 
drug release. 
Waxy material to form pulsed-release barrier 
Tablets or capsules were coated with a hydrophobic wax-surfactant layer which 
was made from an aqueous dispersion of camuba wax, beeswax, polyethylene sorbitan 
monooleate, and hydroxypropyl methylcellulose, to form the TimeClock®. The lag time 
for the system was found to be independent of normal physiological conditions, such as 
pH, food, and the anatomical position of the body (58). 
Polyacrylic methacrylate copolymer to form pulsed-release barrier 
Geoghegan et al . (59,60) described a sustained-release formulation containing 
diltiazem, fumaric acid, and talc coated onto non-pareil seeds using polyvinyl pyrolidone 
as the binding agent. Subsequently the drug layered pellets were coated with Eudragit 
RS®:Eudragit RL ® (4:1). The drug release from this system showed a two hour delay. 
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Noda et al. (61,62) developed an organic acid-induced sigmoidal drug release system 
using a Eudragit RS polymer film as pulsed release barrier. 
Enleric materials to form pulsed-release barrier 
Various enteric materials, e.g., cellulose acetate phthalate, hydoxypropyl 
methylcellulose phthalate, polyvinylacetate phthalate, and the Eudragit® acrylic 
polymers, have been extensively used for gastroresistant, enterosoluble coatings to obtain 
pulse release in the intestine. An erodable association polymer system formed between a 
hydrogen-donating polymeric carboxylic acid of cellulose acetate phthalate and a 
hydrogen-accepting ethoxylated nonionic surfactant (Pluronic® F 127) was investigated 
for its applicability to pulsatile drug delivery (63). Such association polymers are erodable 
at neutral or higher pH but insoluble at low pH. This type of dosage form is prepared 
either by coating the immediate release portion of the drug over an enteric or delayed 
release coated core tablet or by press-coating the granulation containing an initial dose of 
the drug over the core which has been coated with an enteric material. 
Press coating technology for tablet dosage forms was used to form hydroxypropyl 
methylcellulose barriers with erodable and/or gellable characteristics to achieve time-
prograrnmed release of drugs by Conte et al . (64). From a technology and automated 
manufacturing perspective, press coating is a relatively complex and expensive process 
that requires advanced tableting equipment. On the other hand, multiple unit systems such 
as beads require a long coating process time to build up a pulsed-release barrier, due to 
the large surface area of the substrates to be coated. Additionally, a drug layering or core 
making process for multiple unit systems is time-consuming. Aqueous wax dispersion 
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was evaluated for controlled-release coating of beads (65). At the higher coating level, a 
two-hour lag time was achieved for the model drug theophylline and three hours was 
required for complete release of theophylline after the lag time. Thus, by combining the 
systems that have different release characteristics, oral drug preparations with various 
release patterns such as, repeat action, zero order, first order, bimodal, and sigmoidal 
patterns can be achieved. The findings reported in the literature so far did not combine the 
matrix system with the conventional coating technique to deliver a highly water soluble 
low dose drug that demonstrates an immediate release followed by a lag for 3-4 hours and 
the second dose in a zero order fashion. Hence, this study was undertaken to develop a 
pulsed-release delivery system using albuterol as a model drug. 
Albuterol, a syrnpathomimetic amine derivative of B-phenyl ethylamine, is a 
potent selective B-adrenergic agonist with less Beta1 adrenergic activity, and preferential 
Beta2 adrenergic activity that provides bronchodilation with little myocardial stimulation 
(66). As a result it is used as a bronchodilator to treat chronic obstructive airway diseases 
in adults and children. 
Albuterol is readily absorbed from the GI tract. Initial activity occurs within 15 
minutes and lasts for a period of 4-5 hours . The drug is excreted in urine in about 24 
hours with about 50 % of the orally administered drug is excreted within 3-4 hours. 
Maximum plasma albuterol concentration of about l 8ng/ml is achieved within 2 hours 
after administration of 4 mg as syrup (66). The peak plasma concentration of albuterol 
and its metabolites are reported as 5.1-11.7 µg percent at 2.5 to 3 hours after an oral dose 
of 4 mg (66). 
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Albuterol is metabolized to a polar metabolite in humans, which has spectral and 
chemical properties different from the parent drug. Albuterol is contraindicated in 
patients with cardiovascular disorders. Teratogenic effects have been reported for 
albuterol in animals and oral administration of the drug has been shown to delay preterm 
labor (66). 
However, owing to a short-half life of 3-5 hours the drug must be administered 3-
4 ·times daily to maintain a therapeutic concentration. Unfortunately this requires careful 
observance of the treatment regimen a requirement that often interferes with the ability to 
achieve full therapeutic benefit from the treatment. Albuterol may be administered in a 
variety of dosage forms and is available on the market in the form of albuterol sulfate 
syrup, and tablets for oral administration, also in the form of albuterol for oral inhalation. 
The tablets are available as 2 mg and 4 mg immediate release and 4 mg repeat action 
tablets. The repeat action tablets are designed to deliver 2 mg immediately via a coated 
outer most layer and 2 mg slowly from the core for a period of 3-4 hours (66). The oral 
inhalation dosage form provides a metered dose of 90 µg of albuterol for each actuation. 
The only controlled release oral dosage form of albuterol on the US market is Proventil® 
Repetabs and the market potential of this dosage form is significant. The main objective 
of this pulsed-release dosage form is to improve compliance by reducing the number of 
doses from four to two per day. 
Various types of controlled release dosage forms of albuterol have been developed 
and reported (67,68,69). These include wax matrix hydrophilic polymer matrix, osmotic 
pump and acrylic resin polymer encapsulated slow release. An extended release 
formulation of albuterol is marketed as Proventil® Repetabs but the detailed technology is 
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not reported. However first marketed in the l 950's using old technology, no further 
modifications in the design and processing methods of these dosage forms have been 
made presently. Contents as reported in the labeling of the marketed products ohhis type 
are derived from natural origin. These excipients show variability in content, drug release 
and often give less than reproducible results. 
Processing of excipients obtained from natural origin is difficult and often prone 
to microbial contamination, which in tum requires strict quality control testing before 
processing into a dosage form. Organic solvents are needed in processing these materials 
which is hazardous. The recovery of these solvents also adds to the manufacturing cost. 
This investigation was undertaken to develop a new pulsed-release dosage form 
with consistent drug release that combines polymer matrix and aqueous coating 
technology. This approach eliminates the use of organic solvents and uses an aqueous 
coating to retard drug release from the core for several hours after the first dose is 
released from the outermost layer. This method increases the efficiency of manufacturing 
and decreases variability by eliminating the use of excipients obtained from the natural 
origin, thereby giving a cost effective product, which is advantageous in this era of cost 
reduced health care. 
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Based on the above discussion, the specific objectives of this research were: 
I. To develop two different controlled release formulations using matrix tableting 
technology to produce distinct drug release characteristics with a target release of 3 
and 6 hours. To evaluate the processing parameters that affect tablet characteristics 
during scale-up from pilot to production size batches. 
2. To evaluate aqueous coating techniques in an attempt to develop a seal coating that 
will protect and retard drug release from the controlled release matrix system. To 
study the effect of polymer coating level on drug release and identify the optimum 
polymer formulation required to retard drug release. 
3. To develop a coating process that will allow coating of a small dose of drug onto core 
tablets that will meet USP standards for solid dosage forms. To study the effect of 
process variables that influence coating uruformity at both pilot and large scale 
production. 
4. To identify the critical process variables that influence coating uruformity and to 
optimize these variables using statistical design of experiments. To evaluate the 
stability of the optimized formulation under ambient and accelerated storage 
conditions. 
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HYPOTHESIS TESTED HEREIN 
It should be possible to develop a pulsed-release tablet dosage form for low dose water 
soluble drug using the conventional coating technique in conjunction with the matrix 
diffusion controlled release technique, which can release one dose of the drug as soon as 
ingested followed by the release of the second dose of the drug in a near zero-order 
release fashion for a period of 3-6 hours. 
22 
SECTION II 
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An Approach to Scale-up of A Controlled Release Tablet Dosage Form For A Water 
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Manuscript II 
Development of Immediate Release Dose For A Pulsed-Release Tablet: Part-I: Seal Coat 
Development (To be submitted to Pharmaceutical Development and Technology) 
Manuscript III 
Development of Immediate Release Dose For A Pulsed-Release Tablet: Part-I!: 
Immediate Release Coat Development (To be submitted to Pharmaceutical Development 
and Technology) 
Manuscript IV 
An Investigation of Uniformity of Aqueous Film Coating Containing Low Dose Active 
Drugs Using Statistical Design of Experiments (To be submitted to Pharmaceutical 
Technology) 
24 
MANUSCRIPT I 
AN APPROACH TO SCALE-UP OF A CONTROLLED RELEASE 
TABLET DOSAGE FORM FOR A WATER SOLUBLE DRUG 
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ABSTRACT 
The effect of scale-up on granulation and direct compression of controlled release 
tablet formulation containing low dose active drug made with hydroxypropyl 
methylcellulose (HPMC) as a base excipient was investigated. The model drug used was 
albuterol sulfate. Albuterol, a sympathomimetic amine is a potent selective beta 
adrenergic agonist used as a bronchodilator to treat chronic obstructive airway diseases in 
adults and children. The drug has a short half-life of 3-4 hours and must be administered 
3-4 times daily to maintain a therapeutic plasma level. 
Various concentrations of polymer and tableting excipients were evaluated and an 
optimum concentration, which gave near zero order release, was determined. Direct 
compression formulation containing < 2% of the drug developed at the pilot scale level 
was scaled up to a production size batch. A High Performance Liquid Chromatography 
(HPLC) assay method was used to determine the drug content in the formulation. 
Granulation and tablet characteristics were evaluated in an attempt to identify the 
optimum scale-up parameter for the large scale batches. To examine the impact of 
formulation and processing equipment on the drug content uniformity in the blend and 
tablet, statistical analysis along with, USP criteria for solid dosage form was applied. 
Batches manufactured at two different scales exhibited similar granulation and tablet 
properties for the two formulations studied. 
Changes in the compression force significantly affected the tablet hardness for 
both formulations. However, the tablet hardness or the dwell time did not significantly 
affect the drug release. Observed F2 values for both the scales of manufacturing, and all 
the pair-wise comparisons were > 83 suggesting that the drug release characteristics are 
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reproducible and similar based on SUPAC F2 criteria. Stability studies indicate that the 
developed formulation was stable for a period of 3 months when stored at 25°C ambient 
conditions. The most important factor that should be considered in scaling-up of direct 
compression formulation of low dose active drug include adjustment of the blending time 
to blender rpm and capacity based on the size of the blenders used at various stages of 
scale-up. 
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1.0 Introduction 
Scale-up of solid dosage forms, particularly controlled release dosage forms, can 
lead to changes in both pharmaceutical parameters and drug release profiles from 
laboratory scale to production scale. Such inconsistencies are construed to be mainly the 
result of variations in raw materials and equipment differences (1,2). To date, a number of 
studies have been performed to resolve the problem of variation in raw materials (3 ,4,5); 
However, difficulties in scale-up may also result from poor in-process controls or 
incorrect extrapolation from small-scale studies. A major source of problems related to 
equipment differences is the failure to apply engineering models and scale-up factors 
when a process is transferred from pilot scale to production scale. In practice, this initial 
transfer to production scale is often empirical or trial and error rather than a systematic 
application of engineering principles. 
Until recently, there was no regulatory mechanism to evaluate the scale-up 
process except comparing the in-vitro dissolution profile of product at the various levels 
of scale-up to determine the reproducibility of the drug release and other product 
properties to be followed by bioequvalence studies characteristics. Recently SUP AC-IR 
and SUPAC-MR (Scale-up and Post Approval Change) guidelines for immediate release 
and modified release dosage forms were established by FDA (6) . 
Scaling-up of a dry granulation process should be achieved without problems as 
long as the mixing equipment geometry is similar. Issues related to blending are uniform 
mixing of excipients with drug, segregation of particles and end point control, all of 
which are a function of blender rpm and mixing time. Generally, production equipment is 
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much more efficient in mixing and milling than are similar types of laboratory-scale 
equipment. It is therefore important that the effects of this improved efficiency on the 
manufacturability and characteristics of the final dosage form be assessed during scale-
up. The greatest difficulty observed as a result of the added efficiency of production 
equipment is overlubrication and its consequent effect on tablet hardness, capping and 
dissolution (3). Differences between tablet presses result in different compression times 
and may have an effect on the tablet's final characteristics. Such problems may arise with 
materials that undergo time-dependent stress relaxation. The differences attributable to 
press type have been related to the presence or absence of a gravity feed or a forced feed 
system in certain feed frames than to the event of compression itself (7) . 
The manufacture of matrix tablets by direct compression is an economical and 
simple process bearing a high commercial interest. Hydrophilic polymers such as HPMC, 
alginates and xanthum gum are well known and widely used in the development of 
controlled release formulations (8,9) . However, there are some distinct disadvantages of 
these excipients that complicate the development and commercial production of tablets 
using these materials. These are the lack offlowability, hampering the direct compression 
process, poor mixing of granulation, affecting the drug content uniformity and 
compaction. In addition to these issues, it gets even more complicated when it comes to 
scale-up of dry granulation direct compression process for low dose active drug. 
The goal of the present study is to systematically evaluate the relevant processing 
parameters on both pilot and production scales. This investigation includes the evaluation 
of granulation characteristics for a slow and fast releasing formulation using various 
grades of hydroxypropyl methylcellulose, on the small scale and production scale. Also 
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included were comparison of the tablet attributes, content uniformity, assay and 
dissolution profiles of the controlled release matrix tablets prepared from the direct 
compression granulation developed at two different scales for both the formulations. The 
results obtained from the two different scales were statistically analyzed to draw 
conclusions about the effect of scale-up on formulation characteristics and establish 
optimized process parameters. 
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2.0 Methods 
2.1 Materials: 
Albuterol Sulfate, USP obtained from (Propharmaco, Nobel Industries, Italy); 
Starch 1500, NF (Colorcon, West Point, PA); Lactose DT (Quest International Hoffman 
Estates, IL); Methocel® K JOO LV and K 15 M (Dow Chemical Company, Midland, Ml); 
Magnesium Stearate, NF (ManJlinckrot Inc., St. Louis, MO); Colloidal Sil icon dioxide 
(Division Chemical, Baltimore, MD). All raw materials used complied with the current 
USP/NF grade specifications. 
2.2 Equipment: 
1 and 10 ft3 V-Blender, (Gemco, Middlesex, NJ); Sieve Shaker (Sweco, Florance, 
KY); Micron Air Jet Sieve (Hosokawa Micron Powder Systems, Summit, NJ); Moisture 
Analyzer, Computrac Max 50 (Arizona Instrument, Tempe, AZ); Tablet Press Model 
Beta (Manesty, Liverpool, England); Tablet Press, Kikusui Model: Libra 836 KRCZ 
(Kikusui Seisakusho Ltd., Kyoto, Japan); SM! Force Monitoring System (SM! Inc., 
Pittstown, NJ); Vector Tablet Tester (Vector Corp. , Marion, IA); Friability Tester 
(Erweka Instrument Corp. , Milford, CT); Tap Density Apparatus, (J. Engelsmann A.G., 
Laudwishfen, GmbH, Germany); Tooling 9/32" Standard Concave, (Natoli Engineering 
Co., Chesterfield, MO); Bio-Dis Tester, (Vanke! Industries Inc., Edison, NJ); Shimadzu 
LC-4A, High Performance Liquid Chromatography (HPLC) Equipped with a Shimadzu 
SPD-2AS spectrophotometer detector (Shimadzu, Japan) . 
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2.3 Manufacturing Procedure: 
Two types of tablets containing 2 mg of albuterol were manufactured with the aim 
of achieving an extended release formulation, one with a three hour and the other with a 
six hour release period. The batch sizes selected were 13.5 kg and 135 kg for the pilot 
scale and large scale which yielded I 00,000 and one million (I OX of the pilot scale) 
tablets, respectively. Two different formulations of albuterol sulfate tablets were prepared 
by blending the drug, polymer and filler excipients in a specified order for a total mixing 
time of 29 and 48 minutes using either a 1 ft3 or 1 Oft3 V-blender respectively. The blends 
produced using the 1 ft3 V-blender were compressed using a Manesty BetaPress (pilot 
scale) to determine the initial parameters, such as formulation component concentration, 
blending time, hardness, tablet weight variation and drug release. 
The pilot scale formulation manufactured when scaled up to a batch size of 135 kg 
used a Kikusui Libra tablet press with 9/32" standard concave tooling for compression. 
The fill volume in the lower punch of the tablet machine was adjusted to a theoretical 
weight of 135 mg and compression force was adjusted to obtain a tablet hardness of 7-8 
kilopounds (kp). Figure I shows the process flow diagram for controlled release tablet 
core manufacture. 
2.3.1 Core Tablet Formulation 
Table 1 shows typical albuterol sulfate controlled release core tablet formulation 
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Figure I. Process Flow Diagram for Controlled Release Core Tablets 
Lactose Monohydrate, NF ~I Deagglomeration Starch 1500 Sweco Sieve Shaker 
Methocel~ KIOO LY or K 15 # 30 Mesh 
1 I Albuterol Sulfate, USP 1---+ Blendinp 
landlOft 
Y-Blender 
1 
Evaluations 
Magnesium Sterate, NF 
I-+ Final Blending I-+ Particle Size Colloidal Silicondioxide, NF I and IO ft3 Bulk!fapped Density 
# 30 mesh V-Blender LOD 
1 Evaluations 
Tableting f--. Weight variation 135 mg 9/32 in. SC Hardness 
Manesty Beta/Kikusui Press Friability 
33 
Table 1. Formula for Albuterol Sulfate Controlled Release Tablet Core 
Formulation I Formulation II 
Ingredient Percent mg/tablet Percent mg/tablet 
i_wlv!l_ (w/v!J_ 
Albuterol Sulfate, USP 1.78 2.40 1.78 2.40 
Methocel® (Kl OOL V) 25.04 33.80 - -
Methocel® (Kl5 M) - - 24.00 32.40 
Starch 1500® 25.04 33.80 10.00 13 .50 
Spray Dried Lactose, NF 46.66 63 .00 62.74 84.70 
Colloidal silicon dioxide, NF 0.74 1.00 0.74 1.00 
M~esium Stearate, NF 0.74 1.00 0.74 1.00 
Total 100.00 135.00 100.00 135.00 
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for a fast release (Formulation I) of three hours and a slow release (Formulation Il) of six 
hours. Excipients were selected based on published information (10) . Drug release from 
the matrix core tablets was controlled by a combined diffusion and erosion mechanism. 
This was achieved by inclusion of either a low viscosity (Methocel® KI OOL V) or a high 
viscosity (Methocel® K 15 M) hydroxypropyl methylcellulose polymer along with the 
selection of appropriate ratio of soluble to insoluble filler excipients. Formulation, 
process and processing variables were chosen based on the results of an earlier study (I 0). 
Table 2 summarizes the unit operations for the two scales of manufacture. 
2.4 Granulation Manufacture: 
Dry granulation excipients lactose, pregelatinized starch, Methocel® 
(hydroxypropyl methylcellulose) K 100 LV or K 15 M were deagglomerated using a 
Sweco sieve shaker. The screened materials were then placed in either 1 or I Oft3 V-
blender in the following order: Lactose, Albuterol Sulfate and Starch 1500 and mixed for 
30 minutes. Methocel® was added to the pre-blend and mixed for additional 15 minutes. 
These excipients were premixed for a predetermined amount of time (27 minutes and 45 
minutes for I and I Oft3 respectively). Optimum pre-blend mixing times were determined 
by evaluating drug content uniformity at various mixing intervals. Final blending of the 
granulation was completed by adding colloidal silicon dioxide and magnesium stearate 
(#30 mesh) and mixed for 2-3 minutes. The dry granules were then removed from the 
blender and stored for analysis and subsequent compression into tablets. 
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Table 2. Summary of Scales of Manufacture and Unit Operations 
Scale of Manufacture 
Parameter IX lOX 
Batch Size (kg) 13.5 135 
Batch Size (units) lxl05 Jxl09 
Raw Material Same Source Same Source 
Manufacturing 
Deagglomeration Sweco Sieve Sweco Sieve 
Blender Type (V) I ft3 10ft3 
Tablet Press Manesty Beta Kikusui Libra 
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2. 4. 1 Granulation Properties 
The granule properties examined include the following: granule size distribution, 
tap densities, angle of repose, percent compressibility (Carr index) and percent loss on 
drying. Blend samples of - 0.4 g (3 times the dose of 135 mg) were also collected from 
various locations (n=5) within each leg of the blender using an appropriate set of dies and 
a granulation sampling thief to determine the homogeneity of the final blend. Blend 
homogeneity was determined by assaying the individual samples collected from each 
location of the V-blender for content uniformity of albuterol sulfate. Composite samples 
collected from the drum after discharging the blend were used to determine bulk density, 
particle size and residual moisture. Residual moisture content (LOD) of the granules was 
determined using a thermogravimetric (Computrac Max 50, Arizona Instrument, Tempe, 
AZ) moisture analyzer. A sample weight of approximately 8 grams was spread onto an 
aluminum pan and placed in the analyzer. Table 3 lists the granulation parameters for the 
two different size batches manufactured. 
2.4.2 Particle Size Analyses 
Sieve analyses were performed to obtain a mean granule size and the weight 
distribution for the blend from each batch. A nest of standard sieves. (mesh size 325, 200, 
150, I 00, 80, 60) with a micron jet sieve was used for these analyses. A 25 gram 
composite sample from the dry granulation blend was collected for the evaluation. The 
Sample was coned and quartered to obtain a sample weighing approximately 5 grams for 
analysis. The samples were added to the pre-weighed nest of sieves and allowed to shake 
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bl Gr I . fi I d Ta e 3. anu at10n Processm_g_ Parameters or V-B en er 
Parameter VB-I VB-10 
Blender Size (fi3) 1 10 
Capacity (L) 29 145 
Batch Size (kg) 13 .5 135 
Blender (rpm) 23 14 
Mixing Time - Pre Blend (min) 27 45 
Mixil!&_ Time - Final BlendJ_minJ_ 2 3 
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for 5 minutes with a vacuum pressure setting of I 0.5 to 12 mm of water. The sieves were 
then reweighed to determine the weight fraction of granules retained on each sieve. These 
weights were converted to percent retained values using the initial total weight of the 
granules added and plotted against sieve size. 
2.4.3 Bulk and Tap Densities 
The bulk density of all the formulation components, and the tableting blend was 
evaluated. The bulk density of the granulation was determined by pouring an accurately 
weighed 100 gram sample into a clean dry 250 ml graduated cylinder tap density 
apparatus (J. Engelsmann A.G, GmbH, Germany). The density was then reported as the 
weight of the sample divided by the volume of the cyl inder occupied upon pouring. The 
tapped density of each batch was then determined by subjecting the previously described 
graduated cylinder system to 200 taps from a height of approximately 2 cm. It was 
determined that 200 taps were sufficient to obtain a constant volume for the granulation. 
The tapped densities are also reported as weight per volume. 
2.4.4 Carr Index and Angle of Repose 
Bulk and tapped densities were used to calculate flowability and the indices of 
compressibility derived by Hausner (1967) (11) and Carr (1970)(11,12). The percent 
compressibility (Carr' s index) was calculated as 100 times the ratio of the difference 
between tapped density and bulk density to tapped density. The drug excipient blend was 
placed in a powder funnel with 0.5 cm diameter opening supported using a retard stand 
such that the bottom of the orifice was 10 cm from the bench surface, the powder was 
39 
allowed to flow with the help of gravitational force. The angle of repose which is the 
angle (0) obtained between the free standing powder heap and the horizontal plane was 
measured. 
2.5 Tablet Manufacture: 
The blended granulation was filled in the hopper of a Manesty BetaPress or an 
instrumented Kikusui Libra press (Kikusui, Seisakusho Ltd., Kyoto, Japan). The tablet 
press was setup to compress sixteen or thirty six 7-mm (9/32") shallow convex tablets per 
revolution. The target tablet weight was adjusted to 135 mg, and tablets were produced 
using a pre-compression and main compression force of 300 kg and 1700-2000 kg, 
respectively, to produce a target tablet hardness of 8 kp for the entire batch. Compression 
and ejection forces were analyzed. Instrumentation was used to monitor the 
precompression, main compression and ejection forces as well as machine speeds (rpm) 
at the large scale. Precompression force was kept constant for all formulations during the 
manufacture. 
Table 4 shows equipment, batch sizes, and compression parameters for the 
controlled release tablet batches manufactured at two different scales for both 
formulations. Tablet samples were collected and stored in tightly sealed containers for 
subsequent physical characterization, assay and dissolution test. In-process and composite 
samples from the tableting runs were tested for weight, thickness, hardness and friability. 
Dissolution tests were conducted on compressed core tablets using USP apparatus 3, at 25 
strokes per minute using 250 ml of phosphate buffer (pH 7.4) at 37 ±0.5°C. 
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Table 4. Tabletin_g_ Parameters for Rotary Tablet Press 
Parameter Mane~ Kikusui 
Number of Stations 16 36 
Batch Size (kg) 13.5 135 
Tooling Type B B 
Tablet Punch Size 9/32" 9/32" 
Compression Force (kg) 
- 1700-2000 
Granule Feed FF' IDFb 
Tablets per minute (TPM) 480 2,160 
a -Forced feeder; b -Induced die feeder 
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2.5.1 Weight Variation 
The uniformity in weight of the compressed tablets were determined using the 
weight variation test procedure <905> specified in the United States Pharmacopoeia 
(USP 23} (13). For this test 30 tablets were randomly selected from the bulk sample for 
analysis . Ten of the selected tablets were individually weighed using a calibrated 
analytical balance (Sartorious Corp., Bohemia, NY) and the means and relative standard 
deviations calculated. USP acceptance criteria were applied in the evaluation of the 
results. 
2.5.2 Tablet Thickness and Hardness 
Thickness and hardness were measured individually by selecting 10 tablets 
randomly every fifteen minutes during tableting, using a Vector automatic tablet tester 
(Vector Corporation, Marion, IA). The crushing strength of 10 tablets from each batch 
was recorded in kilopounds (kp) and their means and percent relative standard deviations 
calculated. 
2. 5. 3 Friability 
The tablet friability, resistance to abrasion during handling and coating process, 
was measured using a Roche type friabilator (Erweka Instrument Corp., Milford, CT). 
Fifty tablets were randomly selected from the bulk sample for this test. The tablets were 
weighed and subjected to 100 rotations (25 rpm for 4 minutes) in the friabilator. The 
tablets were then removed from the friabilator, dusted and reweighed. Friability is 
reported as percent weight loss. 
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2. 6 Assay and Drug Release Testing: 
Blend uniformity, tablet content uniformity and assay was performed using a 
validated HPLC procedure. In-vitro drug release was studied in order to mimic in-vivo 
dissolution behavior. The media selected was a phosphate buffer pH 7.4 as recommended 
by USP 23 . The dissolution study was performed using apparatus 3 (Reciprocating 
cylinder, Bio-Dis) (13). The temperature of the dissolution medium was maintained at 37 
± 0.5°C in all the studies. 250 ml of dissolution media was used in each cylinder and the 
stroke speed was set to 20/minute, sink conditions were maintained. Multipoint 
dissolution profiles were performed over a period of 6 hours by collecting samples at 
specified intervals and assaying by HPLC to determine the amount of drug released. Six 
tablets were used for each dissolution run and the percent labeled strength of albuterol 
sulfate dissolved was determined. Dissolution profiles were compared graphically and 
through the use of mathematical fit factor (F2). The F2 metrics equation provides a 
method to accurately compare dissolution profiles. The F2 equation is expressed as (6): 
2. 6.1 High Performance Liquid Chromatography Assay 
An established HPLC assay method was used to test all samples (10). A reverse 
phase High Performance Liquid Chromatography (HPLC) assay was selected due to the 
advantage of direct analysis of aqueous samples, high sensitivity, and separation of 
excipients that would interfere in the assay (11 , 13). A reverse phase column, containing 
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packing LI (Whatman partisil I O-ODS-3, 4.6x250 mm, Cl 8, I 0 µm) in conjunction with 
a variable wave length UV detector was used. 
A number of mobile phase systems were tested. The one, that provided the best 
resolution, consisting of 70% methanol and glacial acetic acid in deionised degassed 
distilled water was chosen for the assay. The flow rate was 1.5 ml per minute, the UV 
detector set to 276 nm and the injection volume was 25 µl (using a WISP). A plot was 
obtained between peak area vs. concentration using standard solutions of albuterol sulfate 
for concentrations ranging from 0-20 µg/ml. The relationship thus obtained was linear 
(r2 > 0.9986) and used for determining the concentration of albuterol sulfate in the 
dissolution sample. 
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3.0 Results and Discussion 
3. 1 Granulation Properties: 
3. 1. 1 Flow Properties 
Table 5 summarizes the granule properties for the different batch sizes. The 
values of Carr index were below 22.2%, indicating a good consolidation characteristic 
(11). Some materials have a high Carr index suggesting poor flow and low 
compressibility (7,11,14). Granulations that produce values in the range of23% or below 
are considered to have fairly good compressibility characteristics (11 , 15). The measured 
angle of repose values for all the four batches ranged between 27-29° suggesting good 
flow characteristics that would enable uniform filling of granulation in the die cavities. 
Generally, flowability of blend is lower than excipient alone. A flow rate between 5-7 
grams per second for all the batch sizes indicates smooth flow characteristics for the 
granulations. As we know from the literature granules with good flow characteristics 
provide even flow for a granulation through the hopper and various sections of the tablet 
press thereby minimizing tablet weight variation (15). There was no significant difference 
in flow characteristics between, all four granulation blends independent of the batch size. 
3.1.2 Loss on Drying 
Malamataris et al . (16) and Malamatris and Karidas (17) reported in-depth 
characterization of the effects of moisture content on the compression properties of 
hydroxypropyl methylcellulose (HPMC) and on the mechanical properties of tablets 
prepared with HPMC as the base excipient. Mosquera et al. investigated the effects 
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Table 5. Summary of Granule Properties 
Batch LOO Bulk Tap Carr Flow Angle of 
Size (%) Density Density Index Rate Repose Blend Uniform&_ 
(kg) (g/cm3) (g/cm3) (%) (g/s) 
_@2_ Mean RSD 
IX-I 3.65 0.57 0.73 21.9 5 28° 101.3 1.7 
IX-II 3.58 0.56 0.71 21.1 6 27° 100.9 2.8 
!OX-I 3.71 0.55 0.74 21.7 6 29° 100.9 1.6 
!OX-II 3.88 0.56 0.72 22.2 7 27° 98.5 1.4 
46 
ofHPMC moisture content on drug release from HPMC-based tablet (18). These authors 
studied the moisture content over the range of 2.25%-10.85% and found no significant 
effects on drug release profile. Granulation blend samples from both formulations were 
dried over a range of temperature starting with 85- l 55°C to identify the optimum drying 
temperature for moisture determination (Figure 2). To determine the moisture content, the 
blend sample was heated to l l 5°C, and moisture losses were recorded by the internal 
balance and automatically reported as percent moisture content. Moisture content as a 
function of loss on drying determined for both formulations at the two different scales 
ranged from 3.58-3.88 % and are similar to the findings reported earlier (16,17,18). This 
indicates that the moisture levels in the granulation are similar among the blends and did 
not have any effect on the physical characteristics of the granulation or tablets. 
3.2 Blend Uniformity: 
Usually the blender capacity should be kept between 70-100% of the working 
volume for uniform mixing and to avoid any potential particle segregation (3, 19). The 
percent capacity utilization for each blend is presented in Table 6. These values were 
calculated using the bulk density measurements obtained from each blend. The percent 
capacity utilization was kept between 84-87% for both 1 ft3 and 1 Oft3 blenders, which is 
considered as the optimum fill volume for these blenders (20). In addition, the mixing 
time for a blend should be adjusted to maintain the same number of revolutions at each 
scale of manufacture. Blending time is critical in achieving uniform mixing and good 
content uniformity (21 ). 
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Table 6. Percent Capacity Utilization Data for I ft3 and I Oft3 V-Blender 
Batch Size (kg) Actual Load Bulle Density Capacity Mixing Time 
(Kg) ~m2_ Utilization ff~ l_min_l 
IX-I 13 .5 0.57 83.6 29 
IX-II 13 .5 0.56 85.l 29 
!OX-I 135 0.55 86.7 48 
lOX-II 135 0.56 85.1 48 
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Over blending may also affect drug release and other tablet properties such as tablet 
disintegration and dissolution (22) . The blending time for the small scale batch was 29 
minutes and the adjusted blend time based on rpm for the large scale batch was 48 
minutes; and was designed to produce a homogeneous blend of drug and excipients with 
uniform distribution of the drug within the blend. Homogeneity of the blend is 
determined by evaluating the individual assay results for samples taken from the various 
locations within the V-blender. The drug content uniformity results for the blend samples 
of both formulation show assay values in the range of 96.4-104.4% for the pilot scale 
batches and 96.6-102.9% for the scale-up batches respectively (Table 7). There was no 
significant difference in the drug content uniformity between the left and right arm of the 
V-shell. These results show the effectiveness of the blending process for both 
formulations in terms of the two blenders, batch size and blending time. The highest 
percent RSD value for the blend uniformity samples collected at multiple locations in the 
blender was found to be < 2.8%, indicating an excellent distribution of drug within the 
blend. Uniformly mixed blends produce uniformly compressed tablets that meet the USP 
content uniformity requirements. Based on this theory and due to low percent active in 
the blend (< 2%), combined with FDA recommendations for blend uniformity analysis 
for the products that require USP content uniformity, it was necessary to evaluate the 
drug content uniformity in the blend. Comparison of the blend uniformity assay values of 
the small scale and large scale blends show no statistically significant difference in the 
content uniformity assay values for formulation I (Table 18 Appendix I). Although 
formulation II showed a statistically significant difference in the blend uniformity for 
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Table 7. Blend Uniformity Results of Unit Dose Blend Samples from V-Blender 
Blend Sample# I I ft3 
Location Formulation I 
LI 101.0 
L2 104.4 
L3 101.5 
L4 98.5 
LS 101.9 
R6 101.4 
R7 102.4 
R8 101.7 
R9 98.5 
RIO 101.5 
Average 101.3 
Range 98.5-104.4 
RSD 1.7 
L- left arm ofV-blender 
R- right arm ofV-blender 
1 ft3 10 ft3 I 0 ft3 
Formulation II Formulation I Formulation II 
Assay% 
103.8 101.4 101.0 
102.8 98.0 99.1 
104.0 100.9 98.0 
101.6 102.0 99.1 
96.5 101.4 99.I 
96.4 102.9 99.4 
99.7 102.3 96.8 
101.8 IOI.I 97.0 
99.2 100.8 96.6 
103.l 98.0 98.7 
100.9 100.9 98.5 
96.4-104.0 98.0-102.9 96.6-101.0 
2.8 1.6 1.4 
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pilot and large scale the assay values for both the 1 ft3 and 10 ft3 blenders of both 
formulations are within the acceptable range of 90-110% with a RSD < 5% as stated in 
the FDA blend uniformity analysis guidance for the industry (23) . ANOV A comparison 
of the blend uniformity assay results of all four batchs shows a statistically significant 
difference between the means of the content uniformity assay values. The blend 
uniformity mean assay value for 1 Oft3 scale of formulation II was found to be 
significantly different when compared with the small scale batch using the multiple range 
test. A complete statistical comparison of these results is included in (Table 19-20 
Appendix I). Interestingly, the large scale blend has a smaller RSD compared to the small 
scale batches. 
3.3 Granule Size Distribution: 
The particle size of the ingredients used in a direct compression hydrophilic 
matrix formulation may have a significant impact on the performance and drug release 
characteristics (16, 17). Differences in the particle size distribution between different 
materials in the formulation may influence the packing behavior of the materials and 
hence influence the material performance during granulation and tableting (11,24). Also 
tablet characteristics such as weight variation may be affected by differences in particle 
size and density (25). With this in mind, it was decided to determine the particle size 
distribution of the drug and the excipient blend used in the formulation. 
The weight distribution of 5 g of granules was measured after 5 min of vibration 
over a nest of standard sieves (mesh size 325, 200, 150, 100, 80, 60). Table 8 shows the 
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Table 8. Weight Distribution of Granules for the Four Batches 
Mesh Size Percent Retained 
l_rnicro'!}_ IX-I !OX-I IX-II !OX-II 
60l_25Q2_ 6.2 6.0 4.0 6.0 
8o])8Ql 9.6 8.7 7.0 5.0 
100]_15QI 9.0 10.0 15.0 14.0 
15oj_lo6)~ 13.0 12.0 17.0 19.0 
2001_751 16.0 16.5 21.0 23.0 
3251_452_ 21.2 21.0 19.0 17.0 
Fines 27.0 26.0 17.0 15.0 
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sieve analysis results for all four batches. Figure 3 shows the particle size distribution 
histogram for the final blend at both scale for formulation I. About !"6 percent of the 
particles are in the range of 180 to 250 microns, 59 percent of the particles are in the 
range of 45 to 150 microns and 27 percent 5: 45 microns, this produces a fairly uniform 
blend. The particle size distribution for formulation II both scales (Figure 4) resembles an 
approximate bell shaped distribution. About 10 percent of the particles are in the range of 
180 to 250 microns, 70% in the range of 45 to 150 microns and 17 percent 5: 45 microns. 
There was no significant difference in particle size distribution between the small scale 
and large scale batches of both formulations. However, there was difference in particle 
size distribution between formulation I and II as expected due to the difference in 
excipient ratios between the two formulations . These results suggest that uniform mixing 
of the granulation have been achieved at both scales of blending. Studies show that 
excipients with angle of repose values < 30° and a particle size < 100 microns exhibit 
excellent flow characteristics (14, 26). Since the particle size of the blend was fairly 
uniform, this eliminates the potential problem of segregation of the excipients and an 
effective flow of granulation was achieved with direct scale-up and compression of the 
granulation. 
3.4 Tablet Properties: 
Tablets were compressed over a range of six hardness values between 5-10 kp for 
both the small scale and the large scale batches to study the effect of various tablet 
attributes such as weight, hardness, friability and drug release. After collecting samples in 
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each hardness range the compression force was increased to the next level of hardness 
and samples collected. Tablet cores were randomly selected from each batch/range to 
measure these physical characteristics. Friability is a term used to describe the resistance 
of tablets to mechanical wear as shown by breakage, chipping, and abrasion during 
coating, high speed packaging and transportation. The resistance of a tablet to a 
mechanical wear is dependent on its ratio of stress to strain, and tensile strength (27). In 
addition, since tbese tablets are to be coated to delay drug release; it is important that the 
tablets withstand tbe physical stress encountered during the coating process (24, 27, 28). 
Since reliable methods of measuring the tensile strength of a tablet have not been 
developed, hardness (force applied in kilopounds (kp) required to break the tablets) is 
used as a measure of compressive tensile strength. To study the effect of compression 
force on the tablet hardness, tablets were compressed at various preset compression forces 
as described above. Tablet hardness increased as the compression force was increased 
showing an almost linear relationship for botb formulations (Figure 5). A minimum 
hardness of 5.5 kp and 6 kp was required to form tablets that required a compression 
force of 500 kg for formulation I and 11 respectively. The highest compression force tested 
was 2000 kg that produced tablets of l 0 kp hardness for formulation I and 9.5 kp for 
fonnulation II. To determine physical characteristics of the tablets, ten tablets from six 
levels of hardness (5-10 kp) were tested for weight, thickness, hardness and friability. 
The tablets produced using the Manesty BetaPress at small scale for botb formulations at 
various target hardnesses were close to the theoretical hardness witb minimal weight 
variation across tbe hardness range studied (Table 9 and 10). Tablets produced at lower 
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Table 9. Effect of Tablet Hardness on Physical Characteristics Using the Manesty BetaPress 
Batch size IX-I 
Tests Tablet Press Speed 25 RPM (400 TPM) 
Target Hardness 
(kp) 5. 6 7 8 9 
Hardness (kp) 4.9 6.3 7.2 8.2 9.1 
Range 4.3-5.2 5.7-6.4 6.8-7.1 8.0-8.7 9.0-9.9 
%RSD 4.2 3.8 3.1 2.9 3.5 
Weight (mg) 135.1 136.3 13 5.0 136.0 137 
Range 135.0-137.5 135.5-138.5 133.5-137.7 136.0-138.0 136.0-139.0 
%RSD 0.5 0.4 0.6 0.5 0.7 
Thickness (inches) 0.141 0.138 0.138 0.138 0.137 
Range 0.140-0.141 0.138-0.140 0.137-0.138 0.137-0.139 0.136-0.138 
%RSD 0.16 0.37 0.29 0.39 0.28 
Friability 
(%) O.Q3 0.02 0.01 0 0 
10 
9.9 
8.9-10.0 
3.2 
137.0 
134.0-138.0 
0.4 
0.136 
0.135-0.1 37 
0.19 
0 
"' 0 
Table I 0. Effect of Tablet Hardness on Physical Characteristics Using the Manesty BetaPress 
Batch size 1 X-II 
Tests Tablet Press Speed 25 RPM (400 TPM) 
Target Hardness 
(kp) 5 6 7 8 9 
Hardness (kp) 4.8 6.1 6.9 8.4 8.9 
Range 4.4-5.2 5.8-6.5 6.3-7.3 8.0-8.9 9.0-10.0 
% RSD 5.2 3.6 3.0 3.2 3.0 
Weight (mg) 136.1 137.3 135.0 138.0 138 
Range 135.0- 136.7 136.5-138.5 133.0-137.0 136.0-139.0 136.0- 140.0 
%RSD 0.5 0.5 0.9 0.6 0.7 
Thickness (inches) 0.141 0.140 0.138 0.138 0. 137 
Range 0.1 40-0 .1 41 0.1 39-0.140 0.137-0.139 0.137-0.1 39 0.136-0.1 38 
%RSD 0.17 0.36 0.28 0.41 0.47 
Friability 
(%) 0.03 0.01 0 0 0 
10 
IO. I 
8.9-10.2 
3.2 
136.0 
134.0-138 .0 
0.8 
0.136 
0.135-0.137 
0.38 
0 
hardness 5 kp showed a larger variation in measured hardness, percent RSD values were 
4.2 and 5.2 compared with 3.0 and 2.9 for the tablets set with higher hardnesses (8, 9 & 
10 kp) for formulation I and II respectively. Tablet thickness was comparable between 
formulat ions and was influenced by the fill weight. Higher fill weight gave a thicker 
tablet and the lower fill weight produced thinner tablets. 
Tablets produced at lower hardnesses were found to be friable for both 
formulations. This can be attributed to the softness of the tablet cores at lower 
compression force. However, the overall friability of these tablets across all hardnesses 
was less than 0.03%, which signifies that they should withstand the physical stress 
applied during coating process. Tablets produced using the Kikusui Libra press at large 
scale for both formulations at various compression forces produced tablets with a 
hardness closer to the theoretical hardness than was seen at the smal ler scale (Table 11 
and 12). A constant press speed of 60 rpm was selected for these hardness studies. 
Tablets produced at lower hardness at 5 kp exhibited larger RSD values compared with 
the tablets produced using compression forces in the range of hardnesses of 6-10 kp, 
indicating a better consolidation at higher compression force. Weight variation was 
minimal for both formulations at small and large scale suggesting that the granulation 
flow characteristics were uniform and is not affected by the type of feeder. This indicates 
that the formulation properties did not have any negative impact on the tablet physical 
characteristics. 
A statistical evaluation {ANOV A) was performed to determine the statistical 
significance of the variability in measured average hardness values for both formulations 
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Table 11 . Effect of Tablet Hardness on Physical Characteristics Using the Kikusui Libra Press 
Batch size I OX-I 
Tests Tablet Press Speed 60 RPM (2160 TPM) 
Target Hardness 
(kp) 5 6 7 8 9 
Hardness (kp) 4.8 6.1 6.9 8.4 8.9 
Range 4.3-5.4 5.8-6.4 6.3-7.4 8.1 -8.8 9.0-10.0 
%RSD 5.1 3.0 2.8 3.0 2.7 
Weight (mg) 136.1 137.3 135.0 136.5 138.0 
Range 134.9-137.4 136.7-139.3 133.5-137.2 136.3-138.8 137.2-140.3 
%RSD 0.5 0.5 0.9 0.6 0.7 
Thickness (inches) 0.141 0.1 40 0.138 0.138 0.137 
Range 0.140-0 .1 41 0.1 39-0.1 40 0.137-0.139 0.137-0 .1 39 0.136-0.138 
%RSD 0.28 0.27 0.28 0.39 0.37 
Friability 
(%) 0.02 0.02 0 0 0 
10 
IO. I 
9.3-10.3 
2.6 
136.0 
134.2-138.1 
0.8 
0.136 
0.135-0.137 
0.38 
0 
"' w 
Table 12. Effect of Tablet Hardness on Physical Characteristics Using the Kikusui Libra Press 
Batch size !OX-II 
Tests Tablet Press Speed 60 RPM (2160 TPM) 
Target Hardness 
(kp) 5 6 7 8 9 
Hardness (kp) 5.1 6.2 7.1 8.4 9. 1 
Range 4.6-5.3 5.8-6.3 6.7-7.3 8.0-8.7 9.0-10.0 
%RSD 4.2 3.2 2.6 2.2 3.1 
Weight (mg) 135.1 136.3 135.2 135.3 136.1 
Range 135.0-136.1 136.2-138.5 133.0-138.0 133.0-137.0 136.1-139.0 
%RSD 0.4 0.9 I. I 1.0 0.7 
Thickness (inches) 0. 141 0.137 0.136 0.136 0.136 
Range 0.140-0.141 0.139-0 .1 40 0.1 34-0. 137 0.133-0.137 0.134-0.1 37 
%RSD 0.16 0.63 0.82 0.92 0.49 
Friability 
(%) 0.02 0.01 0.01 0 0 
10 
10.2 
8.9-10.3 
2.9 
135.4 
134.0-137.5 
0.8 
0.1 36 
0.135-0.137 
0.39 
0 
at both scales of manufacture. Among the comparisons made for 5-10 kp, there was no 
significant difference between average hardness was observed for 6-l 0 kp. However, 
there was a significant difference (P=O.O 183) in average hardness was observed at 5 kp 
hardness, suggesting that at lower compression force, the consolidation of granulation is 
not uniform between tablets. A complete statistical analysis result is presented in (Table 
21-26) Appendix I. Furthermore, comparison of weight, thickness and friability results for 
both formulations manufactured using two different tablet presses show similar results 
suggesting that there is no difference between small and large scale batches/presses. 
3.4.1 Drug Content Uniformity 
Homogeneity is confirmed by the results of the unit dose assay values and relatively 
small RSD values. FDA recommends blend uniformity analysis for the products that 
require content uniformity analysis (23). USP requires this test when the drug product 
contains less than 50 mmigrams of the active ingredient per dosage form unit, or when 
the active ingredient is less than 50 percent of the dosage form unit by weight. Blend 
uniformity analysis or homogeneity testing can be applied to all dosage forms, but is 
recommended for those dosage forms for which the USP requires content uniformity 
testing. For tllls reason the content uniformity of the blend samples and the tablets 
produced with the corresponding blend was evaluated to see if there was a difference 
between assay/RSD for tablets and blend samples at various scales. 
Table 13 compares the blend and tablet content uniformity results for small and 
large scale batches. It can be seen from these results that all the individual assay values 
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Tablet Press 
Batch Size 
Stage 
!Assay(%) 
Range 
RSD (%) 
Blend 
101.3 
98.5-104.4 
1.7 
Table 13 . Content Uniformity Results for Blend and Tablet Cores 
Manesty BetaPress Kikusui Libra Press 
IX-I IX-II IOX- 1 I OX-II 
Tablet Blend Tablet Blend Tablet Blend Tablet 
100.7 100.9 100.6 100.9 99.1 98.5 99.8 
98.9-102.7 96.4-104.0 97.1-105.4 98.0-102.9 97.3-100.6 96.6-101.0 98.5-102.1 
1.3 2.8 2.7 1.6 I.I 1.4 1.2 
for the blend samples are within 96.6-104.4%, and the highest RSD value observed was 
2.8% for formulation [] at the small scale. The RSD values decreased as the batch size 
increased for both formulations. Furthermore, it can be seen that all the individual assay 
values for the corresponding tablet samples are within 97.1-105.4%, and the highest RSD 
value observed was 2.7% for formulation II at the small scale. Thus all pass USP 
requirements for solid dosage form content uniformity. The RSD values decreased as the 
batch size increased for both formulations. A statistical analysis using multiple sample 
comparison was performed to evaluate the difference between the blend and tablet 
content uniformity values. The analysis showed that there was no statistically significant 
difference between the content uniformity assay values of the blend sample and the 
corresponding tablet cores at the 5% level (ANOV A test results are presented in Table 
27-30 Appendix I). The content uniformity values of the blend samples are reproducible 
in the corresponding tablet cores. These results suggest that a good homogeneity of the 
drug in the granulation have been achieved at both scales and is not affected by the 
additional handling and mixing during compression for both formulations. 
3.4.2 Drug Release 
In order to select a suitable tableting parameter, the effect of tablet hardness on 
drug release was also evaluated. Effect of tablet hardness on drug release is presented in 
Figure 6 and 7 for formulation I at two different scales. The dissolution profiles show a 
100% drug release in 3 hours at all hardness ranges studied. Higher variability in drug 
release was observed at the 1 hour time point. The variability in drug release at early time 
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Figure 6. Effect of Tablet Hardness on Albuterol Sulfate Release for 
Batch Size IX-I (Manesty BetaPress) 
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Figure 7. Effect of Tablet Hardness on Albuterol Sulfate Release for 
Batch Size I OX-I (Kikusui Libra Press) 
68 
point was larger (RSD = 6%) for both scales. This variability may be attributed to the 
difference in time of hydration and diffusion of the drug from tbe tablet matrix for tbe 
different hardness levels produced during manufacture. However, less variability (RSD < 
2%) was observed at the later time points indicating tbat once the hydration is complete 
drug release is consistent between tablets. Furthermore, the time required for 50% and 
75% drug release was deternlined for all hardnesses and a statistical evaluation was 
performed to deternline if tbere were differences in dissolution time. The analysis of 
variance results for these comparisons did not show any statistically significant difference 
in time required for 50% and 75% drug release. Figure 8 and 9 show the effect of tablet 
hardness on drug release for formulation II at the two different scales. Again higher 
variability in drug release was observed at the I hour time point. However, a lower 
variability in dissolution was observed at the later time points indicating drug release is 
consistent after complete hydration of the tablets. In addition, tbe time required for 50% 
and 75% drug release was determined for all hardnesses and a statistical comparison of 
these results show no difference in time required for 50% and 75% drug release 
(Complete ANOV A results for these comparisons are included in Table 31-34 Appendix 
I). It can be seen from tbese results that there is no significant difference between the 
mean drug release obtained for various tablet hardness for formulation II manufactured 
using two different tablet presses. 
Differences between tablet presses that result in different compression levels may 
have an effect on the final characteristics such as tablet hardness, disintegration and 
dissolution (3,7,29). Such problems may arise with materials tbat undergo time-
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Figure 8. Effect of Tablet Hardness on Albuterol Sulfate Release for 
Batch Size IX-II (Manesty BetaPress) 
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Figure 9. Effect of Tablet Hardness on Albuterol Sulfate Release for 
Batch Size lOX-II (Kikusui Libra Press) 
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dependent stress relaxation due to differences in dwell time related to variations in tablet 
press speed (7,30). In order to evaluate this behavior, the effect of tablet press speed with 
constant compression force that yielded tablets of 8 kp hardness was manufactured using 
the Kikusui Libra tablet press. Four different press speeds (40-70 rpm) were evaluated in 
an attempt to study the various tablet attributes and drug release for both formulations at 
the larger scale (Table 14 and 15). Since, it was not possible to adjust the press speed on 
the available Manesty betapress, the effect of tablet press speed on the tablet attributes 
was not evaluated at the pilot scale level for both formulations. For both formulations at 
the large scale, the speed of compaction had little effect on the tablet physical 
characteristics. The effect of compaction speed on the tablet hardness seemed to 
marginally increase with constant applied force. Average hardness ranged from 8.1-8.7 
kp for various press speeds. This phenomenon was observed in both formulations. 
Although the hardness increased with increased press speed, it was not significant to 
impact the tablet physical characteristics. This is further evidenced by the fact that there 
was very small difference in the tablet weight and no difference in tablet thickness with 
the various press speeds. The tablet friability was not significantly affected by the press 
speed and the maximum value observed was < 0.04% for formulation I at 40 rpm. 
Furthermore, the mean dissolution values for tablets manufactured at various 
compression speeds also suggest that the drug release was not affected by varying the 
press speed. It can be seen from Figure l 0 approximately 50% of the drug is released in 
the first hour with minimal variability between various samples. The variability in drug 
release is also minimal across all the samples tested for formulation I at various 
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Table 14. Summary of Tablet Press Speed Study Results (Tablet Hardness 8 kp) 
Batch Size 1 OX-I (Kikusui Libra Press) 
Tests Tablet Press Speed RPM 
40 50 60 
Hardness (kp) 8.1 8.4 8.5 
Range 7.7-9.0 8.2-8.7 8.2-9.0 
%RSD 4.0 2.0 2.6 
Weight(mg) 135.0 135.0 136.0 
Range 134.0-137.0 133.0-137.0 135.0- 138.0 
%RSD 0.63 0.68 0.72 
Thickness (inches) 0.137 0.137 0.137 
Range 0.137-0.138 0.137-0.138 0.136-0.138 
%RSD 0.30 0.32 0.40 
Friabili!i{PercenQ 0.04 0.01 0 
70 
8.6 
8.0-9.1 
3.4 
136.0 
134.0-138.0 
0.74 
0.137 
0.135-0. 138 
0.42 
0.02 
-.J 
... 
Table 15. Summary of Tablet Press Speed Study Results (Tablet Hardness 8 kp) 
Batch Size !OX-II (Kikusui Libra Press) 
Tests Tablet Press Speed RPM 
40 50 60 70 
Hardness (kp) 8.1 7.8 8.4 8.7 
Range 6.7-7.3 6.0-7.4 8.0-8.7 6.7-9.5 
%RSD 2.6 3.6 2.2 3.6 
Weight(mg) 134.6 135.3 135.8 135.2 
Range 133.5-136.0 134.0-138.0 133.0-137.0 133.0-137.0 
% RSD 0.53 0.79 I.OJ 0.76 
Thickness (inches) 0.137 0.136 0.136 0.136 
Range 0.137-0.138 0.134-0.137 0.133-0.137 0.134- 0.137 
%RSD 0.46 0.47 0.92 0.68 
Friabil~ercen!l: 0.02 0.01 0 0 
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Figure 10. Effect of Tablet Press Speed on Dissolution for 
Batch Size !OX-I (Kikusui Libra Press) 
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compaction speeds. Figure 11 depicts the dissolution profile for tablets manufactured at 
various press speeds at a constant compression force for formulation II, the dissolution 
profiles are similar suggesting that increased press speed did not have an effect on drug 
release. The variability in drug release at the early time points are large, approximately 
40% of the drug release is observed at the second hour. However, the variability reduces 
as the dissolution time progresses and I 00% drug release is observed at 5 hours as 
expected. Thus we can conclude from these results that both formulations are not 
sensitive to the dwell time which is invariably affected by the compression speed (30). 
Furthermore, the dissolution profiles for the two different formulations are not similar as 
the objective of the research with development of a fast and slow release controlled 
release tablets. Figure 12 compares the dissolution profile for both fast and slow release 
formulations. It can be seen from these results that the two formulations exhibit distinct 
dissolution profile. The formulation I that used low viscosity polymer and high 
concentration of starch released the drug faster as expected and formulation II used a high 
viscosity polymer produced a slow drug release extended up to six hours. Table 16 
summarizes the tablet properties of all formulations manufactured at two different scales. 
The average weight of the tablets manufactured for all batches were acceptable and close 
to the theoretical weight of 135 mg. Average tablet hardness for the batches ranged from 
8.0-8.3 kp indicating that a compression speed of 60 rpm is optimal for the large scale 
manufacture. A friability value of < 0.1 % weight loss was observed for all formulations at 
both scales of manufacture. 
Assay and content uniformity results for all batches manufactured met USP 
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Figure 11. Effect of Tablet Press Speed on Dissolution for 
Batch Size I OX-II (Kikusui Libra Press) 
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Figure 12. Dissolution Profile for Controlled Release Tablets 
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Table 16. Summary of Tablet Properties 
Batch Thickness Hardness Friability Assay Content RSD F2 
Size (in.) (kp) (%) (%) Uniformity (%) 
_fl~ 
IX-I 0.138 8.1 0.1 99.8 100.7 1.3 94.0 
IX-II 0.137 8.2 0.0 100.3 100.6 2.7 83.6 
!OX-I 0.138 8.0 0.0 100.1 99.1 1.1 94.0 
!OX-II 0.138 8.3 0.0 100.2 99.8 1.2 83.6 
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specifications of (90-110%) for assay and content uniformity (90-110% and RSD < 6%) 
for solid dosage forms. The drug content uniformity of the tablets at both scales was 
acceptable with a smaller RSD value. (Table 16). Furthermore, the controlled release 
tablets manufactured for both formulations at different scales showed nearly 
superimposable dissolution characteristics (Figure 13 and 14). 
Dissolution profiles were compared graphically and through the mathematical fit 
factor (F2). The fit factor F2 is 100 when the test and reference profiles are identical and 
approaches 0 as the dissimilarity increases (31 ). The pair-wise comparisons of the 
dissolution results for two different scales of these formulations evaluated using F2 
metrics show a value of 94 and 83.6 for formulation I and II respectively. An F2 value of 
50 or greater indicates that dissolution profiles are similar according to the F2 metrics 
established by SUP AC guidelines (6,31 ). F2 analysis results for these comparisons are 
included in Table 35-36 Appendix I. In addition, the batches manufactured at two 
different scales were stored in HDPE bottles and showed no change in assay or 
dissolution profiles when stored at controlled room temperature (20-25°C) for 3 months 
(Figure. 15-17). 
Based on the evaluation of various compression study results, final tableting 
parameters were selected for the manufacture of the controlled release tablets cores. The 
tableting parameter that produced robust tablets with low friability, minimal weight 
variation and hardness was selected as the final compression parameter for manufacturing 
the controlled release tablets. Table 17 summarizes the optimum tableting parameters 
selected for the tablet manufacture. The press speed selected was 25 rpm for the Manesty 
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Figure 13. Effect of Scale-up and Type of Tablet Press on Drug Release 
Formulation I 
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Figure 14. Effect of Scale-up and Type of Tablet Press on Drug Release 
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Figure 15. Dissolution Profile for Controlled Release Tablets 
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Figure 16. Dissolution Profile for Controlled Release Tablets 
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Figure 17. Controlled Release Tablet Assay 
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Table 17. Optimized Tableting Parameters 
Tablet Press Speed Fill Weight Hardness Friability 
% 
BetaPress 25 8 <0.5 
Small scale 
Kikusui Libra 60 135 8 1700-2000 <0.5 
Lar e scale 
86 
BetaPress for the small scale and 60 rpm for the Kikusui Libra press for the large scale 
production. The tablet weight 135 mg and 8 kp hardness was selected for both 
formulation I and II . Tablets thus produced using the established tableting parameters 
were used for further development and coating studies. 
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4.0 Summary and Conclusions 
Over or inadequate mixing of granulation could potentially lead to segregation of 
particles and would result in non-homogenous blend. This may result in non uniformity 
of the drug substance in the dosage form and variability in the drug release. The blending 
equipment used for both small and large scale was geometrically similar. The most 
important factors that should be considered in scaling-up of the granulation process 
include adjustment of the blending time and head space to blender capacity based on the 
size of the blenders used at various stages of scale-up to maintain constant blending 
geometry and equivalent mixing. The batches manufactured at different scales exhibited 
similar granulation properties for the two formulations studied. 
Tableting scale-up is principally different from that of mixing because there is no 
dimensional changes as the batch volume is increased due to process replication at higher 
speeds. Although selecting an appropriate compression force to obtain the desired 
hardness is critical in obtaining reproducible drug release characteristics. Our studies 
show that varying tablet hardness for both formulations did not influence drug release. 
The tablets produced using two different tablet presses for a range of speeds exhibited 
similar tablet characteristics and dissolution profiles. The statistical evaluation of the 
dissolution results indicate that there is no statistically significant difference between the 
mean drug release at the 5% level for two different batch sizes. 
Furthermore, for both the scales of manufacture, all the pair-wise comparisons of 
the mean dissolution results for both formulations were equivalent based on SUP AC F2 
criteria. These findings indicate, appropriate in-process controls and the use of scaling 
88 
factors are essential for successful scale-up. Results also suggest that a direct scale-up of 
the controlled release tablet formulation with a mechanical robustness is possible from 
the pilot to the production scale. The proposed characterization technique gives an insight 
into the equipment capabilities and thus is suggested for use in scale-up of direct 
compression granulation and tableting processes. 
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MANUSCRIPT II 
DEVELOPMENT OF IMMEDIATE RELEASE DOSE FOR A 
PULSED-RELEASE TABLET 
PART I 
SEAL COAT DEVELOPMENT 
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ABSTRACT 
Acid polymers can be applied to solid dosage forms as enteric coatings from 
aqueous solutions of alkali salts, organic solvent solutions, or pseudolatex dispersions. 
Because of their insolubility in water, enteric resins historically have been applied using 
alcohol and other organic solvents. Current interest in enteric material focuses on water-
insoluble resins that contain free carboxylic acid groups. These groups ionize at pH 
values higher than five and solubilize the resins, thereby releasing the drug from the core. 
The coatings from these resins resist water and gastric fluid but begin to dissolve in the 
intestine at pH 5-8. 
This investigation was under taken to study the effect of various levels of polymer 
coating, identify the optimum polymer coating required to delay the drug release of the 
second dose from the matrix core for a period of 3 to 4 hours. Evaluate in-vitro drug 
release characteristics of a coated tablet under conditions that mimic the in-vivo 
dissolution behavior. Various levels of polymer coating were evaluated and an optimum 
concentration that results in adequate seal coating and delayed release was determined. 
The formulation developed during pilot studies was scaled-up to a production size batch. 
Various physical characteristics of the coated and uncoated tablets were evaluated as 
specified in the USP 23. 
Two different types of Eudragit® polymers were used to coat controlled release 
core tablets containing 2 mg of albuterol by spraying from aqueous coating systems. 
Initially an Accela-Cota perforated coating pan was used to coat an aqueous polymer 
latex dispersion to retard the drug release from tablet cores for a period of 3-4 hours . 
. These tablets were further coated with a mixture of polymer and drug to deliver 2 mg of 
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albuterol as immediate release. Scale-up coating parameters were determined for seal 
coating process. 
A High Performance Liquid Chromatography assay method was used to determine 
drug release from dissolution samples. Dissolution testing was performed using USP 
apparatus 3 (Reciprocating cylinder). Drug release obtained from botb formulations at 
two different scales showed differences in the release characteristics. The in-vitro 
dissolution data shows that the drug release can be delayed by the application of tbe 
Eudragit® S and Eudragit® L 30 D-55 polymers at a level of 4.7 mg/cm2 and 5.6mg/cm2 
respectively. The results also demonstrate that Eudragit® S I 00 and Eudragit® L 30 D-55 
polymers can be successfully used in an aqueous system to obtain a delayed release effect. 
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1.0 Introduction 
Frequently, a marginally delayed release of the active drug is sufficient enough to 
avoid plasma concentration peaks. In this way it is possible to improve compatibility 
without significantly delaying the therapeutic effect. A more substantial influence on 
pharmacokinetics is required where the active drug (such as albuterol sulfate) has a short 
half-life of two to tluee hours and is administered two to three times daily. In such cases a 
therapeutically effective blood level can be achieved by rapid release of an initial dose 
that is then followed by delayed release of the second dose. Active drug with uniform 
solubility over the entire pH range of the digestive tract, or at least in the predominant 
range from approximately pH 5 to 7, can be provided with delayed-release coatings of pH 
dependent and independent permeability coatings. This is achieved by mixing or 
combining water-insoluble permeable coating agents with enteric polymers containing 
carboxyl groups that dissolve between pH 5 and 7 (I). 
Shellac is a naturally occurring resin that is processed from the secretion of the 
beetle Kerria /acca. Historically shellac was the material of choice for enteric coating (2). 
Despite the advantage that shellac films are considerably less permeable to water than 
films made from organic polymers, the pharmaceutical use of shellac as an adjuvant has 
greatly declined (3). Due to imperfect charge quality, which is more dependent on the 
method of refinement than the insect strain or host tree. Zein is another naturally 
occurring material that is an alcohol-soluble protein extracted from corn gluten that can 
be dissolved in arnmoniated water to produce a coating system. Zein is an extremely 
versatile polymer for applications involving controlled release, taste masking, enteric and 
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delayed release coating ( 4). Unfortunately due to its natural origin this material suffers 
from the above-mentioned disadvantage (2,3). 
Today, aqueous coating of enteric material is experiencing the type of success that 
film coating had nearly two decades ago. Acrylic copolymers are probably the fastest-
growing type of enteric system to replace naturally occurring materials. Two of the most 
useful polymers in this category are Eudragit® L 30 D-55, a copolymer of methacrylic 
acid and ethyl acrylate, is a 30% solid in emulsion and Eudragit® S I 00, a copolymer of 
methacrylic acid and methyl methacrylate (2) . These polymers will be evaluated in this 
study to evaluate their efficacy in producing delayed release seal coating of core tablets. 
Various types of coating pans are used for pharmaceutical coating. However, 
perforated pans are the equipment of choice when it comes to tablet coating, simply 
because of the efficiency and the economic advantage. These coating pans are available in 
various sizes and spray gun configurations. The number of spray guns employed depends 
on the size of the coating pan, small coating pans use one or two guns, larger pans use 
three to four guns. In larger coating pans, it is often beneficial to increase the number of 
spray guns to obtain broad area coverage and uniform spray patterns and droplet size. 
Variation in the size of the coating pan could lead to problems such as overwetting, 
sticking, picking and peeling due to inappropriate spray rates (5) . 
The goal of the present study is to systematically evaluate the relevant 
processing parameters of both a pilot scale (24") and a production scale (48") coating pan. 
These investigations include the evaluation of coated tablet characteristics of two 
different releasing formulations, fast and slow release, at small scale and production 
scale. The parameter to be evaluated includes the effect of polymer coating level, the 
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delayed release effect, coating uniformity and dissolution profiles of the coated tablets 
manufactured at two different scales. 
2.0 Objective 
The objective of the present study was to develop a seal coat for a controlled 
release matrix tablet in an attempt to retard drug release for a period of two to three hours 
followed by controlled release for a period of three to six hours in a near zero-order 
fashion . To identify the scale-up parameters, characterize and compare the coated tablet 
attributes, such as effect of polymer level, coating uniformity and dissolution profiles of 
the formulations manufactured at two different scales (pilot and production scale). 
3.0 Methods 
3.1 Materials: 
Albuterol Sulfate, USP (Propharmaco, Nobel Industries, Italy) ; Starch 1500, NF 
(Colorcon, West Point, PA); Lactose DT (Quest International, Hoffman Estates, IL); 
Methocel® (Dow Chemical Company, Midland, Ml); Magnesium Stearate, NF 
(Manllinckrot Inc. , St. Louis, MO); Colloidal Silicon dioxide (Division Chemical, 
Baltimore, MD); Talc, USP (Amenda Drug and Chemical Co., Irvington, NJ); Opadry® II 
White (Colorcon, West Point, PA); Eudragit® S 100, Eudragit® L 30 D-55 (Rohm 
Pharma, GmBH, Germany); Ammonium Hydroxide, NF (Morflex Inc., Greensboro, NC); 
Triethylcitrate, NF (Morflex Inc., Greensboro, NC). All raw materials used complied with 
the current USP/NF grade specifications. 
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3.2 Equipment: 
1 and 10 ft3 V-Blender, (Gemco, Middlesex, NJ); Sieve Shaker (Sweco, Florance, 
KY); Micron Air Jet Sieve (Hosokawa Micron Powder Systems, Summit, NJ); Moisture 
Analyzer, Computrac Max 50 (Arizona Instrument, Tempe, AZ); Tablet Press Model: 
Beta (Manesty, Liverpool, England); Tablet Press, Kikusui Model: Libra 836 KRCZ 
(Kikusui, Seisakusho Ltd., Kyoto, Japan); SMI Force Monitoring System (SMI Inc., 
Pittstown, NJ); Vector Tablet Hardness Tester (Vector Corp., Marion, IA); Friability 
Tester (Erweka Instrument Corp. , Milford, CT); Tap Density Apparatus (J. Engelsmann 
A. G., Laudwishfen, GmbH, Germany); Tooling 9/32" (Natoli ,Engineering Co. , 
Chesterfield, MO); High Speed Disperser, Model: 89 (Premier Mill Corp., Reading, PA); 
Laser Diffraction Particle Size Analyzer, Mastersizer 2000 (Malvern Instruments, 
Southborough, MA); Peristaltic Pump, Masterflex Model: 7520-10 (Cole Parmer, 
Chicago, IL); pH meter, Model: 811 (Orion Research Inc., Cambridge, MA); Accela-Cota 
24" and 48" (Thomas Engineering, Hoffman Estates, IL); Bio-Dis Tester (Vanke! 
Industries Inc. , Edison, NJ); Shirnadzu LC-4A, High Performance Liquid 
Chromatography (HPLC) Equipped with a Shimadzu SPD-2AS spectrophotometer 
detector (Shimadzu, Japan). 
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3.3 Core Tablet Formulation: 
Table I shows typical albuterol sulfate controlled release core tablet formulations 
that provide fast release (Formulation I) 3 hours and slow release (Formulation II) 6 hours 
respectively. Drug release was designed to be controlled by a combination of a diffusion 
and erosion mechanism from the matrix core tablets. This was achieved by inclusion of 
one of the low or high viscosity hydroxypropyl methylcellulose polymer, along with the 
selection of an appropriate ratio of soluble to insoluble filler excipients. Formulation, 
components, process and processing variables were chosen based on the results of an 
earlier study (5). 
3.4 Manufacturing Procedure: 
Controlled release albuterol sulfate tablets were prepared by blending the drug, 
polymer and filler excipients in a specified order using either a I ft3 or I 0 f3V-blender. 
These blends were compressed using a Kikusui Libra tablet press with 9/32" standard 
concave tooling. The fill volume in the lower punch of the tablet machine was adjusted to 
a theoretical weight of 135 mg and the compression force was adjusted to obtain a tablet 
hardness in the range of 7-8 kilopounds. Table 2 shows tableting parameters for 
controlled release tablet batches. Figure l shows the manufacturing process flow diagram 
used in the manufacture of albuterol sulfate controlled release core tablets. 
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Table 1. Tablet Fonnulation for AJbuterol Sulfate Controlled Release Tablet Cores 
Ingredient Fonnulation I Fonnulation II 
Percent w/w m~ablet Percent w/w m:i/iablet 
Albuterol Sulfate, USP 1.78 2.40 1.78 2.40 
Methocel® (Kl OOL V) 25 .04 33.80 - -
Methocel® (Kl5 M) - - 24.00 32.40 
Pregelatinized Starch, NF 25.04 33.80 10.00 13.50 
Spray Dried Lactose, NF 46.66 63.00 62.74 84.70 
Colloidal silicon dioxide, NF 0.74 1.00 0.74 1.00 
M~esium Stearate, NF 0.74 1.00 0.74 1.00 
Total 100.00 135.00 100.00 135.00 
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b Ta le 2. Tableting Parameters for A Rotary Tablet Press 
Parameter Condition 
Number of Stations 36 
Batch Size (kg) 135 
Tooling Type B 
Tool Size 9/32" 
Compression Force (kg) 1200 
Granule Feed IDF' 
Tablets per minute (TPM) 2160 
' Induced die feeder 
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Figure I. Process Flow Diagram for Albuterol Sulfate Controlled Release Tablets. 
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3.4.1 Granulation Manufacture 
The dry granulation excipients, lactose, Starch 1500 (pregelatinized starch), 
Methocel® (hydroxypropyl methylcellulose) K 100 LV or K 15 M were deagglomerated 
using a Sweco sieve shaker. The screened materials were then placed in either a 1 ft3 or a 
I 0 ft3 V-blender in the following order. Lactose, albuterol sulfate, pregelatinized starch 
and hyroxypropyl methylcellulose. These excipients were mixed for a (27minutes for 1 ft3 
and 45 minutes for 10 ft\ Final blending of the granulation was completed by adding 
colloidal silicon dioxide and magnesium stearate (#30 mesh) and mix.ing for 2-3 minutes. 
The dry granules were then removed from the blender and stored for analysis and 
subsequent compression into tablets. 
3.4.2 Sustained Release Matrix Core Tablet Manufacture 
The manufactured granulation was filled in to the hopper of a Manesty BetaPress 
or an instrumented K.ikusui press. The tablet press was setup to compress sixteen or thirty 
six 7-mm shallow convex tablets per revolution. The target tablet weight was adjusted to 
135 mg, and tablets were produced using a pre-compression and main compression force 
of 300 kg and 1500 kg respectively to produce a target tablet hardness of 8 kp for the 
entire batch. Tablet samples were collected and stored in tightly sealed containers for 
subsequent physical characterization such as weight variation, thickness, hardness and 
friability. Assay and dissolution studies were also performed. The uniformity in weight of 
the compressed tablets were determined using the weight variation test procedure <905> 
specified in the United States Pharmacopoeia (USP 23). In-process and composite 
samples of the core tablets were tested for weight variation, thickness, hardness and 
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friability. Dissolution testing was conducted on compressed core tablets using an USP 
apparatus 3, at 25 strokes per minute using 200 ml of simulated intestinal fluid TS. 
3.5 Tablet Coating: 
3.5.1 Delayed Release Coating Suspension Preparation 
Eudragit® S I 00 and Eudragit® L 30 D-55 have different film forming properties, 
and require a certain degree of neutralization for aqueous coating. The recommended 
neutralization, level for Eudragit® S JOO (with IM NH.iOH) is 15% (mole) (6). Eudragit 
s® I 00 powder was dispersed in purified water; to this dispersion a liquid ammonia 
solution was added and mixed for a predetermined time. Triethyl citrate was added to this 
mixture and mixed for additional time. Talc was dispersed separately in purified water 
using the Premier Mill dispersator; this dispersion was added to the Eudragit dispersion to 
form the coating suspension. For formulation Il Eudragit® L 30 D-55 that was available as 
a latex dispersion, was plasticized with triethyl citrate. Talc was dispersed separately 
using the Premier Mill dispersator, in purified water; this dispersion was then added to 
the Eudragit® L 30 D-55 dispersion to form the coating suspension. Figure 2 shows the 
process flow diagram used to prepare the delayed release coating suspension for 
formulation I and Il. 
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Figure 2. Process Flow Diagram for Delayed Release Coating Suspension Preparation. 
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3.5.2 Delayed Release Coating 
A 24 or 48 inch Accela-Cota (Thomas Engineering, Hoffinan Estates, IL) was 
loaded with approximately 12 or 130 kg of tablets equivalent to eighty nine thousand or 
one million tablets. The tablets were coated using either Eudragit S or L delayed-release 
coating suspension formulations presented in Table 3 and 4 respectively. The Eudragit 
coating suspension was sprayed through either one or three spray guns equipped with a I-
mm spray nozzle and using a, pan speed ranging from 4-8 rpm, airflow of 1600 ft3 /min, 
pan pressure of -0.0Sin. water, and a product temperature of 32°C. Spray to bed distance 
was maintained constant (I 0 inches) for all the coating trials. A Masterflex peristaltic 
pump equipped with silicon tubing was used to deliver the coating suspension. Processing 
parameters are listed in Table 5. Coated tablets were allowed to dry for 30 minutes at 
40°C before cooling and discharge. 
3. 6 Assay and Drug Release Testing: 
In-vitro drug release was studied at various pH's in order to mimic the in-vivo 
dissolution behavior. The pH's selected were 0.1 N hydrochloric acid pH l.2, acetate 
buffer pH 4.7, and phosphate buffer pH 7.4 as recommended by USP 23. The dissolution 
study was performed using Apparatus 3 (Reciprocating cylinder, Bio-Dis) (8). The 
temperature of the dissolution medium was maintained at 37 ± 0.5°C in all studies. 250 
ml of dissolution media was used in each cylinder, the stroke speed was set to 20/minute 
and, sink conditions were maintained. Multipoint dissolution profiles were constructed by 
collecting samples at specified intervals and assayed by HPLC to determine the amount 
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Table 3. Formula for Eudragit S Delayed Release Coating Suspension 
Ingredient Content 
Percentw/w m_g/_tablet 
Eudragit® S 100 12.0 6.75 
Aqueous Anunonia Solution IN 6.1 -
Triethyl citrate, NF 6.0 3.38 
Talc, USP 4.0 2.25 
Purified Water, USP 71.9 
-
Total 100.0• 12.38 
'contains 22% w/w of total solids and 15% w/w of polymer 
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Table 4. Formula for Eudragit L Delayed Release Coating Suspension 
Ingredient Content 
Percent w/w mj6ablet 
Eudragit® L 30 D-55 5o.o• 9.45 
Triethyl citrate, NF 1.5 0.95 
Talc, USP 3.5 2.20 
Purified Water, USP 45.0 
-
Total 100.00 12.6 
• contains 15% w/w of polymer 
b contains 20% w/w of total solids 
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Table 5. Coati11g_ Parameters for Accela-Cota for Dehiyed Release Coating_ 
Parameter C-24 C-48 
Drum Size (Inches) 24 48 
Batch Size (kg) II 135 
Pan (rpm) 12 4- 6 
Number of Spray Gun I 3 
Spray Rate (g/min/gun) 25 65 
Bed to Spray Distance (inch) 8 IO 
Atomizing Air Pressure (Bar) I 1.5 
Inlet Air Temperature \'C) 60 60 
Product Temperature \'C) 32 32 
Drying Time (min) 30 30 
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of drug released. Blend uniformity, tablet assay and content uniformity were determined 
using a validated HPLC procedure. 
3. 7 High Performance Liquid Chromatography Assay: 
A reverse phase High Performance Liquid Chromatography (HPLC) assay was 
selected due to the advantage of direct analysis of aqueous samples, high sensitivity, and 
separation of excipients that may interfere with the assay (8). A reverse phase column, 
contairung packing LI (Whatman partisil 10-0DS-3, 4.6x250 mm, C!8, IO µm) in 
conjunction with a variable wave length UV detector was used. 
A number of mobile phase systems were tested. The one, that provided the best 
resolution, consisted of 70% methanol and glacial acetic acid in deiorused degassed 
distilled water was chosen for the assay. The flow rate was 1.5 ml per minute, the UV 
detector set to 276 nm and the injection volume was 25 µI (using WlSP). The linear 
relationship between peak area vs. concentration was determined using standard solutions 
of albuterol sulfate ranging from 0-20 µg/ml. to calculate the concentration of albuterol 
sulfate in the dissolution sample. 
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4.0 Results and Discussion 
4.1 Granule properties: 
Table 6 summarizes the granule properties. Values of Carr index ranged from 
20.1-23. l %, indicating good flow and consolidation characteristics. Angle of repose 
values ranged between 27 - 29° which also suggest smooth flow characteristics for the 
granulations. Loss on drying values were similar for all formulations and ranged from 
3.25 - 3.92%. Blend homogeneity is confirmed by the results of the mean unit dose assay 
values ranging from 99.5-101.2% with relatively small RSD values. The percent RSD 
variability for the blend uniformity samples collected at multiple locations in the blender 
was found to be $ l .8%, indicating low variability and good blend uniformity. These 
results show the effectiveness of blending process for both formulations at both pilot and 
scale-up levels in terms of batch size and blending time. 
4.2 Controlled Release Tablet Core Properties: 
Friability is a term used to describe the resistance of tablets to mechanical wear as 
shown in breakage, chipping, and abrasion during coating, high-speed packaging and 
transportation. The resistance of a tablet to a mechanical wear is dependent on its ratio of 
stress to strain, and tensile strength. Twenty tablets were tested for weight, thickness, 
hardness and friability. Based on earlier compression study results, final tableting 
parameters were selected for the manufacture of the controlled release tablet cores. Table 
7 summarizes the tablet properties for all formulations manufactured. Friability values of 
$ 0.3% were observed for all formulations at both scales of manufacture. 
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Table 6. Summary of Granule Properties 
Batch Size LOO Bulk Tap Carr Angle of 
(kg) (%) Density Density Index Repose Blend Uniform& 
(g/cm3) (g/cm3) (%) 
_®_ Mean RSD 
Pilot 3.53 0.57 0.71 20 .1 28° 100.5 1.5 
Formula! 
Pilot 3.58 0.56 0.72 21.1 27° 100.9 1.8 
Formula II 
Scale-up 3.92 0.55 0.78 23.l 29° 101.2 1.6 
Formula! 
Scale-up 3.25 0.56 0.70 22.2 27° 99.5 1.7 
Formula II 
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Table 7. Summary of Tablet Properties (Controlled release core) 
Batch Size [\Veight Thickness Hardness Friability Assay Content RSD 
(kg) (mg) (in.) (kp) (%) (%) !Uniformity (%) 
i_o/~ 
Pilot 135.2 0.138 8.l 0.1 99.8 100.7 l.3 
Formula I 
Pilot 135.6 0.137 8.0 0.1 100.3 100.6 2.7 
Formula II 
Scale-up 134.9 0.138 8.0 0.0 100.l 99.l I.I 
Formula! 
Scale-up 135.4 0.138 8.2 0.3 100.2 99.8 l.2 
Formula II 
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A low friability value for compressed tablets suggests that the tablet cores are rugged and 
can withstand the mechanical stress generated during the coating process. Hence, these 
tablet cores are acceptable for the coating purposes. Assay and content uniformity results 
for all controlled release core tablet batches manufactured met USP specifications for 
assay and content uniformity for solid dosage forms. Tablets manufactured at two 
different scales were used for the coating studies. 
4.3 Coated Tablet Properties: 
4.3. l Eudragit® S Coating 
Tablets were initially coated with various levels of Eudragit S polymer to retard 
the drug release from the tablet cores and to serve as a seal coat over which the loading 
dose was applied as an immediate release. Coatings were applied in the range of 
2.5-5.0% polymer weight gain based on tablet core weight. Table 8 shows the tablet 
physical characterization and film disintegration results for applied levels of polymer 
coating. It can be seen from these results that the tablet weight increases when the 
polymer application level was increased. The tablet hardness also increased gradually 
from 9.2-14.5 kp as the coating level increased. These results also show large variabil ity 
of the cores in terms of weight, thickness, hardness and diameter at the initial stages of 
polymer application (2.3 mg/cm2) and the variability reduced when the tablets received 
more coating 2.8 mg/cm2 and above. Hence, the variability in the tablet weight with 
polymer levels of $ 2.8 mg/cm2 can be explained by the fact that the tablets did not 
receive uniform coating of the material during the initial stages of the coating process. 
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Table 8. Tablet Characteristics for Various Levels ofEudragit S Polymer Coating 
Coating Level 2.5 3.0 3.5 4.0 4.5 5.0 
(% w/w) 
Polymer Applied 2.3 2.8 3.3 3.7 4.2 4.7 
_{_m_g/cm2l 
Weight (mg) 141.2 142.4 143.7 144.9 146.2 147.4 
RSDi_o/~ 1.6 I. I 0.9 1.2 0.8 1.0 
Thickness (mm) 3.51 3.52 3.54 3.56 3.57 3.59 
RSD _{_o/tl_ 0.9 0.7 0.8 0.7 0.8 0.8 
Hardness (kp) 9.2 1 l.7 12.5 13.1 13.9 14.5 
RSD§~ 2.9 2.0 2.1 1.9 1.8 2.l 
Diameter (mm) 7.19 7.21 7.23 7.25 7.26 7.27 
RSD§_tl_ l.0 0.8 0.7 0.8 0.9 0.8 
Disintegration Time' 150 216 252 312 348 342 
_io;e~ 3.8 2.9 2.5 2.7 2.4 2.2 
'Disintegration media phosphate buffer pH 7.4; n=6 
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Reduced variability at higher coating levels suggests that the film coat is homogeneous 
and tablets are well sealed, which was further confirmed by the gastric-resistant test. 
Effect of coating thickness on film disintegration was determined for various levels of 
Eudragit S coating. Coating film disintegration time changed slightly for the tablets 
coated with 3.3 mg/cm2 polymer (3.5% w/w). Coating film disintegration time increased 
as a result of increased coating film thickness, 150 seconds for tablets coated with 2.3 
mg/cm2 and 342 seconds for tablets coated with 4.7 mg/cm2 . Increasing the coating 
thickness from 3. 7 mg/cm2 and beyond had little effect on the film disintegration time. 
Table 9 shows the coated tablet disintegration and dissolution properties in the 
gastric fluid . The film coatings disintegrate at low levels of polymer coating 3.3 mg/cm2 
indicating poor film integrity at these levels. It can be seen from these results that a 
release of 35.5% was observed at a coating thickness of 2.3 mg/cm2 and that increasing 
the coating thickness improved the film integrity and reduces the drug release until no 
drug was released at > 3.7 mg/cm2 applied coating level. The film was intact at a 
thickness of 3.7 mg/cm2 and beyond. Furthermore, no drug release into the simulated 
gastric fluid was detected from the tablets coated with~ 3.7 mg/cm2 during the 2-hour 
gastric resistance test. Figure 3 shows the effect of amount of polymer coating on drug 
release. Drug release is significantly affected by the amount of polymer applied at the 
lower level until 3.3 mg/cm2 application. As the polymer applied increases the drug 
release gradually decreases and no drug release was observed after 3.7 mg/cm2 of 
polymer application. Thus, we can conclude that to produce a delayed release effect a 
minimum of3 .7 mg/cm2 of polymer coating is required for adequate seal coating, which 
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Table 9. Dissolution Results for Eudragit S I 00 Film Coated Tablets (T 120) 
Simulated Gastric Fluid 
Coating Polymer Disintegration Albuterol 
Level Applied Time Release 
ff~ J..m_g/cm2_ J..mil_l)_ Jo/~ 
2.5 2.3 2.8 35.5 
3.0 2.8 3.5 29.0 
3.5 3.3 5.5 9.5 
4.0 3.7 Intact 0.0 
4.5 4.2 Intact 0.0 
5.0 4.7 Intact 0.0 
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Figure 3. Effect of Coating Film Thickness on Albuterol Release 
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is similar to the results reported earlier (9). 
Table I 0 shows the coated tablet properties for Eudragit S coated tablets for 
formulation I at both the pilot and scale-up. Although 3.7 mg/cm2 polymer application 
gave adequate gastric-protection, 5% ( 4. 7 mg/cm2) polymer coating level was chosen to 
accommodate any variability in the coating process during routine manufacture. Results 
indicate a good recovery and efficiency (98.9%) for the tablets coated using the large 
coating pan (Accela-Cota 48"). However, the coating process using the small coating pan 
used in the pilot study shows poor recovery (91.5%) was not efficient when compared 
with the large coating pan. There is a clear indication that the large scale manufacturing 
process is more efficient than the small scale. Effect of moisture on drying temperature 
was studied to determine the optimum drying temperature for the coated tablets (Figure 
4) . Moisture loss measured as percent loss on drying was linear for a period of 480 
minutes. After which the loss on drying was constant and no moisture loss observed. The 
maximum percent moisture loss observed was 3.3% w/w, which is similar to the loss on 
drying values obtained for the dry granulation and uncoated tablets, suggesting that the 
coating process did not impart any additional moisture to the tablet cores. Weight 
variation for the delayed release coated tablets was found to be comparable for the two 
different batch sizes, with reproducible LOD values. 
Dissolution results for coated and uncoated tablets is presented in Figure (5) . It 
can be seen form these comparisons that the uncoated tablets release drug faster than the 
coated tablets as expected. A polymer coating thickness of 3. 7 mg/cm2 produces a slower 
drug release approximately 10 percent slower compared with the uncoated tablets, and as 
the dissolution continues further almost all of the drug (JOO percent) was released at the 
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Table 10. Summary Coating Properties ofEudragit® S Coated Tablets 
Batch Size % Polymer coated Efficiency Tablet Weight Assay LOD 
Theoretical Actual % mg_ %RSD % % 
Pilot 5.0 4.9 91.5 147.7 1.6 99.8 2.8 
Formula I 
Scale-up 5.0 5.0 98.9 147.3 1.2 98.9 3.6 
Formula! 
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end of four hour. Tablets coated with 4.7 mg/cm2 produced similar effect suggesting that 
the increased coating thickness beyond 3.7 mg/cm2 did not have significant effect on the 
rate and extent of drug release. 
4.3.2 Eudragit L 30 D-55 Coating 
Tablets were initially coated with various levels of Eudragit L polymer to retard 
the drug release from the tablet cores and to serve as a seal coat over which the loading 
dose was applied as an immediate release. Coatings were applied in the range of 3-7% 
polymer weight gain based on tablet core weight. Table 11 shows the tablet physical 
characterization and film disintegration results for applied levels of polymer coating. It 
can be seen from these results that the tablet weight increases as expected when the 
polymer application level was increased. The tablet hardness also increased gradually 
from 8.6-15 .8 kp as the coating level increased. These results also show large variability 
of the cores in terms of weight, thickness, hardness and diameter at the initial stages of 
polymer application (2.8 mg/cm2) and the variability reduced as the tablets received more 
coating 4.2 mg/cm2 and above. Therefore, the variability in the tablet weight with 
polymer levels of s; 3. 7 mg/cm2 can be explained by the fact that the tablets did not 
receive uniform coating of the material during the initial stages of the coating process. 
Reduced variability at higher coating levels suggests that the film coat is homogeneous 
and tablets are well sealed, which was further confirmed by the gastric-resistant test. 
Effect of coating thickness on film disintegration time was determined for various levels 
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Table 11. Summary Results for Various Levels ofEudragit L Film Coating 
Coating Level 3.0 3.5 4.0 4.5 5.0 5.5 6.0 
(%w/w) 
Polymer Applied 2.8 3.3 3.7 4.2 4.7 5.1 5.6 
J_m~m2.l_ 
Weight(mg) 140.4 141.3 142.2 143.1 144.0 144.9 145.8 
RSD (%) 1.4 1.2 1.2 1.0 0.7 0.8 0.9 
Thickness (mm) 3.50 3.51 3.53 3.54 3.55 3.55 3.56 
RSD (%) 0.9 0.7 0.8 0.7 0.8 0.7 0.6 
Hardness (kp) 8.6 9.7 11.5 12.3 13 .7 14.5 14.8 
RSD (%) 2.9 2.0 2.1 1.9 1.8 2.1 2.3 
Diameter (mm) 7.20 7.22 7.23 7.24 7.26 7.26 7.28 
RSD(%) 1.0 0.8 0.7 0.6 0.6 0.5 0.4 
Disintegration Time• (sec) 163 216 252 3 12 348 342 341 
RSD (%) 3.8 2.9 2.5 2.7 2.4 2.2 2.8 
'Coating film disintegration time, disintegration media phosphate buffer pH 7.4; n=6 
6.5 7.0 
6.1 6.5 
146.00. 147.6 
8 0.8 
3.57 3.58 
0.6 0.7 
14.9 15.8 
1.8 2.5 
7.29 7.29 
0.5 0.5 
350 348 
2.6 2.7 
of Eudragit L coating. Coating film disintegration time increased slightly as a result of 
increased coating film thickness, 163 seconds for tablets coated with 2.8 mg/cm2 and 348 
seconds for tablets coated with 6.5 mg/cm2• Increasing the coating thickness from 4.7 
mg/cm2 and beyond had little effect on the film disintegration time and was similar to the 
effect observed with Eudragit S coating. 
Table 12 shows the coated tablet properties in the simulated gastric fluid. The film 
coating disintegrates at 2.8 mg/cm2 and up to a level of 5.1 mg/cm2 of polymer 
application indicating poor film integrity at the lower coating levels. It can be seen from 
these results that at 2.8 mg/cm2 polymer application the drug release is 25%, a coating 
thickness of 4.7 mg/cm2 improves the film integrity and reduces the drug release until no 
drug was released at<: 5.6 mg/cm2 applied polymer coating level. The film was intact at a 
coating thickness of 5.6 mg/cm2 and beyond. Furthermore, no drug release into the 
simulated gastric fluid was detected from the tablets coated with<: 5.6 mg/cm2 during the 
2-hour gastric resistance test. Figure 6 shows the effect of amount of polymer coating on 
drug release. Drug release is significantly affected by the amount of polymer applied at 
the lower level until 5.6 mg/cm2 application. As the polymer applied increases the drug 
release gradually decreases and no drug release was observed after 5.6 mg/cm2 of 
polymer application. Thus, we can conclude that to produce a delayed release effect a 
minimum of 5.6 mg/cm2 of polymer coating is required for adequate seal coating. 
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Table 12. Dissolution Results for Eudragit L Film Coated Tablets (T 120) 
Simulated Gastric Fluid 
Coating Level Polymer Applied Disintegration Albuterol 
(%) (mg/cm2) Time (sec) Release(%) 
3.0 2.8 140 25.0 
3.5 3.3 175 22.5 
4.0 3.7 180 20.3 
4.5 4.2 205 20.5 
5.0 4.7 207 15.5 
5.5 5.1 220 8.0 
6.0 5.6 Intact 0.0 
6.5 6.1 Intact 0.0 
7.0 6.5 Intact 0.0 
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Table 13 shows the coated tablet properties for Eudragit L coated tablets for 
formulation II at both the pilot and large scale. Although 5.6 mg/cm2 polymer application 
gave adequate gastric-protection, 7% (6.5 mg/cm2) coating level was chosen as discussed 
earlier to accommodate any variability in the coating process during routine manufacture. 
Results indicate a good recovery and efficiency (99.8%) for the tablets coated using the 
large coating pan (Accela-Cota 48"). However, the coating process using the small 
coating pan used in the pilot study shows poor recovery (97.6%) and was not efficient 
when compared with the large coating pan. Although the pilot scale (24" pan) coating 
process for Eudragit L 30 D-55 is more efficient when compared with the Eudragit S 
coating process, the efficiency is still low. There is a clear indication that the large scale 
manufacturing process is efficient than the small scale independent of the formulation. 
Effect of moisture on drying temperature was studied to determine the optimum drying 
temperature for the coated tablets (Figure 7). Moisture loss measured as percent loss on 
drying was linear for a period of 480 minutes. After which the loss on drying was 
constant and no moisture loss observed. The maximum percent moisture loss observed 
was 3% w/w, which is similar to the loss on drying values obtained for the dry 
granulation and uncoated tablets, suggesting that the coating process did not impart any 
additional moisture to the tablet cores. Weight variation for the delayed release coated 
tablets was found to be comparable for the two different batch sizes, with reproducible 
LOD values. 
Dissolution results for coated and uncoated tablets is presented in Figure (8). It 
can be seen from these comparisons that the uncoated tablets release drug faster than the 
coated tablets as expected. A polymer coating thickness of 5 .6 mg/cm2 produces a slower 
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Table 13. Summary of Tablet Properties for Eudragit L Coated Tablets 
Batch Size % Polymer coated Efficiency Tablet Weis!!! Assay LOD 
[!ieoretical Actual % m_g_ %RSD % % 
Pilot 7.0 6.8 97.6 144.8 1.9 100.1 3.2 
Formula II 
Scale-up 7.0 7.0 99.8 148.1 1.7 99.8 2.9 
Formula II 
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~ Uncoated Core 
--0- 5.6 mg/cm 2 
-T- 6.5 mg/cm 2 
drug release approximately 10-15 percent slower across all the time points compared with 
the uncoated tablets, and as the dissolution continues further almost all of the drug (100 
percent) was released at the end of six hour. Tablets coated with 6.5 mg/cm2 produced 
similar effect suggesting that the increased coating thickness beyond 5.6 mg/cm2 did not 
have significant effect on the drug release. 
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5.0 Conclusions 
Batches manufactured at two different scales exhibited similar granulation and 
tablet properties for the two formulations studied. Tablets produced using two different 
tablet presses exhibited similar tablet characteristics and dissolution profiles. A film 
thickness of 3.7 mg/cm2 or greater was required to provided adequate seal coating and 
delayed release characteristics for the Eudragit® S 100 coating on a fast release core 
formulation. Furthermore, a film thickness of 5.6 mg/cm2 was required for Eudragit® L 
30 D-55 film to provide adequate delayed release for the slow release formulation. 
However both film coatings disintegrated within in a short period of time when exposed 
to simulated intestinal fluid. No difference in film disintegration time was observed 
between the two different coatings when treated at pH 7.4. The rate and extent of drug 
release was not affected within a reasonable increase in film thickness. Since the Eudragit 
L films are designed to dissolve at pH 5.5 and higher, a in-vivo evaluation may be 
necessary to identify potential impact of these property on the in-vivo drug release and 
absorption. 
Tablets manufactured at small scale using small coating pan had larger variability 
in film thickness at lower coating level. It appears that the variability in coating 
uniformity is a function of batch size, larger equipment uses larger pan load increased 
number of spray guns and hence is more efficient and uniform coating. Thus we can 
conclude that the large coating pan is efficient compared to the small coating pan. 
Because of the size, shape and operating speeds of the coating pans differ for various 
types of coating pan, the parameters obtained from one size and type of equipment cannot 
be applied to the other even though the operating principles are same. In addition 
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identification and optimization of the coating parameters that influence the coating film 
thlckness and uniformity would help reduce the variability observed in the coating. 
Furthermore, the tablets produced had satisfactory physical characteristics and was used 
for further coating studies to develop the immediate release coating of the second dose of 
the drug. 
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MANUSCRIPT III 
DEVELOPMENT OF IMMEDIATE RELEASE DOSE FOR A 
PULSED-RELEASE TABLET 
PART II 
IMMEDIATE RELEASE COAT DEVELOPMENT 
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ABSTRACT 
Aqueous film coating of solid dosage forms is a process that continues to grow in 
importance in the pharmaceutical industry. Aqueous film coating process can influence 
the quality of the final coated dosage form, such as surface characteristics, gloss, coating 
efficiency and coating uniformity. There is also a widespread interest in evaluating the 
uniformity of the film coatings. The reason for this interest is that the uniformity of the 
coating affects the quality of the tablet finish , accuracy of the dose delivered and 
functionality of the coating. 
The aim of this study was to examine the influence of processing parameters on 
the uniformity of the coating applied to deliver low dose active ingredient in the 
immediate release portion of a pulsed release tablet dosage form containing immediate 
and delayed release of water soluble drug. The effect of mixing on coating suspension 
and the spray rate on coating uniformity was evaluated. A method for assessing the extent 
and uniformity of film-coat application by the determination of albuterol sulfate in the 
coating was used to determine the charge of tablets in the coating pan in the pilot scale 
and production scale. 
Tablet characteristics such as weight variation, thickness, hardness and content 
uniformity were compared using statistical analysis to evaluate the reproducibility of the 
coating process and the final product at different scales. Dissolution testing of the coated 
tablets was performed using USP apparatus 3. Formulation stability was evaluated at 
various storage conditions to determine the robustness of the developed product. Coating 
solution mixing speed did not have an impact on the homogeneity of the suspension. 
Tablets coated using 24" coating pan produce larger variability in the coating and had 
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low process efficiency. On the other hand the larger coating pan showed better efficiency 
and uniformity of coating suggesting a better process choice for the application of active 
drug onto the tablets. Results indicate that longer processing time improved the coating 
uniformity. Perforated coating pan can be used to apply film coatings containing low 
dose active drug and coatings applied using two different coating equipment at different 
scales exhibited similar tablet properties. 
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1.0 Introduction 
Pharmaceutical coatings are applied to compressed tablets for a variety of reasons, 
some as simple as improving the aesthetics of the tablet, color for marketing etc. Others 
relate to the performance of the product itself. There is a growing interest in 
incorporating soluble and insoluble active drugs into the coating of coated tablets. For 
this technique to be useful for delivering active drug via the coated film, the variation in 
coating between the tablets must be minimal. Application of active drug onto tablet cores 
using conventional spray coating processes is very challenging. Various coating 
techniques and processes for the application and delivery of active drug via a tablet 
dosage form have been studied in detail elsewhere (I). A number of process variables and 
additives in the coating affect the uniform application of the film forming material onto 
the tablet cores (2). Such variables affect the quality, appearance and performance of the 
final film. Coatings may be applied by spraying a solution or suspension containing 
dissolved or undissolved drug substance and/or pigment onto a large number of tablets 
tumbling in a rotating pan (1,3) . 
Aqueous film coating is a process that is routinely employed today as unit process 
in the preparation of pharmaceutical solid dosage forms ( 4,5,6). Uniform color on the 
color-coated tablets as perceived visually usually marks the end point of the coating 
process. However, when applying film coatings with colorless films or with colors 
similar to the tablet core, a visual color check may not be the appropriate method for 
determining the end point. One variable identified to more accurately determine the 
coating end point is the weight gain of the tablets during the coating process. Along with 
the weight gain measurements, assay of the coating material may be used to confirm the 
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coating end point and evaluate the uniformity of the coating film application. An 
alternative method for quantifying the amount of film-coat applied to a tablet 
incorporating marker compounds into the coating medium have been reported and 
materials such as potassium bromide (7), tartrazine (8), and FDC Blue # l (9) have been 
considered for this purpose. In each case, the coat was removed from the tablet by 
dissolution in an aqueous medium and the marker detected using an appropriate 
analytical method. 
The goal of the present study is to systematically evaluate the relevant processing 
parameters in both pilot scale (24 ") and production scale ( 48 ") coating pans. These 
investigations include the evaluation of coated tablet characteristics using two differently 
releasing tablet core formulations, fast and slow release, at the small scale and production 
scale to make recommendations for further optimization and modification to the coating 
process to obtain a uniform drug coating with reduced intra-batch variability. 
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2.0 Objective 
The objective of the present study is to develop an immediate release coat for a 
seal coated controlled release matrix tablet in order to deliver a low dose immediate 
release of an injtial dose of drug. To identify the coating parameters, characterize and 
compare the coated tablet attributes, such as weight variation, assay, coating uniformity 
and dissolution profiles of the formulations manufactured at two different scales (pilot 
and production scale). 
3.0 Methods 
3. 1 Materials: 
Albuterol Sulfate, USP (Propharmaco, Nobel Industries, Italy); Opadry® II Whjte 
(Colorcon, West Point, PA); Seal coated matrix tablets containing 2 mg of albuterol 
previously prepared. All raw materials used complied with the current USP/NF grade 
specifications. 
3.2 Equipment: 
Accela-Cota 24" and 48" (Thomas Engineering, Hoffman Estates, IL); Peristaltic 
Pump, Masterflex Model 7520-10 (Cole Parmer, Chicago, IL); Moisture Analyzer, 
Computrac Max 50 (Arizona Instrument, Tempe, Arizona); Vector Tablet Hardness 
Tester (Vector Corp. , Marion, IA); pH meter, Model 811, (Orion Research Inc., 
Cambridge, MA); Bio-Dis Tester (Vanke! Industries Inc., Edison, NJ); Srumadzu LC-4A, 
High Performance Liquid Chromatograph (HPLC) Equipped with a Shimadzu SPD-2AS 
spectrophotometer detector (Srumadzu, Japan). 
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3.3 Tablet Coating: 
3.3.1 lmmediate Release Coating Suspension Preparation 
Albuterol sulfate was dissolved in purified water; to this solution Opadry® II was added 
and mixed to obtain a homogeneous coating suspension. The immediate release coating 
suspension formulation is presented in Table 1. A coating suspension sample was 
collected at the end of the mixing process to determine the amount of albuterol sulfate in 
the final coating suspension. The coating mixture was continuously stirred during and 
until used for processing. 
3.3.2 Determination of Moisture in the Coating material 
It was necessary to determine the moisture level in the coating material because 
the coating end point was determined based on the amount of solids applied calculated on 
a dry film weight basis. The amount of moisture in the coating material (Opadry® II) was 
used to adjust the amount of moisture that would contribute to the final tablet weight gain 
as part of total solids. A thermal gravimetric and Karl fisher moisture analysis was 
performed to determine the amount of moisture. 
3.3.3 Immediate Release Coating Procedure 
Delayed release seal coated matrix tablets manufactured previously were used as 
substrate for the immediate release coating. Development, characterization and evaluation 
of seal coated tablets are discussed in detail in manuscript II part I. The delayed release 
seal coated tablets were loaded into the coating pan, pre-warmed for five minutes and the 
immediate release albuterol sulfate coating suspension was sprayed onto the 
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Table I. Formula for Albuterol Sulfate Immediate Release Coating 
Ingredient Content 
Percent w/w m_.B!'!ablet 
Albuterol Sulfate, USP 3.00 2.46 
Opadry II® (Y-22-7719)8 8.00 6.54 
Purified Water, USP 89.00 -
Total 100.00 9.00 
• Proprietary blend of ready to use coating material consisting of film forming material, 
plastisizer and opacifier for film coating purposes. 
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tablets. The tablets were coated using the coating suspension formulation presented in 
Table 1 and the processing parameters listed in Table 2. The pilot scale coating was 
performed in 24" coating pan, at a pan speed of 12 rpm, airflow of 200 ft3/min, pan 
pressure of-0.06 to-0.08in. water and a product/exhaust temperature of 38°C. A quantity 
of tablets equivalent to twelve kilograms was placed in the pan and preheated for 5 
minutes at 40°C, the inlet and outlet temperatures were maintained at 59 ± 2°C and 40 ± 
2°C. The pan was rotated at a speed of 12 rpm and the coating suspension was sprayed 
continuously using a peristaltic pump at an average spray rate of 25 grams/minute with a 
single spray gun (I-mm nozzle diameter). For the coating applied using the Accela Cota, 
C-48 a quantity of tablet equivalent to 120 kilograms was placed in the coating pan and 
prewarmed for 5 minutes at 40°C, the inlet and outlet temperatures were maintained at 60 
± 2°C and 40 ± 2°C with air volume of 1600 ft3/min The pan was rotated at a speed of 4 
rpm and the coating suspension was sprayed continuously using a peristaltic pump at an 
average spray rate ranging from 50 - 85 grams/minute/gun (I-mm nozzle diameter) using 
three spray guns. The spray to tablet bed distance was maintained at 10 inches for all 
coating trials. The coating suspension was stirred continuously throughout the coating 
process to maintain homogeneity. Average tablet weight gain of 6. 7% solids was applied 
using both pans to deliver a quantity equivalent to 2 mg of albuterol per tablet on the 
coating. 
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T bl 2 C a e oatmg_ p f) A I C arameters or cce a- ota d. R 1 mme 1ate e ease c oatmg 
Parameter C-24 C-48 
Drum Size (Inches) 24 48 
Batch Size (kg) 12 120 
Pan (rpm) 12 4 
Number of Spray Guns 1 3 
Spray Rate (g/min/gun) 25 50-85 
Bed to Spray Distance (inch) 8 JO 
Atomizing Air Pressure (Bar) L 1.5 
Inlet Air Temperature (°C) 58 60 
Product Temperature (°C) 38 38 
Drying Time (min) 30 30 
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3.3. 4 Effect of Mixing on Coating Suspension Homogeneity 
To evaluate the homogeneity of the coating suspension solids and identify the 
optimum mixing speed during the process, the coating suspension was mixed at various 
mixer speeds. Samples were collected from different location in the mixing tank at 
various mixing speeds to confirm a uniform dispersion of solids. Samples were also 
collected from the spraying end of the spray guns at various mixing speeds and at a 
constant spray rate of 85 g/min/gun. To evaluate the homogeneity of albuterol in the 
coating suspension, samples were assayed by HPLC to determine the amount of albuterol 
in the sample and in the coating suspension formulation . 
3.3.5 Effect of Coating Suspension Spray Rate on Uniformity 
To study the effect of spray rate on the coating uniformity, the coating suspension 
was sprayed at 50, 70 and 85 g/min/gun. The seal coated tablets were coated with the 
immediate release coating suspension formulation presented in Table I . Tablet samples 
were collected at each spray rate after applying 30, 50, 75 and 100% of the theoretical 
solid weight gain. Tablet samples were evaluated for weight, thickness and were assayed 
for albuterol sulfate in the coating to determine the uniformity of coating applied at 
various spray rates. 
3.4 Immediate Release Assay: 
Ten tablets were chosen at random from the composite sample obtained from the 
coating pan at the end of the coating process. These tablets were transferred into a sample 
vial and approximately 20 mL of water was added. The sample was vortexed for 1 
minute. The solution was decanted into 500 mL volumetric flask . Then, the vial was 
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rinsed nine times with 20mL water and the rinse solutions were decanted into the same 
500 mL volumetric flask. The 500 mL flask was diluted to volume with water. 12.5 mL 
of this solution was transferred to 200 mL volumetric flask and diluted to volume with 
water. An aliquot of this solution was filtered through a 0.45µm PTFE filter, discarding 
the first 5 mL of the filtrate. This sample was injected onto the chromatographic system. 
3.5 Drug Release Testing: 
The pH's selected were 0.1 N hydrochloric acid pH 1.2, acetate buffer pH 4.7, 
and phosphate buffer pH 7.4 as recommended by USP 23. The dissolution study was 
performed using USP apparatus 3 (Reciprocating cylinder, Bio-Dis) (10). The 
temperature of the dissolution medium was maintained at 37 ± 0.5°C in all the studies. 
250 ml of dissolution media was used in each cylinder and the stroke speed was set to 
20/minute, sink conditions were maintained. Multipoint dissolution profiles were 
performed by collecting samples at specified intervals and assaying by HPLC to 
determine the amount of drug released. Tablet assay and content uniformity were 
determined using a validated HPLC procedure. 
3. 5.1 Assay Procedure 
A reverse phase High Performance Liquid Chromatography (HPLC) assay was 
selected due to the advantage of direct analysis of aqueous samples, high sensitivity, and 
separation of excipients that may interfere with the assay. An aliquot of sample solution 
was filtered through a 0.45 µm PTFE filter, discarding the first 5 ml of the filtrate. A 
reverse phase column (Keystone ODS/H, 5µm 4.6x250 mm) in conjunction with a 
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variable wavelength UV detector was used. The injection volume was 30 µL with a flow 
rate of irnL/minute and column temperature was maintained at 35°C. 
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4.0 Results and Discussion 
Table 3 shows the coating suspension uniformity test results for the samples 
collected at various mixing speeds, from the solution tank and at three different spray 
guns. Although the coating suspension used for the study had an 8% w/w theoretical 
content of Opadry® I1 solid, only - 7.4% of the solids was recovered by gravimetric 
analysis which is equivalent to 92.5% of the theoretical amount of total solids used in the 
preparation of the coating suspension. The difference in the amount of solid recovered 
may be explained by the amount of moisture found in the raw material itself. Table 4 
shows the moisture analysis data for the lots of Opadry® II raw material using various 
methods. These results show that there is approximately 7.5% moisture present in the 
material . These findings also suggest that there is not an actual loss of solids and that the 
low recovery of solids from the samples collected from the spray gun is due to the loss of 
moisture originally present in from the raw material. 
The percent solids determination results obtained from the coating suspension 
sampled from the suspension tank ranged from 7.38 - 7.42%. The amount of solids 
recovered from the samples collected at the spraying end of each spray gun at the 
different mixing speeds for individual samples ranged from 7.29 - 7.42%. The average 
values range from 7.37 - 7.40% with an RSD value $ 0.78% These results suggest that 
the coating suspension solids delivered through each spray gun is fairly consistent, 
uniform and are similar to the results obtained from the samples tested from the tank. 
Furthermore, these results also indicate that the mixing speed did not have an adverse 
effect on the coating suspension homogeneity. The results also show low variability in 
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Table 3. Opadry® II Recovered from the Coating Suspension Using 
G . 1 . ravrmetr_y_ Ana~1s 
Mixer Percent Recovered Average RSD 
Speed 8£rl!Y. Gun Tanlc Solids (%) 
i!£.m..2. A B c (%) 
500 7.39 7.42 7.42 7.38 7.40 0.28 
1500 7.36 7.37 7.31 7.42 7.37 0.61 
2000 7.42 7.36 7.29 7.40 7.37 0.78 
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Table 4. Moisture Content of Three Lots ofOpadry® II 
Lot# Percent Moisture 
LOO Karl-Fisher TGA Gravim~ 
3948 6.5 7.2 7.0 7.4 
5238 7.2 7.3 7.2 7.5 
5328 7.1 7.5 6.8 7.6 
• 8% w/w Opadry® II suspension, n=3 for all determination 
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the percent solids from the spray guns indicating that the suspension flow through the 
various parts of the spray system is consistent between the three spray guns. This is a 
critical property because inconsistencies in the coating suspension flow between spray 
guns may lead to uneven spray patterns ultimately affecting the uniformity of the 
deposited coating material on the tablets (11). Table 5 shows the assay and percent solids 
results recovered for the actual coating suspension. It can be seen from these results at all 
three mixing speeds the specific gravity values range from 1.023 - 1.028, suggesting that 
the solid particles are dispersed uniformly throughout the suspension. This is further 
supported by the fact that the observed assay values for these samples ranged from 2.93 -
3.09% of the theoretical amount of 3% w/w of albuterol sulfate. Furthermore, the 
variability in the amount of active drug recovered from all three mixing speed samples 
from the tank and the spray guns are minimal. A major concern would be non uniformity 
of the coating solids, that may affect the final film characteristics and uniform deposition 
of the coating material on the tablets (11 ,12). These results show that a uniform coating 
suspension can be delivered from each spray gun consistently independent of mixing 
speeds. 
Coating solution spray rate may have a significant effect on the coating film 
uniformity (12). In order to evaluate the effect of coating suspension spray rate on the 
coating uniformity, tablets were coated using three different spray rates (50, 70 and 85 
g/min/gun). Results are presented in Table 6. It can be seen from these results that at a 
spray rate of 50 g/min/gun the weight variation is highest at a RSD of 6.8% which 
indicates that the amount of coating material deposited on each tablet may not be uniform 
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Table 5. Mixing Study Results for Immediate Release Coating Suspension 
Mixer Su~ension Pr~rties 
Speed Sample• Solids RSD Specific RSD 
(rpm) §owlv:)_ J_o/& J[!!V~ J_o/& 
A 7.42 1.023 
500 B 7.36 0.82 1.024 0.26 
c 7.30 1.028 
Tanlc" 7.46 0.91 1.024 0.19 
A 7.40 1.025 
1400 B 7.56 1.71 1.026 0.14 
c 7.31 1.024 
Tank• 7.31 0.56 1.025 0.21 
A 7.39 1.026 
2000 B 7.41 0.64 1.023 0.1 5 
c 7.32 1.025 
Tank" 7.32 0.75 1.024 0.23 
• A,B, and C are the 3 spray guns for the 48 inch coating pan 
b n=3 for all determinations 
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Assay RSD 
J_o/& J_o/& 
3.01 
2.98 0.51 
2.99 
2.93 0.52 
2.98 
2.96 1.39 
3.04 
3.05 0.47 
2.98 
3.09 1.92 
3.07 
2.94 0.39 
Table 6. Tablet Characteristics as a Function of Spray Rate 
Spray Rate Solids We!g_ht Variation Tablet Thickness Albuterol 
(g/min/gun) Applied Weight RSD Thickness RSD Assay RSD 
(%w/w) l_m-82._ .f'I~ J!nm..l l_o/~ .f'I~ .f'/.<0_ 
50 30 148.4 6.8 3.64 3.7 3 l.6 15.5 
70 50 150.4 5.2 3.67 2.9 44.8 11.4 
85 75 152.9 3.9 3.70 2.3 73.8 8.6 
85 100 155.4 l.8 3.72 1.2 IOI.I 5.4 
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at this stage of the process. It should be noted that increasing the spray rate reduced the 
weight variation to 5.2% at 70 g/min/gun and to 1.8% at 85g/min/gun when 100% of the 
solid application is complete. Interestingly, the variation in tablet thickness is minimal 
across the various coating ranges. However, this parameter is difficult to compare 
between various samples, simply because the amount of material being deposited is small 
and the physical measurement is not sensitive enough to pick subtle differences. In 
contrast, the highly sensitive HPLC assay used to measure the content uniformity of the 
coatings shows high variability at the lower spray rate of 50g/min/gun. Also it can be 
seen from these results that increasing the spray rate, further along the process the coating 
uniformity is improved with minimal variability between the tablets. These findings are 
opposite of the results reported in an earlier study, that increasing the coating level does 
not reduce the variability of the coating (9). This may in fact be due to the prolonged 
exposure of the tablets to the coating zone as the number of coating cycles increases 
tablet residence time. At a spray rate of 85 g/min/gun and a level of 75% application of 
solids the calculated percent RSD value for the content uniformity is 8.6%. This 
variability was improved when spraying at 85 g/min/gun and increasing the duration of 
coating time to give a percent sol id application of 100%. Nevertheless when coating was 
applied at a spray rate of 85 g/min/gun for the entire process there was a significant 
improvement in the uniformity of the coating which suggests that uniform coating may 
be obtained using higher spray rates and increasing the duration of coating. 
Table 7 compares the physical characterization results for tablets that were 
uncoated, seal coated and immediate release coated at the different production scales. The 
results show a low variability of the cores in terms of weight, thickness, hardness and 
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diameter for the uncoated tablets for botb batches of tbe pilot and scale-up levels of 
manufacture. Similar results were observed for tbe seal coated tablets for weight, 
thickness and diameter suggesting a wtiform seal coating of the tablet core regardless of 
scale. As expected the seal coated and immediate release coated tablets show an increase 
in tablet weight that is reflected in increased tablet thickness. However, tablet hardness 
increased slightly for the immediate release coated tablets when compared with the seal 
coated tablets and is not significant. Figure I and 2 show the individual assay results of 
the immediate release coating of the tablets coated using the small and the large coating 
pans. It can be seen from Figure I that a majority of the tablet samples assayed had 
values that are further away from the target value of 50% of the intended 4 mg dose for 
the final tablet formulation. It is also evident from Figure 1 that the observed assay values 
are beyond the acceptable± 95% of the calculated mean assay value. The average percent 
albuterol assayed was 49.8 and 50.5 with a standard deviation of 5.6 and 3.6 for small 
scale and large scale respectively. Statistical comparison of tbe average assay values for 
small and large scale did not show a significant difference in average assay for content 
uniformity. However, comparison of standard deviation shows there is a statistically 
significant difference between the variance. Table 8-9 Appendix II show a complete 
statistical evaluation of these results. This may be due to the Jack of wtiform application 
of the coating material, which in turn affects the wtiform distribution of the active drug 
onto the tablets. Coating uniformity may be influenced by a number of parameters such 
as number of spray guns, pan speed, spray rate, tablet mixing and coating material 
concentration in the coating solution (6,9,12,13). A single spray gun was used for the 
small scale (24" pan) coating process. Figure 2 shows the individual assay results for 
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°' 0 
Batch 
Type 
Pilot 
Formula I 
Pilot 
Formula 11 
Scale-up 
Formula I 
Scale-up 
Formula II 
Table 7. Comparison of Tablet Properties 
Weight (mg)ffablet Thickness (mm) 
Seal IR Seal IR 
l!:!_ncoated coated coated Uncoated coated coated 
135.4 147.4 153.6 3.50 3.57 3.66 
134.9 149.7 159.6 3.50 3.62 3.72 
135.2 147.8 155.7 3.50 3.58 3.64 
135.7 149.9 159.6 3.51 3.60 3.71 
Hardness (kp) 
Seal IR 
Uncoated coated coated 
8.1 14.5 15.6 
8.0 13 .5 15 .1 
8.0 14.2 16.2 
8.2 13 .9 14.7 
c: 
~ 
" Q.. 
Figure I . Immediate Release Coating Assay - For Pilot Scale Batch 
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Figure 2. Immediate Release Coating Assay- For Large Scale Batch 
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immediate release coatings applied using 48" coating pan. Variability in the assay value 
for these batches were minimal as compared with the variability observed for the tablets 
coated using 24" coating pan. It may be postulated that improved coating uniformity from 
the small scale to the large scale may be due to the increased number of spray guns used 
to spray the coating suspension that results in a more uniform spray of coating material 
across the tablet bed. Secondly the coating pan speed, which may have significant effect 
on the coating uniformity, in this case 4 rpm vs. 12 rpm for the 48" and 24" respectively. 
It has been shown that slower pan speed improves the coating uniformity, primarily 
because the time tablets reside in the spray zone is longer at lower pan speeds, exposing 
the tablets to the spray zone for a longer period of time (6,12). 
Percent RSD values for entire tablet content uniformity assay values are higher in 
both cases pilot and large scale (Table 10). The percent RSD values ranged from 5.3-
9. 7% indicating that the coating application is not unifom1 and variable between two 
different scales. Although the observed variability for the content uniformity 
measurements for the scale-up batches were small, it barely meets the USP content 
uniformity requirement of RSD < 6% for solid dosage forms. Since the variability is 
reasonably small for the tablets coated using the large scale equipment, identifying the 
influential parameters and optimizing these parameters may be beneficial in further 
reducing the variability in the coating. 
Furthermore, statistical evaluations using ANOV A for the content uniformity 
results of the pilot scale and scale-up batches shown in Table l 0 is included in Table 11-
13 Appendix II. These results do not show a significant difference in the mean content 
uniformity values for the entire tablet. Also the observed P-values for the comparison of 
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standard deviation values are greater than 0.05 (0.2249 and 0.1757) for the whole tablet 
content uniformity values and there is not a statistically significant difference among the 
standard deviation values at the 5% level. Moreover, these results also suggest that the 
film coatings applied using large scale equipment is fairly uniform and reproducible. 
Clearly, there is a lack of uniform coating of the tablets coated using the 24" coating pan, 
suggesting that this may not be a suitable process to deliver precise amount of low dose 
active drug on the coating of the tablet that will meet the USP content uniformity 
requirement for solid dosage forms. 
Table 14 shows the entire tablet assay and content uniformity results for both 
formulations coated using the 24" and 48" coating pan. Actual assay value for all the 
batches range from 95.3-99.3%, suggesting a good recovery of the coating material. 
However, the actual assay values for the tablets manufactured using the 24" coating pan 
is lower than the theoretical assay value, suggesting a lower coating efficiency at this 
scale. On the other hand actual assay values for the tablets manufactured using the 48" 
coating pan closely agree with the theoretical assay value, indicaiing the coating process 
is efficient. Furthermore, the immediate release coated (pulsed-release) tablets 
manufactured for both formulations at different scales showed nearly similar dissolution 
characteristics (Figure 3 and 4). These findings suggest that release of drug from these 
coatings are directly scalable and are independent of batch size. Furthermore, a statistical 
comparison of the mean drug release at t=0.5 hr and at t=8.0 hr was performed for both 
formulations manufactured at different scales and these results show no significant 
difference in drug release at these intervals. Complete ANOV A results for these 
comparisons are included in Appendix I. However, the variability in drug release between 
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Table I 0. Tablet Content Uniformity for Pilot and Large Scale Batches 
Tablet Pilot Scale-up 
Sample# Formula-I Formula-II Formula-I Formula-II 
Assay% 
1 85.2 95.1 91.7 101.9 
2 83 .6 87.6 104.8 107.6 
3 98.5 95.8 100.3 90.9 
4 107.5 79.5 96.7 97.9 
5 92.1 97.9 107.5 95.4 
6 109.5 99.6 101.2 94.2 
7 96.5 107.8 94.6 98.5 
8 95.7 97.8 93 .7 99.3 
9 89.1 98.3 98 .0 104.9 
IO 107.4 85.l 93.8 102.1 
Average 96.5 94.5 98.6 99.5 
Range 83.6- 109.5 79.5 - 107.8 90.9 - 107.6 91.7 - 107.5 
RSD (%) 9.7 8.7 5.1 5.3 
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Table 14. Summary of Albuterol Sulfate Pulsed-Release Tablet Properties 
Assay(%) Content Uniformity" F2 
Batch Size Theoretical Actual Assay]o/:J RSD:io/:J 
Pilot 99.8 96.1 54.1 12.0 89.8 
Formuia I 
Pilot 98.9 95.3 52.l 11.7 66.9 
Formula II 
Scale-up 99.8 99.3 50.5 7.2 89.8 
Formula I 
Scale-up 99.5 98.9 50.3 6.8 66.9 
Formula II 
• unmediate release coatmg n=J 0 for all determinations 
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14 
tablets as a measure of percent RSD values at each time point was larger at the early 
dissolution time points, suggesting that the variability is inherent and needs further 
optimization of the coating process. Moreover, this phenomenon was observed in both 
formulations and is limited to the immediate release portion of the tablet and the 
variability drops as the second dose starts releasing from the seal coated tablet core. 
These findings further suggest that the immediate release is the major contributor of the 
variability in drug release at the early time points. 
The pair-wise comparisons of the dissolution results for two different scales of the 
formulations evaluated using F2 metrics show a value of 89.8 and 66.9 for formulation I 
and II respectively. An F2 value of 50 or greater indicates that dissolution profiles are 
similar according to the F2 metrics established by SUPAC guidelines (14,15,16). F2 
analysis results for these comparisons are included in Table 15-16 Appendix II. In 
addition, tablets coated at two different scales using small and large coating pan were 
stored in HDPE bottles at two different storage conditions controlled room temperature 
(25°C/60% RH) and accelerated conditions ( 40°C/75% RH) for 6 months and showed no 
significant change in assay values (Figure 5 and 6). Observed assay values for stability 
samples showed no significant change in the amount of albuterol from the initial time 
point and until 6 months period. These results suggest that the formulation is stable, and 
the specified storage conditions does not seem to have any detrimental effect on the 
product. Figures 7 and 8 show the effect of storage condition on the drug release 
characteristics of both formulations at both scales of manufacture. It can be seen from 
these results that there is no change in the dissolution pattern at various test intervals 
when the products were stored at 25°C and 60% RH, suggesting that the room 
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temperature storage condition is acceptable. Although there was variability in drug 
release between tablets, the overall drug release pattern for both the formulations were 
similar at various stability test intervals indicating that the storage conditions did not have 
a significant effect on the rate and extent of drug release. 
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5.0 Conclusions 
Immediate release coating formulation and process was developed to incorporate 
water soluble drug in the coating to deliver as immediate release of the initial dose a 
pulsed-release tablet dosage form. The coating equipment used was geometrically similar 
in design for both small and large scale coating process. The most important factor 
should be considered during scaling up of the aqueous coating process include; coating 
solution spray rates, number of spray guns (to obtain a uniform spray on the entire 
surface of the tablet bed), adequate mixing of tablets, pan speed and adjusting the in-
process air volume to provide adequate drying capacity. 
Tablets coated using 24" coating pan produce larger variability in the coating and 
had low process efficiency. Thus we can conclude that using 24" coating pan may not be 
suitable for the application of active drug onto the tablets to deliver low dose. On the 
other hand the larger coating pan showed better efficiency and uniformity of coating 
suggesting a better process choice for the application of active drug onto the tablets. Film 
coatings applied using two different coating equipment at different scales exhibited 
similar tablet properties. Although the large scale process is efficient and uniform, it was 
challenging to meet the USP content uniformity requirements for solid dosage forms. 
However, it may be possible to meet this requirement, once the influential parameters are 
identified and optimized. 
The statistical evaluation of the dissolution results further indicate that there is no 
statistically significant difference between the mean drug release at the 5% level for two 
different scales of coating. Furthermore, for both scales of manufacture, all the pair-wise 
comparisons of dissolution results for both formulations were similar based on SUPAC 
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F2 criteria. Stability study results also suggest that development and direct scale-up of 
immediate release coating formulation of low dose water soluble drug is possible from 
the pilot to the production scale. 
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MANUSCRIPT IV 
AN INVESTIGATION OF UNIFORMITY OF AQUEOUS FILM COATING 
CONTAINING LOW DOSE ACTIVE DRUGS USING 
STATISTICAL DESIGN OF EXPERIMENTS 
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ABSTRACT 
The film coating process can influence the quality of the final coated dosage form, 
such as surface characteristics, gloss, coating efficiency and coating uniformity. Aqueous 
film coating of solid dosage form is a process that continues to grow in importance in the 
pharmaceutical industry. There is also a widespread interest in evaluating the uniformity 
of the film coatings. The reason for this interest is that the uniformity of the coating 
affects the quality of the tablet finish, accuracy of the dose delivered and functionality of 
the coating. Coating uniformity can be improved when the critical parameters are 
understood and optimized. The aim of this study was to examine the influence of 
processing parameters on the uniformity of the coating applied to deliver low dose active 
drug in the immediate release portion (coating) of a pulse-release tablet dosage form 
containing immediate and delayed release of water soluble drug. 
The application of statistical Design of Experiments (DOE) has the potential to 
allow rapid identification and optimization of the processing parameters. A factorial 
design was used to study the critical processing parameters that were known to influence 
film coating process. The parameters of interest are spray rate, coating pan speed and 
drug concentration in the coating solution. The responses measured were coating assay, 
coating uniformity, process efficiency and process duration. The results of analysis of 
variance was used to predict the effect of various processing parameters on the response. 
Results show that coating suspension spray rate and coating pan rotation speed 
significantly affect the coating uniformity. The content uniformity between tablets is 
significantly improved by using a low spray rate, low drug concentration in the coating 
solution and slower pan speed. However, lower spray rate and concentration significantly 
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increase process duration. Coating process efficiency is significantly affected by increased 
spray rate and pan speed. Production size batches manufactured with the selected coating 
parameters produced uniform coatings with a immediate release content uniformity assay 
of 90 - l l 0%, RSD < 7% and the entire tablet content uniformity met the requirements 
specified in the USP for solid dosage form. 
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1.0 Introduction 
There is a growing interest in incorporating soluble and insoluble active drugs into 
the coating of coated tablets. For this technique to be useful for active drug application, 
the variation in coating between the tablets must be minimal. Application of active drug 
onto tablet cores using conventional spray coating processes is very challenging. Various 
coating techniques and processes for the application and delivery of active drug via a 
tablet dosage form have been studied in detail elsewhere (1 ,2,3). A number of process 
variables affect the uniform application of the film forming material onto the tablet cores 
as well as the quality, appearance and performance of the final film. 
Coating may be applied by spraying a solution or suspension containing dissolved 
or undissolved drug substance and/or pigment onto a large number of tablets tumbling in 
a rotating pan (1 ,2). Under normal coating conditions, only the top portion of the tablet 
bed receives coating during each revolution and is limited by application time. Uniform 
color on the color-coated tablets as perceived visually concludes the end point of the 
coating process. This is achieved by increasing the coating time and the coating material 
applied on the core. Poor tablet movement in the drum can lead to differences in the 
amount of material applied to each tablet during the coating process (2). This can result in 
color variation, bridging of embossing on the tablets, and variability in drug release on 
diffusion barrier coated tablets. The problem of variation is seen in the tablet bed as light 
and dark cores during coating while applying a colored film over a light colored core (2). 
While color variation in the coated tablets may cause an elegance problem, variation in 
the coated drug may cause a therapeutic efficacy problem. Tablets that are coated with a 
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functional coating would exhibit a performance problem (e.g., enteric and sustained 
release coating). Many different tablet co~ting machines are on the market, each with 
different configuration and controllable parameter options (1,4) . Various coating 
conditions and equipment configurations also have a profound effect on the development 
of a robust coating process with uniform coating of low dose active drugs . The variables 
that may influence coating uniformity include: mixing, pan rpm, concentration of the 
substrate in the coating solution, number of spray guns, spray pattern and coating time 
(3 ,5). A robust formulation is one that is insensitive to normal coating process variation. 
Normal variation includes the controllable process parameters and environmental factors 
(temperature and humidity) that affect the product quality and performance. 
Generally, in developing and evaluating a coating process we learn through a 
series of activities in which we make conjectures about a process, perform experiments to 
generate data from the process, and then use the information from the experiments to 
establish new conjectures, which lead to new experiments (6) . One strategy of 
experimentation that is widely used in practice is the one-factor-at-a-time approach. The 
major disadvantage of this strategy is that it fails to consider any possible interaction 
between the parameters. Interaction between factors is very common, and if occurring, the 
one-factor-at-a-time approach will produce poor results. An improved approach that 
addresses multiple parameters is the factorial experiment. This is an experimental strategy 
in which multiple parameters are varied together, instead of one at a time. Experimental 
design methods have found broad application in many disciplines, and is a critically 
important tool for improving the performance of both new and previously developed 
manufacturing processes. The application of experimental design techniques early in 
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process development can result in; improved process yields, process efficiency, reduced 
variability and overall savings in development cost. This article describes statistical 
design of experiment (DOE) studies that were conducted as part of the development, 
characterization and evaluation of a pulsed-release tablet dosage form for low dose water 
soluble drug. 
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2.0 Objective 
To use a statistically designed set of experiments to evaluate the individual and 
interactive effects of process variables on the content uniformity of drug in the film 
coating and overall coating application process. 
3.0 Methods 
3. J Materials: 
Albuterol Sulfate, USP (Propharrnaco, Nobel Industries, Italy); Microcrystalline 
Cellulose, USP (FMC Corp., Philadelphia, PA); Starch 1500, NF (Colorcon, West Point, 
PA); Lactose DT (Quest lntemat_ional, Hoffinan Estates, IL); Magnesium Stearate, NF 
(Manllinckrot Inc., St. Louis, MO); Opadry® II (Colorcon, West Point, PA); Eudragit® S 
I 00 (Rohm Pharma, GmbH, Germany); Aqueous Ammonia Solution, NF (Morflex Inc., 
Greensboro, NC); Triethylcitrate, NF (Morflex Inc., Greensboro, NC). All raw materials 
used complied with the current USP/NF grade specifications. 
3.2 Equipment: 
Sieve Shaker (Sweco, Florance, KY); V-blender (Patterson-Kelly, East 
Stroudsburg, PA); Micron Air Jet Sieve (Hosokawa Micron Powder Systems, Summit, 
NJ); Moisture Analyzer, Computrac Max 50 (Arizona Instrument, Tempe, AZ); Tablet 
Press, Kikusui Model Libra 836 KRCZ (Kikusui, Seisakusho Ltd. , Kyoto, Japan); SMI 
Force Monitoring System (SMI Inc., Pittstown, NJ); Tooling 9/32" Standard Concave, 
(Natoli Engineering Co., Chesterfield, MO); Vector Tablet Tester (Vector Corp. , Marion, 
185 
IA); Friability Tester (Erweka Instrument Corp., Milford, CT); Disintegration Apparatus 
Erweka ZT 3-4E (Erweka Instrument Corp., Milford, CT); Masterflex Peristaltic Pump, 
Model 7523-20 (Cole-Parmer Instrument Co., Barington, IL); High Speed Disperser, 
Model 89 (Premier Mill Corp. , Reading, PA); Accela Cota 48" (Thomas Engineering, 
Hoffman Estates, IL); Shimadzu LC-4A, High Performance Liquid Chromatography 
(HPLC) Equipped with a Shimadzu SPD-2AS spectrophotometer detector (Shimadzu, 
Japan) 
3.3 Experimental Design: 
Based on the previous experimental work and available information from the 
literature it was clear that processing conditions significantly affect the uniformity and 
quality of coating (2,3,5,7). Processing parameters can interact both synergistically or 
antagonistically are not additive. Although successive approximation experiments can 
yield incremental improvement in coating quality and performance, the data from these 
experiments do not allow positive identification and quantification of interaction effects. 
Utilization of a factorial design during coating formulation and process development 
overcomes the information limitations of the successive approximation approach and 
more efficiently provides the kind of understanding and results that are needed (5 ,6). 
DOE is a multivariate approach in which two are more variables may be studied in one 
experiment. It is a most efficient method of experimentation that leads to a clear 
definition of variable effects that ultimately leads to process optimization. Even with 
DOE, the amount of work increases significantly as the number of study variables 
increase. Therefore, it was important to pre-screen the process parameters carefully to 
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select those critical parameters that would be expected to have an influence on the 
process. To determine the influence of the coating process variables on the uniformity of 
coating and to identify the relative importance of the estimated effects and any possible 
two-factor interactions, experimental designs were selected using Statgraphics® Plus 
version 3.1 (Manugestics Inc., Rockville MD). Figure I shows the 23 factorial (cube) 
design for evaluating the process variables. 
The Statgraphics software generated an experimental design of 8 coating trials for 
the 23 factorial design. Ideally replication of the experiment is recommended for 
statistical analysis, as this would aid in obtaining an estimate of the experimental error if 
any. Due to limited resources; cost, time and the large quantity of raw material needed in 
scaling up on production size equipment replication is not often feasible. Therefore a 
replicate experiment was not performed to provide a true reading of actual conditions. 
Based on the product quality requirements the six response variables shown in Table I 
were selected for the study. Due to limited resources and time constraints, three critical 
processing variables that were believed to contribute for the most variation from a list of 
ten controilable process parameters that potentially affected the response variables were 
selected (8,9) . The controllable variables were drug concentration in the coating solution, 
coating solution spray rate and coating pan rotation speed. These variables with their 
corresponding usage levels are presented in Table 2. Statistical analysis of the observed 
results for each response was analyzed to determine which of the three factors had the 
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Figure I . Cube Design for Evaluating Spray Processing Variables 
(+)High Level 
(-)Low Level 
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Table 1. Response Variables in the Order of Importance 
Response Variable Units 
Coating assay % 
Relative standard deviation (coating uniformity) % 
Coating process efficiency % 
Loss on drying % 
Process duration hr 
Pan exhaust temperature oc 
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Table 2. Selected Process Variables Usage Levels 
Experiment Variable Level Measurement 
Low Hig_h (Units) 
Drug concentration in coating suspension 2.5 4.0 % 
Spray rate ISO 350 grams/min 
Coating pan speed 4 8 rpm 
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( most effect. Analysis was also performed to estimate how strongly each of the 
experimental factors affects the response. Analysis results were graphically presented as 
pareto charts and response surface graphs to represent the relative significance of the 
effects. A P-value of 0.05 was considered as the criteria for statistical significance. 
Analysis of variance (ANOV A) was used as an alternative tool to justify the estimated 
regression model. All coating trials in this experiment used 7-mm diameter, standard 
convex shaped placebo tablets weighing approximately 135 mg. Total batch weights of 
135 kg of placebo tablet cores were used for each coating trial. Table 3 shows the placebo 
tablet core formulation used in this study. Placebo tablet cores were manufactured using a 
3 6 station instrumented Kikusui rotary tablet press. These placebo tablet cores were then 
seal coated using the 48 inch Accela-Cota, by spraying the coating suspension 
formulation presented in Table 4 and using the fixed processing parameters shown in 
Table 5. These seal coated placebo tablets were used as substrate cores for the immediate 
release coating experimental trials. 
3.4 Granulation Manufacture: 
Excipients were pre screened (deagglomerated) using a Sweco sieve shaker fitted 
with a 20 mesh wire screen. Screened excipients were then placed in a 50 ft3 V-blender 
and mixed for 20 minutes. Magnesium stearate was passed through a 30 mesh screen, 
screened material was added to the blender and mixed for 3 additional minutes. The 
granule properties examined include percent loss on drying, granule size distribution, 
bulk densities and percent compressibility (Carr index). 
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Table 3. Formula for Placebo Tablet Core 
Ingredient Content 
Percent w/w m~ablet 
Microcrystalline Cellulose, USP 30.0 40.5 
Pregelatinized Starch, NF 24.3 32.8 
Spray Dried Lactose, NF 45 .0 60.7 
Mllg!lesium Stearate, NF 0.7 1.0 
Total 100.0 135.0 
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Table 4. Formula for Seal Coating Tablet Cores 
Ingredient Content 
Percent w/w ni[tablet 
Eudragit ~ 100 12.0 6.75 
Aqueous Ammonia Solution IN 6.1 -
Triethylcitrate, NF 6.0 3.38 
Talc, USP 4.0 2.25 
Purified Water, USP 71.9 
-
Total 100.0 12.38 
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Table 5. Coatin Parameters for Seal Coatin 
0 eratin arameter 
Drum Size (inches) 
Batch Size (kg) 
Number of Spray Guns 
Pan Speed (rpm) 
Atomizing Air Pressure (bar) 
Process drying air (cfm) 
Coating level(%) 
D in Time min 
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Accela-Cota 48" 
Condition 
48 
135 
3 
4 
1.5 
1600 
6 
30 
3.5 Tablet Manufacture: 
The manufactured granulation was filled in the hopper of an instrumented Kikusui 
Libra tablet press (Kikusui Seisakusho Ltd. , Kyoto, Japan) . The tablet press was setup to 
compress thirty six 7 mm diameter shallow convex tablets per revolution. The target 
tablet weight was adjusted to 135 mg, and tablets were produced using pre compression 
and main compression force of 300 kg and 1000 kg respectively to produce a target tablet 
hardness of 7 kp for the entire batch. Tablet samples were collected and stored in tightly 
sealed containers for subsequent physical characterization. The uniformity in weight of 
the placebo tablet was determined using the weight variation test procedure <905> 
specified in the United States Pharmacopoeia (USP 23)(10). The weight, thickness, 
hardness was measured using vector automatic tablet tester (Vector Corp., Marion, IA) 
USP acceptance criteria were applied in the evaluation of the results. The tablet friability, 
resistance to abrasion during the handling and coating process, was measured using a 
Roche type friabilator (Erweka Instrument Corp., Milford, CT). Fifty tablets were 
randomly selected from the bulk sample for this test. The tablets were weighed and 
subjected to 100 rotations (25 rpm for 4 minutes) in the friabilator. The tablets were then 
dusted and reweighed to determine loss of abrasion. Friability is reported as percent 
weight loss. 
3.6 Tablet Coating: 
3.6.1 Seal Coating Suspension Preparation 
The seal coating suspension formulation presented in Table 4 was used. Eudragit® 
S 100 powder was dispersed in purified water, added to the dispersion liquid ammonia 
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mixed for 60 minutes. Triethyl citrate was added to th.is mixture and mixed for an 
additional 60 minutes. Talc was dispersed separately in purified water; th.is dispersion 
was then added to the Eudragit dispersion to form the coating suspension. The coating 
mixture was continuously stirred during the suspension preparation process. 
3.6.2 Immediate Release Coating Suspension Preparation 
The immediate release coating suspension formulation is presented in Table 6. 
Albuterol sulfate was dissolved in purified water; to th.is solution Opadry® II white was 
added and mixed to obtain a homogeneous coating suspension. The coating suspension 
sample was collected at the end of the process to determine the amount of albuterol 
sulfate in the final coating suspension. 
3.6.3 Seal Coating Procedure 
A 48 inch Accela-Cota (Thomas Engineering, Hoffman Estates, IL) was loaded 
with 135 kg of compressed placebo tablets. The tablets were seal coated using the coating 
suspension prepared using the formulation presented in Table 4. The coating suspension 
was stirred continuously throughout the process to maintain homogeneity. The solution 
spray guns were calibrated by spraying the coating suspension for a specified amount of 
time and weighing the material sprayed through each spray gun. Spray to tablet bed 
distance was set at 10 inches for all coating trials. The Eudragit coating suspension was 
sprayed using three spray guns equipped with a I mm spray nozzle, pan speed ranging 
from 4-6 rpm, airflow of2000ft3/min, pan pressure of -0.05in. water, and a 
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Table 6. Formula for Albuterol Sulfate Immediate Release Coating 
Ingredient Percent w/w 
Albuterol Sulfate, USP 2.5-4.0 
Opadry® II White 8.5-7.0 
Purified Water, USP 89.00 
Total 100.00 
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product temperature of 32°C. A Masterflex peristaltic pump, equipped with silicon tubing 
was used to deliver the coating suspension. After coating, the tablets were allowed to dry 
in the coating pan for 30 minutes by tumbling at 40°C before cooling. Tablet samples 
were collected at the end of the coating process for physical characterization. 
3.6.4 Immediate Release Coating Procedure 
The seal coated tablets were loaded into a 48 inch Accela-Cota and the immediate 
release albuterol sulfate coating suspension presented in Table 6 was sprayed onto the 
tablets. The coating suspension was sprayed using three spray guns, with process airflow 
of 2000ft3/min, pan pressure of -0.05 inch water, and a target product/exhaust 
temperature of 45°C. The inlet and outlet temperatures were maintained at 59 ± 2°C and 
40 ± 2°C. The coating suspension was sprayed continuously using a peristaltic pump with 
spray guns equipped with I mm spray nozzle. An average tablet weight gain of 8% solid 
was applied which is equivalent to 2 mg of albuterol per tablet. The coating suspension 
was stirred continuously throughout the process to maintain homogeneity. Appropriate 
coating solution spray rate and pan speed were selected as per the randomized 
experimental run created by the design of experiment shown in Table 7 and fixed 
processing conditions shown in Table 8. 
3. 7 Coating Assay: 
A reverse phase High Performance Liquid Chromatography (HPLC) assay 
was selected due to the advantage of direct analysis of aqueous samples, high sensitivity 
and separation of excipients that may interfere with the assay. 
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Table 7. Coatin Ex erimental Trials from Desi of Ex eriments 
Experiment Spray Rate Pan Speed Albuterol Cone. 
Run No. min m %w/w 
I 350 8.0 4.0 
2 350 4.0 4.0 
3 350 8.0 2.5 
4 150 4.0 4.0 
5 150 4.0 2.5 
6 150 8.0 4.0 
7 150 8.0 2.5 
8 350 4.0 2.5 
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Table 8. Fixed Processin Conditions for the Ex erimental Trials Accela-Cota 48" 
0 eratin arameter 
Drum Size (inch) 
Batch Size (kg) 
Solution Spray Pump 
Number of Spray Gun 
Spray Type 
Spray to Bed Distance (inch) 
Atomizing Air Pressure (bar) 
Process Air Volume (cfm) 
Coating level(%) 
D in Time min 
200 
Condition 
48 
130 
Peristaltic 
3 
Continuous 
12 
1.5 
2000 
8 
30 
Twenty tablets were selected at random; each tablet was placed in a separate volumetric 
flask containing 20 mL of water. The sample was sonicated and vortexed for one minute 
until all of the outer coating (immediate release portion) of the tablet was dissolved. The 
solution was decanted into 500 mL volumetric flask. The vial was rinsed with 20 mL 
water total of nine additional times, and the rinse solutions were decanted into the same 
500 mL volumetric flask. The 500 mL flask was diluted to volume with water. 12.5 mL 
of this solution was transferred to 200 mL volumetric flask and diluted to volume with 
water.An aliquot of this solution was filtered through a 0.45 µm PTFE filter, discarding 
the first 5 mL of the filtrate . A reverse phase column (Keystone ODS/H, 5µm 4.6x250 
mm) in conjunction with a variable wavelength UV detector was used. The injection 
volume was 30 µL with a flow rate of lmL/minute and a column temperature of35°C. 
3.8 Relative Standard Deviation (Coating Uniformity): 
Coating uniformity is generally defined as the variation in weight gain of coated 
tablets within a coating trial. In each experimental trial, I 00 tablets were collected before 
and after coating. Twenty tablets were used for weight variation measurements and 
twenty tablets were individually assayed to determine drug content uniformity in the 
coating. For the purpose of this experiment, RSD will be expressed as the first standard 
deviation of the variation in percent assay and is calculated by (5, 11 ): 
%RSD = 
x 
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Where w/0 and wtb are the tablet weights after and before coating respectively. n is the 
number of tablets measured and x is the average weight gain of the n measured tablets 
from the coating trial. All measurements were corrected for moisture content. This 
method provided an effective means of determining the coating uniformity in each 
coating run thereby allowing the assessment of process changes on coating uniformity. 
3.9 Coating Process Efficiency: 
Coating process efficiency is generally defined as a measure of the determined 
actual coating applied expressed as a percentage of the theoretical amount of coating 
intended to be applied. 
CPE= [wg,,lwg,]x 100% 
Where wg, is the theoretical percent weight gain and wg0 is the actual percent weight 
gain, which is computed as: 
Where w10 and wt6 are the total batch weights before and after coating respectively. All 
measurements were corrected for moisture content. 
3.10 Loss on Drying: 
Percent loss on drying is a measure of the moisture content of the tablet. It can be 
extremely important to both tablet cores, coating end point determination and drug 
stability. Percent loss on drying is the moisture content of the coated tablet expressed as 
percent weight. Percent LOD is calculated as follows: 
% LOD = [ w/0 _ Wlb /wtb] X I 00% 
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Where wt0 and wtb are the coated tablets weights before and after drying, respectively. 
The tablets were weighed, dried at 50°C in a temperature-controlled oven for 24 hours 
then reweighed. 
3. 11 Product Bed Temperature: 
Product bed temperature data was obtained from an average of the values recorded 
throughout the coating process. The inlet, outlet and the exhaust temperature were 
measured using a temperature probe integrated with an automatic data collection system. 
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4.0 Results and Discussion 
4.1 Placebo Tablet Core Properties: 
Friability is a term used to describe the resistance of tablets to mechanical wear as 
shown by the breakage, chipping, and abrasion witnessed during coating, high-speed 
packaging and transportation. Tablets were compressed at a target main compression 
force of I 000 kg, which produced a hardness of 7 kp. Ten tablets were collected at 
specified intervals (every fifteen minutes) through out the compression run and were 
tested for weight, thickness, hardness and friability as an in-process control check. 
Tablets produced were close to the target hardness and weight with minimal variation 
across the entire batch. Tablet friability was s; 0.1 %. This yielded tablets that were 
suitable for the coating process. Table 9 shows the placebo tablet properties. 
4.2 Seal Coated Tablet Properties: 
Coating summary results for seal coated tablets are presented in Table I 0. Results 
indicate a good recovery of the amount of solids applied as weight gain. The coating 
efficiency was calculated as a function of polymer weight gain based on the amount of 
solids applied and ranged from 97.6 to 99.8% for all eight batches, suggesting that the 
process is efficient and reproducible. Weight variation for the seal coated tablets was 
minimal with the average tablet weight ranging from 146.2 - 148.4 mg suggesting low 
inter-tablet variability. The observed variation RSD values ranged from 1.3 - 2.3% 
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Table 9. Summary of Tablet Properties (Placebo Core) 
Properties Weight Thickness Hardness Friability Disintegration 
_{m_g}_ _{in_J_ _{K_ll}_ (%2_ _(mi Ill 
Average 135.2 0.140 7. 1 0.1 2.5 
RSD (%) 0.95 0.45 1.7 - 2.8 
205 
Table 10. Summary Results for Seal Coating 
Batch % Polymer coated Efficiency Tablet Weight Loss on 
No. Drying 
Theoretical Actual % A~m:& %RSD % 
I 5.0 4.9 97.8 147.3 1.6 3.2 
2 5.0 4.7 97.6 147.1 2. 1 2.8 
3 5.0 4.8 98.9 146.9 1.3 2.9 
4 5.0 5.1 99.8 148.4 1.7 3.1 
5 5.0 4.9 98.6 147.7 2 .0 2.8 
6 5.0 4.9 99.1 147.2 1.5 3.2 
7 5.0 4.8 98.8 146.2 2.2 2.9 
8 5.0 5.0 99.5 147.9 2.3 3.3 
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inillcating that the coated tablets have minimal variability in weight and hence are 
suitable as a substrate for further coating. Loss on drying values were< 3.3%, and similar 
to the values obtained for the dry granulation. These results suggest that the seal coating 
process does not affect the original moisture level in the granulation. 
A statistical evaluation of the results obtained from these experiments were 
analyzed to identify the influence of each of the three factors (spray rate, pan speed and 
drug concentration in the coating solution) on the coating uniformity, assay, coating 
process efficiency, loss on drying, product temperature and processing time in an attempt 
to select the optimum processing parameters for the large scale production. Analysis of 
variance along with various graphical evaluations of the response data was performed to 
identify the statistical significance of the influential factors. 
4.3 Coating Assay: 
Amount of active drug in the coating is of primary importance, especially since 
the film coating delivers the initial dose of 2 mg, which is 50% of the drug from the 
dosage form and should be readily available as immediate release. Coating drum speed, 
pan charge, amount of material applied and spray pattern were known to affect the 
amount of material deposited on the tablets (7, 12). Hence, it was necessary to explore the 
relationship between the amount of solids applied and the amount recovered. Any 
difference in solid deposition and recovery may affect the amount of active drug in the 
dosage form and potentially result in low assay values. The response results; average 
tablet weight, assay for albuterol, and percent efficiency along with RSD values for the 
tablet samples from the 8 experimental runs is presented in Table 11 (Appendix III). It is 
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immediately apparent from these results that experiments 1, 3 and 7 with higher pan 
speed (8 rpm) show low tablet weight and assay values suggesting a significant loss of 
solid material deposited on the tablet. The loss on drying values for tablet samples for all 
experiments range from 2.3-3.7% and the variability is minimal and are close to the loss 
on drying values of the seal coated tablet cores. These findings suggest that the coating 
process did not impart any additional moisture to the coated tablets that may invariably 
affect the tablet weight gain and assay values. Table 12 (Appendix III) shows the 
ANOV A results for percent .assay response for all 8 experiments. In this case, three 
factors have P-value less than 0.05, indicating that they are significant. The order of 
significance pan speed-albuterol concentration interaction (BC) P=0.0381 followed by 
pan speed (B) P=0.0409 and spray rate (A) P=0.0489 is the least significant of all three 
that affect the amount of coating material deposited on the tablets. The R-Squared 
statistics indicates that the model explains 99.9% of the variability in coating assay 
response which is mostly contributed by these three effects. Figure 2 shows the 
standardized pareto chart for the percent albuterol assay, the results indicate that the 
coating pan speed (B), suspension spray rate (A) and combined pan speed-albuterol 
concentration (BC) were the most important factors that significantly affect the amount of 
albuterol in the tablet coating. These are significant effects because; their associated bars 
cross the vertical line, which represents a 95 percent test of significance. Figures 3-4 
show the main effect and interaction effect for pan speed, albuterol concentration and 
coating suspension spray rate. It can be seen from the assay values (Figure 3) that the 
higher spray rate has a negative impact on the amount of drug coated. Also, it can be seen 
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Figure 2. Standardized Pareto Chart for Assay Response 
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Figure 3. Main Effects Plot for Assay Response 
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Figure 4. Interaction Plot for Assay Response 
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from these plots of assay results, the amount of drug in the tablet coating decreases when 
the coating pan speed and spray rate was increased simultaneously. However, increasing 
the albuterol concentration in the coating solution produces quite opposite effect. 
Increased albuterol concentration in the coating solution increases the assay values . 
Although there is interaction between albuterol concentration in the coating solution and 
spray rate, (Figure 4) it is not prominent. Furthermore, there is no spray rate-pan speed 
(AB) interaction effect that influence coating solids application. Therefore, it can be 
concluded that interaction effect pan speed-albuterol concentration (BC) significantly 
influences the amount of coating material applied on to the tablets. Hence, tablet assay 
values are affected. Similarly, the coatings are not affected by lower pan speed but higher 
pan speed and spray rate has negative impact on the assay. Figure 5 is a response surface 
graph showing the effects of both spray rate (x-axis) and pan speed (z-axis) on assay (y-
axis) across the experiment ranges used. The linear, interaction and curvilinear effects of 
the experiment variables are best visualized using response surface graphs. It is clear from 
the figure that increasing the spray rate reduces the assay value . Figure 5 also shows the 
curvilinear effect of pan speed, which results in reduction in drug coated onto tablets with 
increasing pan speed. The reason for this seems to be, that although the tablets undergo 
large number of rotational cycles in a given time under the spray zone, the actual time 
over which the tablets are exposed under the coating zone is short. These results have 
important practical implications on the uniformity of film coating. In this case increasing 
the pan rotational speed may well be detrimental since, although improving mixing of the 
tablet bed, it may well result in increased coating material carryover, 
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Figure S. Estimated Response Surface Plot for Assay 
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decreased solid deposition on the tablet core and thus a reduced amount of active drug on 
the coated tablets. 
4.4 RSD (Coating Uniformity): 
Coating uniformity is of primary importance, especially since the film coating 
delivers the first dose of 2 mg of albuterol for immediate release. A tablet that has 
received too little coating will have less active drug (leading to low loading dose), while 
the one that received too much coating will deliver an overdose leading to excessive 
therapeutic activity or possible side effects. It is evident from Table 11 (Appendix III) that 
experiment 2 and 8 both with high spray rate show larger RSD values for tablet weight 
(1.53 and 1.67%) and content uniformjty (12.8 and 11.1%) suggesting lack of uniform 
application of the coating material and has the shortest process time. However, 
experiment 5 with low spray rate and longest coating time exhibits the smallest RSD 
value for both tablet weight (0.85%) and content uniformity assay (7.1 %). Table 13 
(Appendix III) shows the ANOV A results for percent RSD response. In thjs case, two 
effects have P-values less than 0.05, indicating that they are significant. Since, the P-
value is 0.0438 for spray rate and interaction effect spray rate-pan speed 0.0318, we can 
conclude that there is a significant interaction between spray rate and pan speed. 
Furthermore, the main effect for spray rate is also significant. The R-Squared statistics 
indicates that the model explains 99.9% of the variability in percent RSD data of which 
65.3% of the variability is contributed by the above mentioned two factors. Figure 6 
presents a standardized pareto chart for percent relative standard deviation for drug 
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content uniformity. The results show that interaction effect pan speed-spray rate {AB) 
and coating suspension spray rate {A) are the two significant factors affecting the percent 
relative standard deviation (their associated bars cross the vertical line, which represents 
the critical 1-value at a P-value of 0.05). 
It is obvious from the relative standard deviation values, higher the spray rate, 
larger the variability in the coating application resulting in poor coating uniformity. Also 
the combined effect of spray rate along with pan speed has an adverse effect on the 
coating uniformity. Figures 7-8 display the main effect and interaction effect of the three 
factors studied in graphic form. It can be seen from this figure that among the three 
factors pan speed seems to have the least effect on the percent relative standard deviation 
for coating uniformity. Both a higher spray rate and increased albuterol concentration in 
the coating solution increases the variability in coating as a result increased percent RSD 
value of the tablet content uniformity. As expected a uniform spray of drug coating onto 
the tablet cores produces less variability in drug content uniformity and smaller RSD 
values. The half-normal probability plot for these effects (Figure 9) shows that two factor 
interaction spray rate-pan speed located further away from the fitted line suggesting that 
they have significant effect on the uniformity of the film coating. Furthermore, the effect 
of spray rate on the coating uniformity is also significant. Figure I 0 is the contour plot 
showing the effect of spray rate and pan speed on percent RSD. It can be seen from the 
plot that a lower RSD value is obtained towards the slower pan speed and spray rate. 
Figure 11 is a response surface graph that also shows the effects of both spray rate (x-
axis) and pan speed (z-axis) on percent RSD (y-axis) across the experiment ranges used 
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Figure 7. Main Effects Plot for Percent RSD 
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Figure 8. Interaction Plot for Percent RSD 
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Figure 10. Contours of Estimated Response Surface for RSD 
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in this study. Lower RSD values for the tablet content uniformity were observed at low 
spray rate and pan speed. 
The content uniformity between tablets is significantly improved by using a low 
spray rate and reduced pan speed. This is primarily due to longer exposure time of the 
tablets cores to the coating spray zone (increased number of revolutions). In contrast, 
increasing the pan speed and spray rate produce poor coating uniformity. This effect may 
be caused due to the turbulent motion of the tablets in the coating pan due to higher pan 
speed and abrasion of tablets resulting in lack of uniform coverage and loss of coating 
material from tbe tablet surface. 
4.5 Coating Process Efficiency: 
Pickard (1979) has defined process efficiency as tbe ratio of mean weight of 
coating found on the tablet to the mean weight of solids applied per tablet from the 
coating solution and often expressed as percent (14). Polymer film coating solution was 
sprayed onto the tablet bed by means of spray guns that are mounted in tbe coating drum. 
It is quite possible not all of the coating material applied to be deposited on to the tablets 
surface. There are number of reasons for this; spray drying of the coating material before 
reaching the tablet surface, abrasion of tablets-tablets, tablets to the pan surface and 
material carry over in the exhaust plenum (12,13,14). In an attempt to examine the 
relationship between the process efficiency with regard to solids deposition and process 
variables such as spray rate, pan speed and drug concentration a statistical evaluation was 
performed on the percent efficiency response results obtained from tbe experiments. In 
this study the coating process efficiency response ranged from 81.2% to 101.2%, 
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indicating a broad range; from inefficient (20% loss) to almost 100% recovery of the 
coated solids. Table 14 (Appendix III) shows the ANOV A results for coating process 
efficiency. Since, the P-values are 0.478 and 0.496, for spray rate and pan speed we can 
conclude that these main effects are significant. The R-Squared statistics indicates that 
the model explains 99.8% of the variability in coating process efficiency. Figure 12 
presents a standardized pareto chart for coating process efficiency. The ranking also 
identifies spray rate followed by pan speed as the significant factor affecting the coating 
process efficiency at the 5% level. Figure 13-14 display the main effects and interaction 
effects of the three factors studied in graphic form. It can be seen from these results that 
among the three factors studied albuterol concentration in the coating suspension seem to 
have the least effect on the coating efficiency. Furthermore, both increased pan speed and 
spray rate reduce the coating efficiency. 
The process efficiencies reported by Kara et al using a 24 inch coating pan to 
measure the material carry over through the exhaust plenum were slightly lower than the 
values obtained from these experiments (12). Earlier studies showed lower process 
efficiency due to lower pan charge along with increased spray rate and pan speed (12, 13). 
Surprisingly that was not the case in our experiments. Our result indicate that a greater 
quantity of coating material applied is lost and that the efficiency of the process becomes 
progressively lower with increasing spray rate and pan speed while the pan charge was 
kept constant in all the experiments. The low process efficiency observed in these 
experiments may be due to the changes in airflow pattern through the tablet bed because 
of increased void spaces in the tumbling tablet bed. 
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Figure 12. Standardized Pareto Chart for Coating Process Efficiency 
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Figure 13. Main Effect Plot for Coating Process Efficiency 
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Figure 14. Interaction Plot for Coating Process Efficiency 
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Figure 15 is a response graph showing the effects of both spray rate and pan speed on 
process efficiency across the experimental ranges used in this study. The direct and 
curvilinear effects of these two variables are responsible for all of the variation in the 
coating process efficiency. It can be seen from the graph that the process efficiency 
decreases as the spray rate and pan speed increases. Conversely, the process is efficient 
and almost I 00% of the coating material applied were recovered at the lower spray rate 
and coating pan speed. 
4.6 Loss on Drying: 
Table 11 (Appendix III) shows the loss on drying measurements for all the 
experiments. The percent loss on drying values ranged from 2.4-3.7%. Figure 16 is a 
standardized pareto chart that graphically presents in rank order the factors responsible 
for the percent loss on drying response. This indicates that spray rate is the single most 
variable that had a substantial effect on this response. However, this effect is not 
significant at the level of alpha 5%. Figure 17-18 display the main effect and interaction 
effect of the three factors studied in graphic form. It can be seen that among the three 
factors, coating suspension spray rate has the most effect on loss on drying. It can 
therefore be considered as another indicator of overwetting or over drying of the coated 
tablets. Although there is interaction effect pan speed-albuterol concentration (BC) it is 
not apparent. 
Coating process efficiency is a measure of the actual amount of coating applied to 
the tablets relative to the theoretical quantity of coating applied. Since, the coating end 
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Figure 15 . Estimated Response Surface Plot for Process Efficiency 
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Figure 16. Standardized Pareto Chart for Loss on Drying 
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Figure 17. Main Effect Plot for Loss on Drying 
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Figure 18. Interaction Plot for Loss on Drying Response 
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point was determined using the tablet weight gain, it was very important to maintain the 
moisture level closer to the actual starting level found in the granulation. Increased or 
decreased moisture level of the tablet cores along the process from the original levels 
could significantly affect the coating end point determination and the amount of solids 
applied (drug substance). This would eventually lead to variation in the amount of drug 
coated onto the tablets and inaccurate coating end point determination. Since, none of the 
factors have a significant effect on the percent loss on drying values, we can conclude that 
the moisture level in the coated tablet is not affected by the processing conditions and that 
the moisture level remains consistent at various processing stages. 
4.7 Exhaust Temperature: 
Exhaust air temperature was used as a measure of product temperature in this 
study, and ranged from 34-41°C. Inlet air temperature, process air volumes and spray 
rates accounted for the majority of the effects on product temperature. Increase in spray 
rate resulted in lower product temperature, as expected. Figure 19, standardized pareto 
chart, graphically presents the product temperature analysis results. Spray rate (A) is the 
only factor affecting the product and or exhaust temperature. Since, only the solution 
spray rate has an effect on the exhaust temperature it can be easily controlled without 
affecting the quality of the product. Moreover, there was no interaction effect of any of 
the factors on the product temperature. 
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Figure 19. Standardized Pareto Chart for Product/Exhaust Temperature 
A:Spray Rate 
BC 
AC 
AB 
C:AJbuterol Con 
B:Pan Speed 
0 2 
233 
3 
Effect 
4 5 6 
4.8 Processing Time: 
Processing time was crucial for any given process. Shorter processing time 
obviously has a significant economical advantage over an extended process. Shorter 
processing reduces the active drug exposure time to the harsh coating environment, saves 
utili ty cost and labor associated with the process. Hence, it was important to evaluate the 
significance of these factors on the process time. In this study the processing time 
response ranged from 3 to 11 hours, indicating that spray rate is the single most variable 
that had a substantial effect on this response. Table 15 in (Appendix III) shows the 
ANOV A results for coating process duration. In this case, only spray rate has a P-value 
less than 0.05, indicating that is significant. The R-Squared statistics indicating that the 
model explains 99.8% of the variabili ty in coating process duration of which spray rate 
contributes to 74%. A longer processing duration means that the tablet residence time in 
the spray zone is longer and going through a large number of passes under the spray zone. 
Figure 20 a standardized pareto chart, graphically presents the processing time analysis 
results. It is immediately evident that spray rate is the significant factor affecting the 
process time at the level of 5% alpha. Figure 21 is the half-normal probability plot of the 
effects on process duration. The spray rate and albuterol concentration are the two points 
that are located further away from the fitted line suggesting that two factors spray rate and 
albuterol concentration have significant effect on the process duration. Processing time 
increased almost 4 fold with lower spray rate and low albuterol concentration as 
expected. It is not surprising that the processing conditions that gave a better uniformity 
had the longest processing time. However, we cannot ignore the fact that the drug 
concentration in the coating solution also contributes to the extended process time. 
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Figure 21 . Half-Normal Probability Plot for Process Duration 
1.8 
"' 
1.5 c
0 
·.g 1.2 
·;; 
(!) 
-0 0.9 
-0 
.... 
Ol 0.6 -0 
·C 
Ol 
U5 0.3 
0 
t 
A:Sp ay Rateo 
;; -c:A!Ou"fi rOfC'on o 
I: 
170 B:Pan S peed 
0 4 8 12 16 20 
Standardized effects 
236 
5.0 Conclusions 
The effect of coating pan rotation speed, coating suspension spray rate and active 
drug concentration in the coating suspension on film coating uniformity was studied 
through the use of statistical design of experiments and chemical testing. These studies 
show that coating suspension spray rate and coating pan rotation speed have a significant 
effect on the coating uniformity of the film which in tum affects the uniformity of the 
active drug delivered via this film coating system. It can be concluded that low spray rate 
and reduced drug concentration in the coating solution can significantly improve the 
content uniformity of the drug being coated onto the tablets. The best possible coating 
parameter with acceptable coating uniformity had low spray rate and slow pan speed. Of 
course, this comes with a price due to extended process time and increased utility cost in 
running the process. 
The coating efficiency is also significantly affected by the spray rate and pan 
speed. Furthermore, the assay values were lower at higher spray rate and pan speed, 
indicating some material carryover through the exhaust plenum might occur during the 
coating process. Material carryover and the significance of various baffie positions in the 
coating pan to improve better mixing and uniformity of coating is debatable, but should 
be tested and is beyond the scope of this study. 
The results of analysis of variance can be used to predict the effect of various 
processing parameters on the response. Preliminary experiments conducted for coating 
trials allowed to identify the critical processing parameters that influence the coating 
process. The use of statistically designed experiments aided in the selection of suitable 
processing parameters for the large scale coating process. Furthermore, the statistical 
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analysis of the measured response allowed to explore the relationship between the 
processing parameters and their optimum levels. Based on the findings appropriate 
coating parameters were chosen for the scale-up and production batches. 
Finally, production size batches manufactured with the selected coating 
parameters met the immediate release coating content uniformity (RSD < 7%) and entire 
tablet content uniformity requirements for the developed product. These findings also 
suggest that it is possible to deliver low dose active drug in the tablet coating without 
compromising the product quality. 
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Table 18. ANOV A Test Results for Blend Uniformity Comparison at Two Scales 
Formulation I 
Analysis of Variance 
---------------------------------------------------------------
Source Sum of Squares Df Mean Square F-Ratio P- Value 
----------------------------------------------------------------
Between groups 0 . 8 1 0.8 0.28 0.6042 
Within groups 51 . 732 18 2.874 
------------------------------------
Total (Corr.) 52 . 532 19 
Formulation II 
Analysis of Variance 
---------------------------------
Source Sum of Squares Of Mean Square F-Ratio P-Value 
---------------------------------------------------------------------------
Between groups 29.0405 1 29.0405 5.88 0.0260 
Within groups 88 . 885 18 4.93806 
--------
Total (Corr.) 117.925 19 
IV 
.... 
.... 
Table 19. ANOVA Test Results for Blend Uniformity Comparison of All Four Batches 
Analysis of Variance 
Source Sum of Squares Df Mean Square F- Ratio 
-------------------------------------------------
Between groups 49.3008 3 16 . 4336 4 . 21 
Within groups 140 . 617 36 3.90603 
- ------ -
Total (Corr.) 189 . 918 39 
The ANOVA table decomposes the variance of the data into two 
components : a between-group component and a with i n - group component. 
The F-ratio , which i n this case equals 4.20724 , is a ratio of the 
between-group estimate to the with i n- group est i mate . Si nce the 
P- va l ue of the F- test is less than 0 . 05 , there is a statist i ca l ly 
significant difference between the mea n s of the 4 variables at the 
95 . 0 % confidence level . To determine wh ich means are significantly 
different from which others , Multiple Range Test was performed . 
P- Value 
0 . 0119 
..., 
... 
"' 
Table 20. Multiple Range Test (Fisher Least Significant Difference) 
Multiple Range Tests 
Method : 95 . 0 percent LSD 
Count 
FormIIlOX 10 
FormilOX 10 
FormIIlX 10 
FormilX 10 
Mean 
98.48 
100. 88 
100. 89 
101. 28 
- - - -- - - - - - - - - - - - - - - - - - - - - - - - - --
Contrast 
ForrnllOX - FormilX 
FormilOX - FormIIlOX 
FormilOX - FormIIlX 
FormllX - FormIIlOX 
FormllX - FormIIlX 
FormIIlOX - FormIIlX 
Homogeneous Groups 
x 
x 
x 
x 
Difference 
-0. 4 
*2. 4 
-0 . 01 
*2 . 8 
0.39 
*-2 . 41 
* denotes a statistically significant difference . 
This table applies a multiple comparison procedure to determine 
+/- Limits 
1. 79255 
1. 79255 
1. 79255 
1. 79255 
1 . 79255 
1 . 79255 
which means are significantly different from which others . The bottom 
half of the output shows the estimated difference between each pair of 
means . An asterisk has been placed next to 3 pairs , indicating that 
these pairs show statistically significant differences at the 95. 0% 
confidence level. · At the top of the page , 2 homogenous groups are 
identified using columns of X' s. Within each column, the levels 
containing X' s form a group of means within which there are no 
statistically significant differences. The method currently being 
used to discriminate among the means is Fisher ' s least significant 
difference (LSD) procedure. With this method, there is a 5.0% risk of 
calling each pair of means significantly different when the actual 
difference equals O. 
N 
.,, 
°' 
Source 
Between groups 
Within groups 
Total (Corr.) 
Source 
Between groups 
Within groups 
Total (Corr . ) 
Table 21. Comparison of Measured Hardness at 5kp Multiple Batches 
Analysis of Variance 
Sum of Squares 
0.558 
1. 762 
2.32 
Of Mean Square 
3 0.186 
36 0.0489444 
39 
F- Ratio 
3.80 
Table 22. Comparison of Measured Hardness at 6kp Multiple Batches 
Analysis of Variance 
Sum of Squares 
0.076 
l. 5 
1.576 
Of Mean Square 
3 0.0253333 
36 0 . 0416667 
39 
F-Ratio 
0.61 
P- Value 
0.0183 
P-Value 
0.6141 
N 
~ 
_, 
Source 
Between groups 
Within groups 
Total (Corr.) 
Source 
Between groups 
Within groups 
Total (Corr.) 
Table 23 . Comparison of Measured Hardness at 7kp Multiple Batches 
Analysis of Variance 
Sum of Squares 
0.18675 
1 . 613 
1. 79975 
Df Mean Square 
3 0 . 06225 
36 0.0448056 
39 
F- Ratio 
1. 39 
Table 24. Comparison of Measured Hardness at 8kp Multiple Batches 
Analysis of Variance 
Sum of Squares 
0.009 
1. 73 
1 . 739 
Df Mean Square 
3 0.003 
36 0 . 0480556 
39 
F- Ratio 
0.06 
P- Value 
0 . 2617 
P-Value 
0.9793 
~ 
00 
Source 
Between groups 
Within groups 
Total (Corr.) 
Source 
Between groups 
Within groups 
Total (Corr . ) 
Table 25. Comparison of Measured Hardness 9kp Multiple Batches 
Analysis of Variance 
Sum of Squares 
0.347 
1. 664 
2 . 011 
Of Mean Square 
3 0 . 115667 
36 0.0462222 
39 
F-Ratio 
2.50 
Table 26. Comparison of Measured Hardness 1 Okp Multiple Batches 
Analysis of Variance 
Sum of Squares 
0.34275 
1. 857 
2.19975 
Of Mean Square 
3 0.11425 
36 0.0515833 
39 
F-Ratio 
2.21 
P- Value 
0.0748 
P- Value 
0 . 1032 
"' .... 
"' 
Table 27. ANOVA Test Results for Blend and Tablet Content Uniformity Assay 
Formulation I (Batch Size IX) 
Analysis of Variance for BldlXI - Type III Sums of Squares 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
-----------------------------------------------------
MAIN EFFECTS 
A:Scale 0.747556 1 0 . 747556 0 . 31 
B:Stage 0 . 00355556 1 0.00355556 0 . 00 
RESIDUAL 41.2644 17 2.42732 
TOTAL (CORRECTED) 43 . 58 19 
All F-ratios are based on the residual mean square error. 
The ANOVA table decomposes the variability of BldlXI into 
contributions due to various factors .The P-values test the statistical 
significance of each of the factors . Since no P- values are less than 0.05 , 
none of the factors have a statistically significant effect on BldlXI 
at the 95 . 0% confidence level . 
0 . 5862 
0 . 9699 
"' V> 
0 
Table 28. ANOVA Test Results for Blend and Tablet Content Uniformity Assay 
Formulation I (Batch Size I OX) 
Analysis of Variance for BldlOXI - Type III Sums of Squares 
Source Sum of Squares Df Mean Square F-Ratio 
------------------------------------------------------
MAIN EFFECTS 
A:Scale 0 . 4205 1 0.4205 0 . 25 
B : Stage 5.3045 1 5.3045 3 . 16 
RESIDUAL 28.5245 17 1.67791 
-----------------------------------------
TOTAL (CORRECTED) 37.7895 19 
All F-ratios are based on the residual mean square error. 
The P-values test the statistical significance of each of the factors . 
Since no P-values are less than 0 . 05 , none of the factors have a 
statistically significant effect on BldlOXI at the 95 . 0% confidence 
level . 
P-Value 
0 . 6231 
0.0933 
N 
~ 
Table 29. ANOVA Test Results for Blend and Tablet Content Uniformity Assay 
Formulation II (Batch Size IX) 
Analysis of Variance for BldlXII - Type III Sums of Squares 
Source Sum of Squares Df Mean Square F-Ratio 
--- ---------------------------------------------------
MAIN EFFECTS 
A: Scale 0 . 868056 1 0.868056 0 . 43 
B: Stage 2 . 56806 1 2 . 56806 1. 29 
RESIDUAL 33.9489 17 1. 997 
--------------------------------------------------------
TOTAL (CORRECTED) 50 . 1295 19 
All F- ratios are based on the residual mean square error . 
The P-values test the statistical significance of each of the factors . 
S i nce no P-values are less than 0.05 , none of the factors have a 
statistically significant effect on Bld l XII at the 95.0% confidence 
level. 
P-Value 
0.5185 
0. 2725 
N 
"' N 
Table 30. ANOVA Test Results for Blend and Tablet Content Uniformity Assay 
Formulation II (Batch Size I OX) 
Analysis of Variance for BldlOXII - Type III Sums of Squares 
Source Sum of Squares Of Mean Square F- Ratio 
------------------------------------------------------
MAIN EFFECTS 
A: Scale 0. 896056 1 0 . 896056 0 . 11 
B:Stage 1 . 44006 1 1.44006 0 . 18 
RESIDUAL 135 . 597 17 7.97629 
------------------------------------------------
TOTAL (CORRECTED) 137.037 19 
All F-ratios are based on the residual mean square error . 
The P- values test the statistical significance of each of the factors. 
Since no P- values are less than 0 . 05 , none of the factors have a 
statistically significant effect on BldlOXII at t h e 95 . 0% confidence 
level. 
P-Value 
0.7416 
0.6762 
N 
"' 
..,., 
Table 3 1. ANOV A Test Results for Dissolution Comparison Tablet Hardness Study Time for 50% Release 
Source 
Between groups 
Within groups 
Total (Corr.) 
Formulation I 
Analysis of Variance 
Sum of Squares 
0.0 
72. 0 
72 . 0 
Df Mean Square 
1 0. 0 
10 7.2 
11 
F-Ratio P-Value 
0.00 1.0000 
Table 32. ANOV A Test Results for Dissolution Comparison Tablet Hardness Study Time for 75% Release 
Analysis of Variance 
-------------------------------------------
Source Sum of Squares Df Mean Square F- Ratio P- Value 
----------- --------------------------------------
Between groups 5.33333 1 5.33333 0.22 0 . 6484 
Within groups 241. 333 10 24 .1333 
------------------------------------
Total (Corr.) 246.667 11 
IV 
V> 
.,,. 
Table 33 . ANOVA Test Results for Dissolution Comparison Tablet Hardness Study Time for 50% Release 
Source 
Between groups 
Within groups 
Tota l (Corr . ) 
Formulation 11 
Ana l ysis of Variance 
Sum of Squares 
0 . 0833333 
40 . 8333 
40 . 9167 
Of Mea n Square 
1 0 . 0833333 
10 4. 08333 
11 
F-Ratio P- Va lue 
0 . 02 0 . 8892 
Table 34. ANOVA Test Results for Dissolution Comparison Tablet Hardness Study Time for 75% Release 
Ana lysis of Va ria nce 
-------------------------------
Source Sum of Squares Of Mean Square F- Ratio P-Va lue 
--------------------------------------------------
Between groups 280 . 333 1 280 . 333 2 . 7 1 0.1309 
Within groups 1035 . 33 10 103 . 533 
---------------------------------
Total (Corr . ) 13 15 . 67 11 
"' V> 
V> 
Table 35. F2 Analysis for Dissolution Comparison 
Controlled Release Tablets (Formulation-I) 
Time Point Batch Size 1 X Batch Size 1 OX Difference Calculations 
0 
0 
2.56 
l.44 
0.64 
0.49 
0 0 
1 56.8 
2 88.4 
3 98.7 
4 98.7 
0 
58.4 
89.6 
99.5 
99.4 
0 
-1.6 
-l.2 
-0.8 
-0.7 
0 0 
5.13 
1.732857143 
0.759658881 
75.96588812 
F2 = 94.03093098 
Table 36. F2 Analysis for Dissolution Comparison 
Controlled Release Tablets (Formulation-II) 
Time Point Batch Size IX Batch Size 1 OX Difference Calculations 
0 0 0 0 0 
-1 46.3 43.4 2.9 8.41 
2 68.2 65.3 2.9 8.41 
3 83.7 81.1 2.6 6.76 
4 92.3 91.9 0.4 0.16 
"' 
5 99.3 99.1 0.2 0.04 
V> 6 100.3 101.2 -0.9 0.81 
°' 24.59 
4.5 12857143 
0.470732525 
47.07325254 
F2 = 83 .63871035 
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Table 8. Comparison of Content Uniformity Assay for Pilot and Large Scale 
Summary Statistics 
Count 
Average 
Variance 
Standard deviation 
Minimum 
Maximum 
Stnd . skewness 
Stnd. kurtosis 
Sum 
Pilot scale 
30 
49.79 
31.1078 
5.57744 
40.2 
59 . 2 
0.164067 
-1. 07356 
1493.7 
Large scale 
30 
50.52 
13.2368 
3.63825 
44.0 
57.8 
-0.218458 
-0.887946 
1515.6 
N 
V> 
\C) 
Table 9. Comparison of Standard Deviation Deviations for Coating Content Uniformity 
Pilot scale 
Standard deviation 5.57744 
Variance 31.1078 
Df 29 
Ratio of Variances = 2 . 3501 
95.0% Confidence Intervals 
Large scale 
3.63825 
13. 2368 
29 
Standard deviation of Pilot scale: [4.44191 , 7.49783] 
Standard deviation of Large scale: [2.89752,4.89095] 
Ratio of Variances: [1 . 11856,4.93754] 
<-tests to Compare Standard Deviations 
Null hypothesis: sigmal = sigma2 
(1) Alt. hypothesis: sigmal NE sigma2 
f = 2.3501 P-value = 0.0245823 
(2) Alt. hypothesis : sigmal > sigma2 
f = 2.3501 P-value = 0.0122912 
This option runs an f-test to compare the variances of the two 
samples . It also constructs confidence intervals for each standard 
deviation and for the ratio of the variances . Of particular interest 
is The confidence interval for the ratio of the variances extends from 
1 . 11856 to 4.93754. Since the interval does not contain the value 1 . 0 , 
there is a statistically significant difference between the standard 
deviations of the two samples at the 95 . 0% confidence level. The 
<-tests shows a P-va lues below 0.05 indicate significant differences 
between the two standard deviations . 
N 
°' 0 
Table I I. ANOVA Test Results for Entire Tablet Content Uniformity 
Analysis of Variance 
Source Sum of Squares Df Mean Square F-Ratio P- Value 
Between groups 
Within groups 
Total (Corr.) 
133. 555 
1854 . 24 
1987 . 79 
3 44.5183 0 . 86 
36 51. 5066 
39 
The ANOVA table decomposes the variance of the data into two 
components: a between-group component and a within-group component . 
The F-ratio , which in this case equals 0 . 864324 , is a ratio of the 
between-group estimate to the within-group estimate . Since the 
P-value of the F-test is greater than or equal to 0 . 05, there is not a 
statistically significant difference between the means of the 4 content 
uniformity variables at the 95.0% confidence level . 
0. 4 685 
""' "' 
Table 12. Multiple Range Comparison Results for Entire Tablet Content Uniformity 
Method: 95.0 percent LSD 
Count Mean Homogeneous Groups 
-----------------------------------------------------------
PilotIITab 10 94.45 x 
Pilot ITab 10 96. 51 x 
ScaleupITab 10 98.23 x 
ScaleupIITab 10 99.27 x 
------------------------------------------------------------
Contrast Difference +/ - Limits 
---------------------- -------------------------------------------
Pilot ITab - PilotIITab 2.06 6.50931 
Pilot ITab - ScaleupIITab -2.76 6 . 50931 
Pilot ITab - ScaleupITab -1. 72 6.50931 
PilotIITab - ScaleupIITab -4.82 6.50931 
PilotIITab - ScaleupITab -3.78 6.50931 
ScaleupIITab - ScaleupITab 1. 04 6.50931 
* denotes a statistically significant difference. 
This table applies a multiple comparison procedure to determine 
which means are significantly different from which others. The bottom 
half of the output shows the estimated difference between each pair of 
means. There are no statistically significant differences between any 
pair of means at the 95 . 0% confidence level. At the top of the page , 
one homogenous group is identified by a column of X' s . Within each 
column, the levels containing X' s form a group of means within which 
there are no statistically significant differences. The method 
currently being used to discr iminate among the means i s Fisher ' s least 
significant difference (LSD) procedure. 
N 
"' N 
Tablet 13. Hypothesis Testing for Standard Deviation Values oflmmediate Release Coating 
Cochran ' s C test : 0.421559 P-Value = 0.22489 
Bartlett ' s test: 1.15462 P-Value = 0.175737 
Hartley ' s test: 3 .41011 
The three statistics displayed in this table test the null 
hypothesis that the standard deviations within each of the content 
uniformity assay values for various batches are the same. 
Of particular interest are the two P-values. Since the smaller of 
the P-values is greater than or equal to 0 . 05 , there is not a 
statistically significant difference amongst the standard deviation' 
at the 95.0% confidence level. 
N 
°' w 
Time lhr 
0.5 
2 
3.5 
5 
8.5 
12 
Table 15. F2 Dissolution Comparisons for Formulation-I 
(Pi lot vs. Scale-up) 
Pilot Form 1 
48.3 
49.3 
49.3 
49 .3 
98.4 
98.4 
Scale-uo Form I Difference 
49.8 -1.5 
49.8 -0.5 
49.8 -0.5 
49.8 -0.5 
99.8 -1.4 
100.5 -2.1 
F2 = 
Calculations 
2.25 
0.25 
0.25 
0.25 
1.96 
4.41 
9.37 
2.561666667 
0.624796649 
62.47966488 
89 .78693457 
"' i: 
Table 16. F2 Dissolution Comparisons for Formulation-II 
(Pilot vs. Scale-up) 
Time (hr) Pilot Form II Scale-up Form II Difference 
0.5 48.6 51 .9 -3.3 
2 48.3 52.5 -4.2 
3.5 52.9 52.5 0.4 
5 56 .9 52.5 4.4 
8.5 97.3 89.9 7.4 
12 97.2 101.4 -4.2 
F2 = 
Calculations 
10.89 
17.64 
0.16 
19.36 
54.76 
17.64 
120.45 
21.075 
0.217829256 
21 .78292561 
66.90581042 
Appendix III 
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N 
°' 
°' 
Experiment 
Run No. 
I 
2 
3 
4 
5 
6 
7 
8 
Table 11 . Summary of Response Result for Experiments 
Wei_g_ht Variation Content Uni formi!r_ LOD Exhaust 
(mg) RSD Assay RSD (%) Temperature 
J_o/~ _{_o/~ J'.Y~ _tg_ 
155.9 1.11 97.9 9.1 3.4 35 
156.6 1.53 100.9 12.8 3.6 36 
153.9 1.01 81.2 9.5 3.7 35 
154.I 1.13 98.2 9.9 2.3 42 
157.4 0.85 108.0 7.1 2.4 41 
156.9 1.05 102.3 9.9 2.3 40 
155.9 1.07 95.3 9.7 2.8 41 
157.1 1.67 99 .1 I I. I 3.5 34 
Efficiency Process 
(%) Time 
_(_hrs}_ 
92.0 3 
97.1 3 
82.2 6 
92 .1 8 
101.2 II 
100.1 8 
94.5 10 
97.0 6 
"' 
°' 
_,
Table 12. Analysis of Variance Result for Coating Assay 
Analysis of Variance for Assay - Immediate Release Optimization 
Source Sum of Squares 
------
A: Spray Rate 76 . 2612 
B:Pan Speed 108 . 781 
C:Albuterol Con 30.8113 
AB 18.9112 
AC 56.7112 
BC 125. 611 
Total error 0 . 45125 
Total (corr.) 417 . 539 
R-squared = 99 . 8919 percent 
R-squared (adjusted for d.f . ) = 99 . 2435 
Standard Error of Est . = 0.671751 
Mean absolute error= 0.2375 
Durbin-Watson statistic = 1.0 
Df Mean Square F-Ratio 
-----------------
1 76.2612 169.00 
1 108 . 781 241. 07 
1 30. 8113 68 . 28 
1 18. 9112 41. 91 
1 56. 7112 125 . 68 
1 125. 611 278.36 
1 0.45125 
----------
7 
percent 
Assay= 176 . 965 - 0 . 100125*Spray Rate - 8 . 50729*Pan Speed -
22.1083*Albuterol Con - 0.0076875*Spray Rate*Pan Speed + 0.0355*Spray 
Rate*Albuterol Con+ 2 . 64167*Pan Speed*Albuterol Con 
P- Value 
0.0489 
0.0409 
0.0767 
0.0976 
0 . 0566 
0 . 0381 
N 
°' 00 
Table 13 . Analysis of Variance Result for Coating Uniformity RSD 
Analysis of Variance for RSD - Immediate Release Optimizati on 
Source Sum of Squares Of Mean Square F- Ratio P- Value 
--------------------------------------------------
A:Spray Rate 4 . 205 1 
B: Pan Speed 0 . 98 1 
C : Albuterol Con 2 . 205 1 
AB 8 . 0 1 
AC 0.405 1 
BC 2 . 88 1 
Total error 0.02 1 
-------- -------------- --------------------
Total (corr . ) 18 . 695 7 
R- squared = 99 . 893 percen t 
R- squared (adjusted for d.f.) = 99 . 2511 percent 
Standard Error of Est. = 0 . 141421 
Mean absolute error = 0.05 
Durbin- Watson statistic = 1.0 
4. 205 210.25 
0 . 98 49.00 
2 . 205 110 . 25 
8 . 0 400 . 00 
0 . 405 20 . 25 
2 . 88 144 . 00 
0 . 02 
RSD = -10 . 9 + 0 . 047 *Spray Rate+ 2 . 375*Pan Speed+ 3 . 85*Al bu t erol Con 
- 0 . 005*Spray Rate*Pan Speed - 0 . 003*Spray Rate* Albuterol Con -
0.4*Pan Speed *Albutero l Con 
0 . 0438 
0 . 0903 
0.0604 
0.031 8 
0 . 1392 
0.0529 
"' 
"' \0 
Table 14. Analysis of Variance Result fo r Coating Process 
Analysis of Variance for Efficiency - Immediate Release Optimization 
Source Sum of Squares 
A: Spray Rate 88.445 
B: Pan Speed 81. 92 
C: Albuterol Con 22.445 
AB 25.205 
AC 5 . 12 
BC 37 . 845 
Total error 0 . 5 
Total (corr . ) 26 1. 48 
R-squared = 99 . 8088 percent 
R- squared (adjusted for d.f.) = 98 . 6615 
Standard Error of Est . = 0.707107 
Mean absolute error = 0 . 25 
Durbin- Watson statistic = 1 . 0 
Of Mean Square F- Ratio 
-----------------
1 88.445 176 . 89 
1 81 . 92 163 . 84 
1 22 . 445 44 . 89 
1 25 . 205 50 . 41 
5 .1 2 10 . 24 
1 37.845 75.69 
1 0.5 
----------------
7 
percent 
Efficiency= 129 . 683 - 0.0146667*Spray Rate - 4 . 09375*Pan Speed -
9 . 13333*Albuterol Con - 0 . 008875*Spray Rate*Pan Speed + 
0 . 0106667*Spray Rate*Albuterol Con + l . 45*Pan Speed*Albuterol Con 
P-Value 
0.0478 
0.0496 
0 . 0943 
0 . 0891 
0.1928 
0.0729 
N 
_, 
0 
Table 15. Analysis of Variance Result for Coating Process Duration 
Analysis of Variance for Process Time - Immediate Release Optimization 
Source Sum of Squares Df Mean Square F- Ratio P-Value 
-----
---------------------------
A:Spray Rate 45 . 125 
B:Pan Speed 0.125 
C : Albuterol Con 15.125 
AB 0.125 
AC 0.125 
BC 0.125 
Total error 0.125 
------------------------------------
Total (corr.) 60 . 875 
R-squared = 99.7947 percent 
R-squared (adjusted for d.f.) = 98.5626 
Standard Error of Est. = 0 . 353553 
Mean absolute error = 0.125 
Durbin-Watson statistic = 1.0 
1 45.125 361. 00 
1 0.125 1. 00 
1 15 . 125 121. 00 
1 0.125 1. 00 
1 0 . 125 1. 00 
1 0.125 1. 00 
1 0 . 125 
----------------
7 
percent 
Process Time = 20.3542 - 0.0220833*Spray Rate - 0 . 489583*Pan Speed -
l.91667*Albuterol Con + 0.000625*Spray Rate*Pan Speed -
0.00166667*Spray Rate*Albuterol Con + 0.0833333*Pan Speed*Albuterol Con 
0 . 0335 
0.5000 
0.0577 
0.5000 
0 . 5000 
0 . 5000 
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